| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Alterity Therapeutics Limited$5.43
+0.05 (+0.93%)
D 20Pipeline Score Richly Valued Pharma · Clinical
Market Cap
3.51 B
EPS
-0.58
P/E Ratio
-6.94 $
Value Trade
62.84 K
-6.97 %
Week
-12.66 %
1 Month
24.7 %
3 Month
18.62 %
6 Month
-68.15 %
5 Year
-99.37 %
All Time
Cash Data
Cash Position
12.35 K
Monthly Burn
12.35 K
Runway
12,345 mo
Overview
Volume
5.82 K
52 Week Range
2.66 - 7
% held by Insiders
4.67 %
% held by Institutions
1.77 %
Enterprise Value
3.48 B
Total Shares
18.13 M
Short %
0.31 %
Float Shares
17.28 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Alterity Therapeutics Limited
573Total events
2Upcoming
70Tier-1 (high impact)
2007 – 2026Coverage
Upcoming catalysts 2
Event history 571
Jul 7, 2026
▲End Of Phase 2 MeetingATH434FDA Meeting
FDA End-of-Phase 2 meeting minutes received confirming registrational pathway
Multiple System Atrophysource ↗
Jun 9, 2026
▲End Of Phase 2 MeetingATH434FDA Meeting
Successful End-of-Phase 2 meeting with FDA agreeing on key elements of Phase 3 design
Multiple System Atrophysource ↗
Jun 2026
◆End Of Phase 2 MeetingATH434FDA Meeting
End-of-Phase 2 meeting with FDA
Multiple System Atrophysource ↗
May 27, 2026
May 18, 2026
◆Oral PresentationATH434Presentation
ATH434 Clinical Update and Phase 3 Planning at MSA Symposium 2026
Multiple System Atrophy (MSA)source ↗
May 15, 2026
◆Poster PresentationATH434Presentation
Results from a Randomized, Double-Blind, Placebo-Controlled Study of ATH434 in MSA using CSF NfL as a Covariate at MDSANZ Scientific Meeting
Multiple System Atrophy (MSA)source ↗
May 12, 2026
◆Oral PresentationPresentation
Quantitative Susceptibility Mapping Detects Progressive Iron Accumulation in Early MSA (Abstract #03335) at ISMRM 2026
Multiple System Atrophy (MSA)source ↗
May 11, 2026
▲PublicationPresentation
Publication of QSM MRI biomarker study in NeuroImage
Multiple System Atrophysource ↗
May 11, 2026
▲FDA Feedback ReceivedATH434FDA Meeting
Positive FDA feedback from two Type C meetings
Multiple System Atrophysource ↗
May 2026
▲Oral PresentationATH434Presentation
Oral presentation at ISMRM 2026 on QSM detecting progressive iron accumulation in early MSA
Multiple System Atrophysource ↗
May 2026
▲Poster PresentationATH434Presentation
Poster presentation at MDSANZ Scientific Meeting on Phase 2 results using CSF NfL as covariate
Multiple System Atrophysource ↗
Apr 30, 2026
Drug Pipeline Intelligence
D20
Pipeline Score $2M
Pipeline ValueRichly Valued
Valuation Signal2
Drugs Scored0.0x
rNPV / MCap Top 18%
Small Cap (rank 748 of 911)
Percentile RankAlterity Therapeutics Limited faces pipeline headwinds (20/100), with $16M risk-adjusted pipeline value, with 2 assets in development.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ATH434 Small molecule | Multiple System Atrophy | Phase 2 | NCT05864365 | 27% | $8M | COMPLETED | 10 | - | - | Feb 26, 2025 | - | Apr 1, 2025 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
ATH434 Fast TrackOrphan | Multiple System Atrophy | Phase 2 | 2026-06-09 | 48% slowing of disease progression versus placebo; clinically and statistically significant efficacy Read More | Alterity Therapeutics Achieves Alignment with U.S. FDA on Pivotal Phase 3 Program for ATH434 in Multiple System Atrophy Read More | |
ATH434 Fast TrackOrphan | Multiple System Atrophy | Phase 2 | 2026-06-09 | 48% slowing of disease progression versus placebo; clinically and statistically significant efficacy Read More | Alterity Therapeutics Achieves Alignment with U.S. FDA on Pivotal Phase 3 Program for ATH434 in Multiple System Atrophy Read More | |
ATH434 Fast TrackOrphan | Multiple System Atrophy | Phase 2 | 2026-06-09 | 48% slowing of disease progression versus placebo; clinically and statistically significant efficacy Read More | Alterity Therapeutics Achieves Alignment with U.S. FDA on Pivotal Phase 3 Program for ATH434 in Multiple System Atrophy Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in ATHE
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
ATHE Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
ATHE▼ -6.8%on this news
Alterity Therapeutics Receives FDA End-of-Phase 2 Meeting Minutes Confirming Registrational Pathway for ATH434 in Multiple System Atrophy
Alterity Therapeutics has received official FDA minutes confirming the outcomes of its End-of-Phase 2 meeting for ATH434 in treating Multiple System Atrophy (MSA). The FDA agreed that a single pivotal Phase 3 trial, along with confirmatory evidence, could support approval. The company plans to initiate Phase 3 trial activities by the end of 2026.
Read more →ATHE▲ +9.4%on this news
Alterity Therapeutics Achieves Alignment with U.S. FDA on Pivotal Phase 3 Program for ATH434 in Multiple System Atrophy
Alterity Therapeutics announced a successful End-of-Phase 2 meeting with the FDA, achieving alignment on the Phase 3 program for ATH434 in Multiple System Atrophy (MSA). The FDA approved key elements including the study population, dosing regimen, and primary endpoint. The pivotal trial is set to begin by the end of 2026, following promising Phase 2 results.
Read more →ATHEAlterity Therapeutics Data Presentations Support Advancement of ATH434 into Phase 3 in Multiple System Atrophy
Alterity Therapeutics announced advancements in its development program for ATH434, aimed at treating Multiple System Atrophy (MSA). Presentations at medical conferences highlighted promising Phase 2 data, including significant slowing of disease progression. The company plans to hold an end-of-Phase 2 FDA meeting in mid-2026 to discuss the path forward for Phase 3 trials.
Read more →ATHEAlterity Therapeutics Announces Publication Demonstrating the Utility of Quantitative MRI as a Biomarker for Multiple System Atrophy
Alterity Therapeutics announced a peer-reviewed study demonstrating that quantitative susceptibility mapping (QSM) MRI effectively detects disease-specific iron accumulation in Multiple System Atrophy (MSA) patients. This method can differentiate MSA from Parkinson's disease and correlates with clinical severity, supporting the use of QSM as an objective imaging biomarker. The findings enhance the potential for earlier diagnosis and monitoring of therapies like Alterity's ATH434.
Read more →ATHEAlterity Therapeutics to Deliver Presentations at Multiple Medical Conferences in May 2026
Alterity Therapeutics has announced its participation in several medical conferences in May 2026, where it will present findings related to its development program for Multiple System Atrophy (MSA). Key presentations will include updates on the clinical efficacy of its lead asset, ATH434, and its Phase 3 trial plans. The conferences will take place in locations such as Cape Town, Sydney, and London.
Read more →ATHEAlterity Therapeutics Releases Appendix 4C – Q3 FY26 Quarterly Cash Flow Report & Corporate Update
Alterity Therapeutics has reported positive developments regarding its ATH434 program for Multiple System Atrophy (MSA). The company has received FDA alignment for its Phase 3 program and presented new efficacy data from its Phase 2 trial. Leadership has been strengthened with new appointments, and discussions for strategic collaborations are ongoing. The company maintains a solid cash position.
Read more →ATHEAlterity Therapeutics Receives Positive FDA Feedback Following Second Type C Meeting on ATH434 Phase 3 Program in Multiple System Atrophy
Alterity Therapeutics has received positive feedback from the FDA following its second Type C Meeting regarding the Phase 3 program for ATH434 in treating Multiple System Atrophy (MSA). This feedback supports the company's plans for chemistry, manufacturing, and control elements of the program. The company is preparing for a pivotal trial and aims to finalize plans with the FDA by mid-2026.
Read more →ATHE▼ -6.5%on this newsshared move
Alterity Therapeutics Presents New Analysis of ATH434 Phase 2 Trial Data in Late Breaking Science Session of the American Academy of Neurology
Alterity Therapeutics presented new analyses of ATH434’s Phase 2 trial data during a Late Breaking Science Session at the American Academy of Neurology meeting. The results demonstrated a significant reduction in functional decline in Multiple System Atrophy (MSA) patients using the MuSyCA composite scale. The data confirmed ATH434’s efficacy in slowing disease progression, reinforcing the drug's clinical profile and paving the way for Phase 3 trial preparations.
Read more →ATHE▲ +12.6%on this news· ran to +30% by day 1shared move
Alterity Therapeutics Appoints Highly Experienced Biotech Executive Ann Cunningham to its Board of Directors
Alterity Therapeutics has appointed Ann Cunningham as an independent Non-Executive Director. With over 25 years in the biotech sector, Cunningham's expertise is expected to enhance the company's strategic direction as it prepares for the Phase 3 development of ATH434 for Multiple System Atrophy. Her experience in commercial strategy will be crucial for the company's growth.
Read more →ATHE▲ +6.4%on this news· ran to +30% by day 3shared move
Alterity Therapeutics Announces Late-Breaker Oral Presentation at the American Academy of Neurology Annual Meeting
Alterity Therapeutics announced that Dr. Daniel Claassen will present at the AAN Annual Meeting. The presentation will focus on the company's lead asset, ATH434, which has shown promising results in treating Multiple System Atrophy (MSA). Alterity is preparing to initiate a Phase 3 trial for this rare disease, furthering its commitment to neurodegenerative disease therapies.
Read more →ATHEAlterity Therapeutics to Host Virtual KOL Event to Share New Insights on ATH434 for the Treatment of Multiple System Atrophy
Alterity Therapeutics announced a virtual KOL event to discuss ATH434, its lead candidate for treating Multiple System Atrophy (MSA). The event will feature insights from prominent experts in the field, including Dr. Roy Freeman and Dr. Daniel Claassen. It aims to address the unmet needs in MSA treatment and provide updates on ongoing clinical trials.
Read more →ATHE▲ +13%on this news
Alterity Therapeutics Receives Positive FDA Feedback Following Type C Meeting on ATH434 Phase 3 Program
Alterity Therapeutics has announced that it received positive feedback from the FDA following a Type C Meeting regarding its Phase 3 program for ATH434, aimed at treating Multiple System Atrophy (MSA). This feedback confirms alignment with the FDA on critical clinical and non-clinical aspects as the company prepares to initiate the pivotal trial. CEO David Stamler highlighted this as a significant step toward further discussions, including an upcoming End-of-Phase 2 meeting scheduled for mid-2026.
Read more →ATHEAppendix 3B - Proposed issue of securities Announcement Summary Entity name ALTERITY THERAPEUTICS LIMITED Announcement Type New announcement Date of this announcement 19/3/2026 The Proposed issue is: A placement or other
Alterity Therapeutics Limited announced a proposed issue of 150 million options with an expiration date set for five years from the issuance at an exercise price of A$0.02. The announcement is part of a capital raising strategy, which needs security holder approval scheduled for May 27, 2026. If approved, this issuance aims to enhance the company's financial resources. However, uncertainties remain regarding the time frame for this approval and the specific uses of the raised funds.
Read more →ATHEMarch 2026 ASX Announcement UNMARKETABLE PARCEL SALE FACILITY Alterity Therapeutics Limited (ASX:ATH) (ATH or the Company ) announced today that it has established an opt-out unmarketable parcel sale facility ( Facility)
Alterity Therapeutics Limited (ASX:ATH) has introduced an opt-out unmarketable parcel sale facility for shareholders with less than $500 worth of shares. This initiative aims to facilitate the sale of small shareholdings without incurring brokerage fees. Approximately 59.2% of the company's shareholders fall under this category, representing a significant portion of their investor base. Shareholders wishing to retain their shares must act by submitting a retention form by April 24, 2026.
Read more →ATHEAlterity Therapeutics to Participate in the Bell Potter Healthcare Horizons Summit
Alterity Therapeutics announced that CEO David Stamler will participate in the Bell Potter Healthcare Horizons Summit on March 12-13, 2026. He will engage in a fireside chat focused on optimizing late-stage clinical trials and hold one-on-one meetings with investors. The company is preparing to initiate a Phase 3 trial for its lead asset, ATH434, which has shown promising results in earlier trials.
Read more →ATHEAlterity Therapeutics Appoints Daniel O. Claassen, M.D., M.S., as Chief Medical Advisor
Alterity Therapeutics has appointed Dr. Daniel O. Claassen as Chief Medical Advisor, effective March 2026. Dr. Claassen, a renowned neurologist with extensive experience in neurodegenerative diseases, will guide the clinical development of ATH434, which has shown efficacy in Phase 2 trials. His expertise is expected to be crucial as the company advances to Phase 3 trials.
Read more →ATHEAlterity Therapeutics Recognizes Multiple System Atrophy (MSA) Awareness Month in March and the Urgent Need for Disease-Modifying Treatments
Alterity Therapeutics is recognizing Multiple System Atrophy (MSA) Awareness Month while advancing its investigational therapy, ATH434, in late-stage clinical development. MSA is a rapidly progressive neurodegenerative disease with no approved treatments. The company highlights the urgent need for disease-modifying therapies, supported by positive Phase 2 trial results showing clinical benefits and a favorable safety profile for ATH434.
Read more →ATHEAlterity Therapeutics: Appendix 4C – Q2 FY26 Quarterly Cash Flow Report & Corporate Update
Alterity Therapeutics reported positive developments in its Phase 2 trial for ATH434, a treatment for Multiple System Atrophy (MSA). The company is preparing for an End-of-Phase 2 meeting with the FDA and has a robust cash position to support its advancement into Phase 3. The CEO highlighted the potential commercial opportunity for ATH434, estimated at US$2.4 billion.
Read more →ATHEJanuary 2026 Appendix 4C - Q2 FY26 Quarterly Cash Flow Report & Corporate Update Phase 2 Data Strengthened, Strong Cash Position, and Phase 3 Planning Well Advanced Highlights Phase 2 data for ATH434 in Multiple System A
Alterity Therapeutics (ATHE) reported its Q2 FY26 cash flow and corporate update, highlighting advancements in the Phase 2 trial of ATH434 for Multiple System Atrophy (MSA). The company announced strengthened efficacy signals and a planned End-of-Phase 2 meeting with the FDA in mid-2026 to discuss pivotal Phase 3 trial design. With a robust cash position of A$49.2 million, Alterity is well-positioned to continue its development efforts and engage in potential partnerships. The update reflects positive momentum in their disease-modifying therapy pipeline.
Read more →ATHEAlterity Therapeutics Issues Shareholder Letter Highlighting 2025 Progress and Key Objectives for 2026
Alterity Therapeutics has successfully completed its Phase 2 trials for ATH434, showing promising results in treating multiple system atrophy (MSA). The company is now preparing for a Phase 3 clinical program, aiming to address the unmet needs of MSA patients. With a strengthened leadership team and positive physician feedback, Alterity is positioned for significant growth in 2026.
Read more →ATHEAppendix 3G - Notification of issue, conversion or payment up of unquoted equity securities Announcement Summary Entity name ALTERITY THERAPEUTICS LIMITED Date of this announcement Thursday
Alterity Therapeutics Limited has announced the issuance of 18 million unlisted options as part of an employee incentive scheme, with an exercise price of $0.008 and an expiry date of January 9, 2031. This issuance is not intended to be quoted on the ASX and reflects the company’s strategy to motivate and retain key personnel. The announcement underscores the company's ongoing initiatives to enhance its financial framework through equity incentives.
Read more →ATHEJanuary 2026 Corporate Presentation Forward looking statements 2 This presentation may contain some statements that may be considered "Forward - Looking Statements", within the meaning of the US Securities Laws. Thus, an
Alterity presented positive findings from Phase 2 trials of ATH434, a drug candidate for treating Multiple System Atrophy (MSA), a Parkinsonian disorder with no approved treatments. The data suggests ATH434's potential as a disease-modifying therapy that addresses the underlying pathology of neurodegenerative diseases. The company emphasizes the importance of careful clinical development to ensure patient safety and regulatory approval. Additionally, they continue to explore the application of ATH434 for other related disorders, enhancing its therapeutic profile and market potential.
Read more →ATHEAppendix 3Y Change of Director ' s Interest Notice Rule 3.19A.2 Appendix 3Y Change of Director's Interest Notice Information or documents not available now must be given to ASX as soon as available. Information and docum
Alterity Therapeutics Limited has filed a Change of Director's Interest Notice for director David Stamler, indicating no new acquisitions of securities but reporting the expiration of significant unlisted options. The notice reflects existing holdings, with a notable disposition of over 91 million unlisted options, which has affected the overall securities position held by the director. No new interests or securities were acquired in this notice, emphasizing a period of inactivity in terms of new investment by the director.
Read more →ATHEAppendix 3H - Notification of cessation of securities Announcement Summary Entity name ALTERITY THERAPEUTICS LIMITED Announcement Type New announcement Date of this announcement Wednesday
Alterity Therapeutics Limited has announced the cessation of 91,392,720 options expiring on January 6, 2026. The options, identified as ATHAAD, have ceased due to expiry without any exercise or conversion. Following this cessation, the total issued capital will be affected, contributing to potential changes in the company's market capitalization. No consideration will be paid for this cessation, and further changes to capital may be impacted by pending announcements.
Read more →ATHEAppendix 3Z Final Director's Interest Notice Rule 3.19A.3 Appendix 3Z Final Director's Interest Notice Information or documents not available now must be given to ASX as soon as available. Information and documents given
Alterity Therapeutics Limited has submitted a Final Director's Interest Notice regarding its director Brian Meltzer. This notice includes details of Meltzer's relevant interests in securities, specifically noting a holding of 326,666 fully paid ordinary shares through BT Portfolio Services (SMSF). The notice complies with ASX listing rules and indicates that any unavailable information must be provided to ASX when available. The document outlines the formalities concerning the director's securities and contracts as mandated by corporate regulations.
Read more →ATHEAppendix 3X Initial Director's Interest Notice Rule 3.19A.1 Appendix 3X Initial Director's Interest Notice Information or documents not available now must be given to ASX as soon as available. Information and documents g
Alterity Therapeutics Limited submitted its Initial Director's Interest Notice to the ASX, detailing information about newly appointed director Julian Babarczy. The notice includes the director's securities interests where applicable, although no specific interests were reported. It is noted that all information submitted to ASX can become publicly available. The regulations concerning director's interests have been acknowledged.
Read more →ATHEResults of 2025 Annual General Meeting MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA - 21 November 2025: In accordance with ASX Listing rule 3.13.2 and Section 251AA of the Corporations Act 2001 (Cth), the attached informa
Alterity Therapeutics Limited held its Annual General Meeting on November 21, 2025, where shareholders approved several resolutions. The company has shown positive clinical data for its lead asset, ATH434, particularly in treating Multiple System Atrophy. Alterity continues to focus on developing innovative therapies for neurodegenerative diseases and has a robust drug discovery platform. CEO David Stamler authorized this announcement, highlighting the company's commitment to addressing significant medical needs.
Read more →ATHECEO's presentation Dr David Stamler 21 November 2025 Forward looking statements 2 This presentation may contain some statements that may be considered "Forward - Looking Statements", within the meaning of the US Securiti
Dr. David Stamler presented ATHE's ATH434, a promising drug candidate targeting multiple system atrophy (MSA) and other neurodegenerative diseases. The drug has received positive Phase 2 clinical data, demonstrating robust efficacy in a double-blind study. ATH434 also holds Orphan Drug designation, highlighting its potential to address significant unmet medical needs in the MSA patient population. The drug's oral administration is favored by both patients and doctors, enhancing its appeal in the competitive landscape of neurodegenerative treatments.
Read more →ATHEChairman's Address 2025 Annual General Meeting Good morning, everyone. Thank you for joining us here in Melbourne for Alterity Therapeutics' Annual General Meeting. Standing before you today is both a privilege and a poi
During the 2025 Annual General Meeting, Alterity Therapeutics' Chairman reflected on his two decades of leadership and the company's achievements in neurodegenerative disease therapies. The company has successfully completed Phase 2 trials for its lead asset, ATH434, in Multiple System Atrophy (MSA), showing promising results and receiving FDA recognition. The Chairman emphasized the positive impact on patients and families while also announcing his and another board member's departure, expressing confidence in the firm's future direction.
Read more →ATHEASX ANNOUNCEMENT 21 November 2025 Alterity Therapeutics Announces Board Changes to Support the Next Phase of Growth Alterity Therapeutics Limited ACN 080 699 065 (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company") ann
Alterity Therapeutics has announced key board changes ahead of its Annual General Meeting on November 21, 2025, to prepare for the next phase of growth. Founding shareholder Geoffrey Kempler and long-serving Non-Executive Director Brian Meltzer will retire, allowing new leaders to guide the company's future. The strategic succession plan aims to ensure continuity and leverage diverse skills amidst the advancement of its lead clinical asset, ATH434, towards Phase 3 development for Multiple System Atrophy.
Read more →ATHEASX ANNOUNCEMENT 13 November 2025 Disclosure under Takeovers Panel Guidance Note 20: Equity Derivatives Alterity Therapeutics Limited ACN 080 699 065 (ASX: ATH, NASDAQ: ATHE) ("the Company") advises that it has received
Alterity Therapeutics Limited has disclosed receipt of a notice from Regal Funds Management Asia Pte Limited regarding long equity derivative positions under the Australian Takeovers Panel Guidance Note 20. The notice pertains to two funds managed by Regal, namely the Amazon Market Neutral Fund and the Zambezi Absolute Return Fund. The disclosed positions include 50,000,000 ordinary shares as of November 10, 2025, equivalent to 0.46% of total shares, with no material changes to prior disclosures reported.
Read more →ATHEAlterity Therapeutics to Present at the Bell Potter Healthcare Virtual Conference
Alterity Therapeutics announced that CEO David Stamler will present a corporate update at the Bell Potter Healthcare Virtual Conference. The company focuses on developing disease-modifying therapies for neurodegenerative diseases, particularly Parkinson's disease. Their lead asset, ATH434, has shown promising results in clinical trials for Multiple System Atrophy.
Read more →ATHE▲ +8.3%on this newsshared move
Alterity Therapeutics Presents Promising Impact of ATH434 on Orthostatic Hypotension and Disease Progression in MSA at the 36th International Symposium on the Autonomic Nervous System
Alterity Therapeutics presented data on ATH434's impact on orthostatic hypotension and disease progression in Multiple System Atrophy (MSA) at the 36th International Symposium on the Autonomic Nervous System. The analysis from the Phase 2 trial indicated promising efficacy, particularly in the higher dose group. The company is preparing for Phase 3 trials and has received FDA designations for ATH434.
Read more →ATHE▼ -8.5%on this news
Alterity Therapeutics: Appendix 4C – Q1 FY26 Quarterly Cash Flow Report
Alterity Therapeutics has released its Q1 FY26 cash flow report, highlighting positive clinical results for ATH434 in treating Multiple System Atrophy (MSA). The company is preparing for a Phase 3 trial and has engaged with the FDA to discuss necessary data. With a cash position of A$54.56M, Alterity is optimistic about ATH434's market potential.
Read more →ATHE▼ -8.5%on this newsshared move
Appendix 4C - Q1 FY26 Quarterly Cash Flow Report Highlights New analysis of ATH434-201 double blind trial strengthens efficacy signal at high dose level Positive data from ATH434-202 open-label trial demonstrates similar
Alterity Therapeutics has reported positive results in its ongoing clinical trials for ATH434, a treatment for Multiple System Atrophy (MSA). The recent quarterly cash flow report highlights the positive outcomes of the ATH434-201 double-blind trial as well as favorable data from the ATH434-202 open-label study. The company is also engaging with the U.S. FDA to prepare for a potential Phase 3 trial, indicating promising progress in the regulatory process. Overall, Alterity's findings strengthen its position in the neurodegenerative disease treatment market.
Read more →ATHEALTERITY THERAPEUTICS LIMITED ("the Company") ABN 37 080 699 065 21 October 2025 ALTERITY THERAPEUTICS LIMITED ANNUAL GENERAL MEETING - NOTICE AND PROXY FORM Dear Shareholders 2025 ANNUAL GENERAL MEETING The Company's an
Alterity Therapeutics Limited is set to hold its Annual General Meeting on November 21, 2025, at Deloitte Australia's offices in Melbourne. The meeting will cover the company's financial report for the year ending June 30, 2025, among other resolutions. Shareholders are encouraged to submit proxy votes and questions in advance. Additionally, the company will provide updates through its website and ASX Announcement Platform if there are any changes to the meeting's arrangements.
Read more →ATHE▲ +5.9%on this news
Form 604 Corporations Act 2001 Section 671B Notice of change of interests of substantial holder To Company Name/Scheme Alterity Therapeutics ltd (ATH) ACN/ARSN 080 699 065 1. Details of substantial holder (1) Name Regal
Regal Funds Management Pty Limited has reported an increase in its substantial holding in Alterity Therapeutics Ltd, raising its voting power from 13.76% to 14.93% as of October 10, 2025. This change follows a series of transactions in which Regal acquired additional ordinary shares across multiple dates. The company aims to maintain control over its voting interests for strategic decision-making within Alterity Therapeutics.
Read more →ATHEAlterity Therapeutics Presents Positive Data from ATH434 Phase 2 Trial at the 2025 International Congress of Parkinson’s Disease and Movement Disorders
Alterity Therapeutics presented positive data from its Phase 2 trial of ATH434 for Multiple System Atrophy (MSA) at the 2025 MDS Congress. The trial demonstrated that ATH434 slowed disease progression and stabilized orthostatic hypotension. New analyses strengthened the efficacy signal, particularly at the 75 mg dose. The study also advanced understanding of MSA diagnosis through neuroimaging and biomarker analysis.
Read more →ATHE▲ +6.1%on this news
Alterity Therapeutics to Deliver Multiple Presentations at the 2025 International Congress of Parkinson’s Disease and Movement Disorders
Alterity Therapeutics announced that data from its ATH434-201 Phase 2 trial will be presented at the 2025 International Congress of Parkinson's Disease and Movement Disorders. The trial demonstrated significant clinical efficacy and safety for ATH434 in treating Multiple System Atrophy (MSA). This presentation aims to inform the movement disorder community about ATH434's potential as a disease-modifying therapy.
Read more →ATHESeptember 2025 ASX Announcement DATE OF AGM AND CLOSING DATE FOR DIRECTOR NOMINATIONS Alterity Therapeutics Limited (ASX:ATH, NASDAQ:ATHE) ( Alterity or the Company ) advises that, in accordance with ASX Listing Rule 3.1
Alterity Therapeutics Limited has announced that its Annual General Meeting (AGM) will take place on November 21, 2025. The closing date for director nominations is set for October 1, 2025. Stakeholders can expect further details in a forthcoming Notice of Meeting, which will be shared with shareholders and made available on the company's website.
Read more →ATHEForm 604 Corporations Act 2001 Section 671B Notice of change of interests of substantial holder To Company Name/Scheme Alterity Therapeutics Limited ACN/ARSN 080 699 065 1. Details of substantial holder (1) Name The Bank
The Bank of New York Mellon Corporation has reported a change in its substantial holding in Alterity Therapeutics Limited, as per the Form 604 notice. Their voting power has decreased from 29.29% to 25.16%, reflecting changes in their relevant interests in voting shares. The report details specific class and number of securities affected, alongside changes in association with pertinent entities within the BNYMC Group. The notice is dated September 16, 2025.
Read more →ATHEAlterity Therapeutics Presents ATH434-201 Phase 2 Data at the American Neurological Association Annual Meeting
Alterity Therapeutics presented data from its ATH434-201 Phase 2 trial at the American Neurological Association Annual Meeting. The study showed that ATH434 effectively slowed disease progression in patients with Multiple System Atrophy (MSA) and was well tolerated. The findings highlight ATH434's potential as a disease-modifying therapy, with positive implications for patient outcomes.
Read more →ATHEAppendix 2A - Application for quotation of securities Announcement Summary Entity name ALTERITY THERAPEUTICS LIMITED Announcement Type New announcement Date of this announcement Monday
ALTERITY THERAPEUTICS LIMITED has announced the application for quotation of over 1.66 billion new ordinary securities on the ASX, following previous announcements regarding securities issuance. This move is part of a broader strategy to enhance its capital structure and market presence, with the quoted securities expected to boost the overall issued capital of the company. The issue price for the new securities is set at AUD 0.012, which may attract investor interest. However, no specific negatives were highlighted in the announcement.
Read more →ATHEASX ANNOUNCEMENT 15 September 2025 Notice Under Section 708A(5)(e) of the Corporations Act This notice is given by Alterity Therapeutics Limited ACN 080 699 065 (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), und
Alterity Therapeutics Limited has issued a notice under section 708A(5)(e) of the Corporations Act regarding its issuance of fully paid ordinary shares. The notice indicates that on 15 September 2025, the company issued 1,666,666,663 shares. This announcement is part of the company's compliance with regulatory requirements in Australia.
Read more →ATHEAlterity Therapeutics Raises A$20.0 million in Strategic Placement
Alterity Therapeutics has successfully raised A$20 million through a placement to professional investors. The funds will support the development of ATH434, which has shown positive results in Phase 2 trials for Multiple System Atrophy. CEO David Stamler expressed optimism about the company's future and plans to engage with the FDA regarding further development.
Read more →ATHEAppendix 3B - Proposed issue of securities Announcement Summary Entity name ALTERITY THERAPEUTICS LIMITED Announcement Type New announcement Date of this announcement 8/9/2025 The Proposed issue is: A placement or other
Alterity Therapeutics Limited has announced a proposed placement to issue approximately 1.67 billion ordinary fully paid securities. The proposed issue will be priced at AUD 0.012 per security and is subject to ASX approval. The company aims to utilize this funding mechanism for potential business initiatives, although specific purposes for the raised funds have not been disclosed.
Read more →ATHEMarket Announcement 4 September 2025 Alterity Therapeutics Limited (ASX: ATH) - Trading Halt Trading in the securities of Alterity Therapeutics Limited ( ATH') will be halted at the request of ATH, pending the release of
Alterity Therapeutics Limited has requested a trading halt for its securities at the Australian Securities Exchange (ASX) pending the announcement of significant information. The trading halt will remain in effect unless ASX decides otherwise, potentially impacting investor sentiment. Details regarding the nature of the anticipated announcement remain undisclosed, leading to uncertainty in the market regarding the company's future actions.
Read more →ATHEAlterity Therapeutics to Present at the Biotech Showcase
Alterity Therapeutics announced that CEO David Stamler will present a corporate update at the Biotech Showcase on September 3, 2025, in Australia. The company focuses on developing disease-modifying therapies for neurodegenerative diseases, particularly Parkinson's disease. Their lead asset, ATH434, has shown promising results in clinical trials for Multiple System Atrophy.
Read more →ATHEAlterity Therapeutics Filed Form 20-F and XBRL data with the SEC MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA - 2 September 2025: Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnolo
Alterity Therapeutics has filed its Annual Report on Form 20-F with the US SEC, containing audited financial statements for the year ending June 30, 2025. The report highlights ongoing efforts in developing disease-modifying treatments for neurodegenerative diseases, particularly focusing on the drug ATH434 for Parkinson's-related conditions. Despite the positive clinical trial outcomes, the company faces several risks related to drug development, financing, and regulatory approvals.
Read more →ATHERules 4.7.3 and 4.10.3 Appendix 4G Key to Disclosures Corporate Governance Council Principles and Recommendations Name of entity Alterity Therapeutics Ltd ABN/ARBN Financial year ended: 37 080 699 065 30 June 2025 Our co
Alterity Therapeutics Ltd has released its corporate governance statement as required by the ASX Corporate Governance Council. This statement details the extent to which the company has adhered to governance recommendations during the financial year ending 30 June 2025. The governance statement, which has been approved by the board, is accessible via the company's investor center online. Additionally, the document outlines the processes for board evaluation and diversity policy disclosures.
Read more →ATHEAppendix 2A - Application for quotation of securities Announcement Summary Entity name ALTERITY THERAPEUTICS LIMITED Announcement Type New announcement Date of this announcement Friday
Alterity Therapeutics Limited has announced the quotation of 1,283,942 ordinary fully paid securities on the ASX as a result of options being exercised. This follows their earlier securities classification under Appendix 2A of the ASX. The securities, issued at an issue price of AUD 0.01, are part of the existing class and will be available following the exercise and conversion of previously issued options. This development may increase the company's total issued capital, reflecting a potentially positive outlook for future trading.
Read more →ATHEAppendix 3G - Notification of issue, conversion or payment up of unquoted equity securities Announcement Summary Entity name ALTERITY THERAPEUTICS LIMITED Date of this announcement Friday
Alterity Therapeutics Limited announced the issuance of unquoted equity securities not intended for quoting on ASX as part of an employee incentive scheme. The company plans to issue 312,400,200 unlisted options expiring on August 8, 2030, at an exercise price of US$0.0086. Notably, CEO David Stamler will receive a substantial number of these securities. This move reflects the company's strategy to bolster employee incentives while also managing its current equity structure.
Read more →ATHEMarket Announcement 4 August 2025 Attached for the information of the market are ASX's query letters to Alterity Therapeutics Limited (ASX:ATH) dated 24 July 2025 and 30 July 2025 and ATH's responses 28 July 2025 and 3 A
On August 4, 2025, Alterity Therapeutics Limited (ASX: ATH) received queries from the ASX regarding its compliance with Listing Rules. These queries stemmed from an isolated error by ATH in categorizing a prior announcement as market-sensitive, prompting an internal review of their governance processes. The ASX has emphasized the importance of immediate disclosure of certain information and warned that failure to comply could result in a suspension of trading for ATH.
Read more →ATHEJuly 2025 Corporate Presentation Forward looking statements 2 This presentation may contain some statements that may be considered "Forward - Looking Statements", within the meaning of the US Securities Laws. Thus, any f
Alterity Therapeutics presented its forward-looking statements during a corporate presentation, focusing on the development of ATH434 for treating multiple system atrophy, a condition currently lacking approved therapies. The company has showcased positive Phase 2 data, highlighting robust efficacy and a large market potential. ATH434 has received Fast Track and Orphan Drug designations, reflecting its significance. However, the company acknowledges uncertainties in projections and potential risks associated with its future trajectory.
Read more →ATHEAppendix 4C – Q4 FY25 Quarterly Cash Flow Report
Alterity Therapeutics announced its Q4 FY25 cash flow report, highlighting the U.S. FDA's Fast Track designation for ATH434 in treating Multiple System Atrophy (MSA). The company reported positive clinical data from its Phase 2 trials, indicating ATH434's efficacy in slowing disease progression and improving symptoms. The cash position as of June 30, 2025, was A$40.66M.
Read more →ATHEAppendix 4C - Q4 FY25 Quarterly Cash Flow Report Highlights Granted U.S. FDA Fast Track Designation for ATH434 to treat Multiple System Atrophy (MSA) Reported positive topline data from open-label Phase 2 clinical trial
Alterity Therapeutics reported key highlights in its Q4 FY25 Quarterly Cash Flow Report, notably the U.S. FDA granting Fast Track designation for ATH434 to treat Multiple System Atrophy (MSA). The company also disclosed positive topline data from the Phase 2 ATH434-201 and ATH434-202 clinical trials, indicating significant clinical benefits such as disease progression slowdown and improvement in neurological symptoms. Overall, the results bolster Alterity's confidence in advancing its MSA program, showcasing ATH434's potential as a disease-modifying therapy.
Read more →ATHE▼ -14.8%on this newsshared move
Alterity Therapeutics Reports Positive Topline Data from Open-Label Phase 2 Clinical Trial of ATH434 in Multiple System Atrophy
Alterity Therapeutics announced positive topline data from its open-label Phase 2 trial of ATH434 in patients with multiple system atrophy (MSA). The trial showed significant clinical benefits, including stabilization of neurological symptoms and reduced disease progression. Neuroimaging results indicated slowed brain atrophy, reinforcing the drug's potential as a treatment for MSA.
Read more →ATHE▼ -14.8%on this newsshared move
Page 1 of 2 15 July 2001 Form 604 Corporations Act 2001 Section 671B Notice of change of interests of substantial holder To Company Name/Scheme Alterity Therapeutics Limited ACN/ARSN 080 699 065 1. Details of substantial
The Bank of New York Mellon Corporation (BNYMC) has reported a change in its substantial holding in Alterity Therapeutics Limited (ATHE). As of July 24, 2025, BNYMC holds approximately 29.29% of the voting shares, an increase from 28.04%. The details of the changes in the number of shares held include various deposits and transfers made over the period from July 7 to July 24, 2025. This report is in compliance with the Corporations Act 2001 and outlines the nature of interests held by BNYMC and its associates.
Read more →ATHE▲ +13.8%on this news· ran to +31% by day 1shared move
Alterity Therapeutics Announces Publication on Novel MRI Endpoint from the bioMUSE Natural History Study - Peer-reviewed publication in Annals of Clinical and Translational Neurology highlights the use of the MSA Atrophy
Alterity Therapeutics has announced the publication of research on the MSA Atrophy Index, an innovative neuroimaging measure for diagnosing and tracking Multiple System Atrophy (MSA), in the Annals of Clinical and Translational Neurology. The study utilized advanced deep learning techniques to improve the assessment of brain atrophy in MSA patients, aiming for more accurate diagnoses and monitoring of disease progression. The findings correlated significant brain volume reductions over time with clinical worsening of MSA, supporting the use of this index in clinical settings. This advancement may lead to better patient selection in clinical trials and improved outcomes in therapy addressing this neurodegenerative disease.
Read more →ATHEAppendix 2A - Application for quotation of securities Announcement Summary Entity name ALTERITY THERAPEUTICS LIMITED Announcement Type New announcement Date of this announcement Thursday
Alterity Therapeutics Limited has announced the application for quotation of 79,999,800 ordinary fully paid securities on the ASX. This issuance is part of options being exercised or convertible securities being converted. The exercise of these options reflects the company’s proactive approach to its securities management, indicating ongoing investment interest and potential capital growth. The company reported that the new securities will rank equally with existing ordinary shares, with an exercise price set at USD 0.003 per security.
Read more →ATHEJuly 2025 By email: melissa.kostopoulos@asx.com.au Melissa Kostopoulos Adviser, Listings Compliance (Melbourne) ASX Limited Dear Melissa Response to Price Query We refer to your letter dated 11 July 2025 wherein the ASX
Alterity Therapeutics Limited (ASX: ATH) has responded to the ASX regarding an increase in its share price and trading volume observed on July 11, 2025. The company confirmed it is unaware of any undisclosed information that would explain the trading activity. However, it noted anticipation surrounding two data releases expected mid-year 2025 and scheduled investor meetings. The company reaffirmed its compliance with ASX Listing Rules and provided details about its continuous disclosure policy to the ASX.
Read more →ATHEAppendix 3H - Notification of cessation of securities Announcement Summary Entity name ALTERITY THERAPEUTICS LIMITED Announcement Type New announcement Date of this announcement Monday
Alterity Therapeutics Limited has announced the cessation of two security options, ATHAAE and ATHAAG, due to the lapse of conditional rights. A total of 4,250,000 and 400,000 respective options have expired unexercised. The announcement indicates that these conditions have not been, or have become incapable of being, satisfied, potentially signaling challenges for the company's future capital raising efforts. The company's updated issued capital reflects a comprehensive total of remaining equity securities available post-cessation.
Read more →ATHEAlterity Therapeutics to Provide Corporate Update in Fireside Chat MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA - 23 June 2025: Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology
Alterity Therapeutics announced that CEO David Stamler will participate in a Fireside Chat to provide a corporate update on June 25, 2025. The focus will be on the progress made in the ATH434 development program for Multiple System Atrophy, following positive Phase 2 trial results released in January. This event underscores the company's commitment to developing disease-modifying treatments for neurodegenerative diseases.
Read more →ATHE▼ -8.5%on this news· ran to -21% by day 3
Alterity Therapeutics Prominently Featured at the International MSA Congress - ATH434 Phase 2 data demonstrated clinically meaningful efficacy on multiple clinical endpoints - - MSA Atrophy Index (MSAai) enhances MSA dia
Alterity Therapeutics recently showcased promising data from its ATH434 Phase 2 clinical trial at the International MSA Congress, highlighting significant efficacy in treating Multiple System Atrophy (MSA). The trial results demonstrate a clinically meaningful reduction in disease severity, with improvements in daily living activities compared to placebo. Additionally, the newly developed MSA Atrophy Index offers enhanced diagnostic capabilities essential for monitoring the disease's progression. Alterity's commitment to advancing therapeutic options for MSA patients is reinforced by positive outcomes from the trial and continued clinical development efforts.
Read more →ATHE▲ +13.5%on this newsshared move
Alterity Therapeutics Announces Multiple Oral and Poster Presentations to be Featured at the International MSA Congress -ATH434 Phase 2 Data to be Presented at Opening Plenary Session - MELBOURNE, AUSTRALIA AND SAN FRANC
Alterity Therapeutics has announced the presentation of its clinical programs related to Multiple System Atrophy (MSA) at the upcoming International MSA Congress from May 9-11, 2025, in Boston. CEO David Stamler will present data from the Phase 2 trial of ATH434, a therapy designed to slow disease progression in MSA, which has demonstrated robust clinical efficacy in preliminary results. Additionally, the company is sponsored at the congress, emphasizing its commitment to improving the quality of life for those affected by MSA.
Read more →ATHEAlterity Therapeutics Announces Multiple Oral and Poster Presentations to be Featured at the International MSA Congress
Alterity Therapeutics announced that it will showcase multiple oral and poster presentations at the 2025 International MSA Congress in Boston. This includes data from their Phase 2 clinical trial for ATH434, demonstrating its efficacy in slowing disease progression in Multiple System Atrophy (MSA). The congress, focusing on MSA research, allows Alterity to engage with the medical community and support patient advocacy. The company's advancements and recent Fast Track Designation from the FDA signify increasing interest and potential for its lead compound.
Read more →ATHE▲ +26.5%on this newsshared move
Alterity Therapeutics Granted U.S. FDA Fast Track Designation for ATH434 to Treat Multiple System Atrophy - Fast Track Designation highlights potential of ATH434 to address high unmet need for individuals with MSA - MELB
Alterity Therapeutics announced that its candidate ATH434 has been granted Fast Track designation by the U.S. FDA for the treatment of Multiple System Atrophy (MSA). This designation acknowledges the drug's potential in addressing the significant unmet medical needs of MSA patients, a condition for which there are currently no approved therapies. The decision follows promising results from the double-blind Phase 2 clinical trial, which reported robust efficacy and a favorable safety profile. The Fast Track designation allows for expedited development and closer collaboration with the FDA as Alterity moves forward in its clinical programs.
Read more →ATHEAppendix 4C - Q3 FY25 Quarterly Cash Flow Report Highlights Reported positive topline data for ATH434-201 randomized, double-blind Phase 2 clinical trial in Multiple System Atrophy (MSA) led by robust clinical efficacy P
Alterity Therapeutics reported positive topline data from its Phase 2 trial of ATH434 for Multiple System Atrophy (MSA), indicating significant potential as a disease-modifying treatment. The trial showed a clinically significant reduction in disease severity and improvements in quality of life measured by various scales. Additionally, the company completed its open-label trial for advanced MSA and secured A$15.0M in financing to accelerate the development of ATH434. They plan to engage with regulatory authorities to further advance treatment options for MSA patients.
Read more →ATHEAppendix 3Y Change of Director's Interest Notice Rule 3.19A.2 Appendix 3Y Change of Director's Interest Notice Information or documents not available now must be given to ASX as soon as available. Information and documen
The ASX has received a Change of Director's Interest Notice for Alterity Therapeutics Limited. This notice includes details of three directors: Peter Marks, Lawrence Gozlan, and Brian Meltzer, along with their relevant interests in securities. The report indicates that there have been changes in the number of options held by these directors, but no securities were disposed of or acquired in a significant manner. The information disclosed must be made public as per ASX regulations.
Read more →ATHEAlterity Therapeutics Presents ATH434-201 Phase 2 Clinical Trial Results at European MSA Symposium MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA - 28 April 2025: Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" o
Alterity Therapeutics presented the positive results of its ATH434-201 Phase 2 clinical trial at the European MSA Symposium. The trial showed a significant reduction in disease severity in patients with Multiple System Atrophy (MSA) when treated with ATH434. Notably, the 50 mg dose achieved a 48% relative treatment effect, and improvements were also observed in patient mobility and neuroimaging outcomes. ATH434 was well tolerated with no serious adverse events reported, indicating its potential for further development as a therapy for MSA.
Read more →ATHEAs at Date: 16 - Apr - 2025 Top Holders Grouped Report Alterity Therapeutics Limited Security Class(es): ATHOPTWC25 - LISTED OPT EXP 26/02/2027 @ $0.028 Display Top: 20 ABN: 27 152 260 814 Level 5, 126 Phillip Street, Sy
On April 16, 2025, Alterity Therapeutics Limited released a report detailing the ownership structure of its securities, specifically for the class ATHOPTWC25, which will expire on February 26, 2027. UBS Nominees Pty Ltd holds the largest share at 29.25%, followed by Citicorp Nominees Pty Limited at 18.11%. The report lists the top 20 shareholders, accounting for roughly 97.89% of the total issued capital of 1,222,300,911 shares. The data provides insights into the distribution of major holders within the company.
Read more →ATHEAppendix 2A - Application for quotation of securities Announcement Summary Entity name ALTERITY THERAPEUTICS LIMITED Announcement Type New announcement Date of this announcement Tuesday
Alterity Therapeutics Limited has announced its application for the quotation of a new class of securities on the ASX, with an exercise price of $0.028, set to expire on February 26, 2027. A total of 1,222,300,911 options are involved in this issuance, reflecting the company’s strategy to raise additional working capital. The announcement includes details pertaining to the quoted and issued capital following this quotation. The company's registered number is ABN 37080699065, and the application suggests proactive steps toward funding its operational needs.
Read more →ATHEDavid Stamler, MD CEO April 2025 Forward Looking Statements This presentation may contain some statements that may be considered "Forward - Looking Statements", within the meaning of the US Securities Laws . Thus, any fo
Alterity Therapeutics, led by CEO David Stamler, aims to transform treatments for neurodegenerative diseases, particularly Multiple System Atrophy (MSA). The company reported positive Phase 2 clinical results for its drug candidate, ATH434, which shows robust efficacy in a patient population that currently lacks approved therapies. With Orphan Drug Designation granted in both the U.S. and Europe, Alterity is strategically positioned to address significant unmet needs in neurodegenerative disorders. The team's extensive experience in neurology adds to the hopeful outlook for ATH434 and its potential market impact.
Read more →ATHEALTERITY THERAPEUTICS LIMITED [ACN 080 699 065] ("the Company") OPTIONS PROSPECTUS This prospectus ( Prospectus ) contains the following offers of options ( New Options ) (each with an exercise price of A$0.028 (2.8 Aust
Alterity Therapeutics Limited has released a prospectus detailing offers of new options with an exercise price of A$0.028, expiring on 26 February 2027. These options are aimed at facilitating secondary trading and were approved by shareholders at a recent general meeting. The company cautions that the offered securities are highly speculative and emphasizes the importance of thorough investor due diligence before participation. The closing date for these offers is set for 22 April 2025, subject to possible changes.
Read more →ATHETopline Data from a Randomized, Double Blind, Placebo Controlled Phase 2 Study of ATH434 in MSA David Stamler 1 , Cynthia Wong 1 , Paula Trujillo 2 , Margaret Bradbury 1 , Christine Lucas 1 and Daniel Claassen 2 1 Alteri
Alterity Therapeutics has released topline data from a Phase 2 study of ATH434 in patients with Multiple System Atrophy (MSA). The study indicates that ATH434 demonstrated clinically meaningful efficacy in modifying disease progression, with significant reductions in alpha-synuclein and oxidative injury. However, differences in baseline pathology may have affected treatment responses. Adverse events were reported at similar rates across all groups, warranting further exploration of ATH434's efficacy and safety.
Read more →ATHEAlterity Therapeutics Presents Encouraging New Data from its ATH434 Phase 2 Trial in Multiple System Atrophy at the American Academy of Neurology Annual Meeting - Clinically Meaningful Efficacy Observed on Multiple Asses
Alterity Therapeutics presented encouraging data from its ATH434 Phase 2 trial during the American Academy of Neurology Annual Meeting. The trial demonstrated clinically significant treatment effects, including a 48% decrease in clinical progression at the 50 mg dose. Imaging results indicated effective target engagement of ATH434 in MSA-affected brain regions, highlighting its potential as a disease-modifying therapy. The company is poised to continue its development and engagement with regulatory authorities for further advancement of this candidate.
Read more →ATHE▼ -8.2%on this newsshared move
Page 1 of 2 15 July 2001 Form 604 Corporations Act 2001 Section 671B Notice of change of interests of substantial holder Alterity Therapeutics Limited To Company Name/Scheme 080 699 065 ACN/ARSN 1. Details of substantial
Alterity Therapeutics Limited received a substantial holding notice from The Bank of New York Mellon Corporation (BNYMC), reflecting changes in voting interests in the company. As of February 18, 2025, BNYMC's voting power has decreased to 24.95% from a previous 33.96%. The notice details various transactions affecting the number of shares held, including deposits and transfers of ordinary shares. The announcement aims to disclose changes in the interests of the substantial holder as mandated by the Corporations Act 2001.
Read more →ATHEAlterity Therapeutics Announces Completion of Placement MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA - 7 April 2025: Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company de
Alterity Therapeutics announced the successful completion of its second tranche of capital placement, securing A$38.79 million to further its drug development efforts. The funding, which saw participation from key company executives and board members, will be directed toward advancing regulatory activities and developing ATH434, its lead candidate. ATH434 has shown promise in treating Multiple System Atrophy (MSA) and recently achieved positive results in a Phase 2 clinical trial. The company is focused on developing disease-modifying therapies for neurodegenerative diseases.
Read more →ATHEASX ANNOUNCEMENT 07 April 2025 Notice Under Section 708A(5)(e) of the Corporations Act This notice is given by Alterity Therapeutics Limited ACN 080 699 065 (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), under s
Alterity Therapeutics Limited has issued a notice under section 708A(5)(e) of the Corporations Act 2001. The notice indicates the issuance of 2,470,521,806 fully paid ordinary shares. The announcement was made on April 7, 2025. The company is registered under ACN 080 699 065 and listed on both ASX and NASDAQ.
Read more →ATHE▼ -5.4%on this news· ran to -18% by day 3shared move
Alterity Therapeutics to Deliver an Oral Presentation of the Positive ATH434 Phase 2 Trial Results at the American Academy of Neurology Annual Meeting MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA - 3 April 2025: Alterity
Alterity Therapeutics has announced that it will deliver oral and poster presentations on the positive results of its ATH434 Phase 2 trial at the upcoming American Academy of Neurology Annual Meeting. This trial demonstrated significant improvements in patients with early-stage Multiple System Atrophy (MSA), with ATH434 shown to improve daily functioning and motor performance. The company has also utilized wearable sensor technology to further evaluate treatment outcomes. ATH434's progression has led to its Orphan Drug Designation, enhancing its potential for market success in treating neurodegenerative diseases.
Read more →ATHEDisclosure of Proxy Votes Alterity Therapeutics Limited Extraordinary General Meeting Monday, 31 March 2025 GPO Box 5193, Sydney, NSW 2001 P 1300 288 664 (aus) or +61 (0)2 9698 5414 (world) F +61 (0)2 8583 3040 E hello@a
Alterity Therapeutics Limited announced the results from its extraordinary general meeting held on March 31, 2025. All proposed resolutions regarding the issuance of shares and options received strong support, with the majority of votes exceeding 90% in favor. This indicates a robust endorsement of the company's strategies from its shareholders, demonstrating their confidence in the company's future endeavors.
Read more →ATHEAlterity Therapeutics Completes Last Patient Visit in ATH434-202 Open-Label Phase 2 Trial in Multiple System Atrophy - ATH434 is a Disease Modifying Drug Candidate Targeting Parkinsonian Disorders - - Topline Data Expect
Alterity Therapeutics has announced the completion of the last patient visit in the ATH434-202 Phase 2 trial for treating advanced multiple system atrophy (MSA). This open-label study aims to evaluate the safety, efficacy, and target engagement of ATH434, a drug candidate designed for neurodegenerative diseases. The topline data from this trial is expected to be reported by mid-year 2025, following previously successful results from a randomized Phase 2 trial. The study's findings could offer crucial insights for further development of ATH434 as a treatment option for MSA.
Read more →ATHEPage 1 of 2 Form 605 Corporations Act 2001 Section 671B Notice of ceasing to be a substantial holder To Company Name/Scheme ALTERITY THERAPEUTICS LTD ACN/ARSN/ABN 37 080 699 065 1. Details of substantial holder (1) Name
JPMorgan Chase & Co. has officially ceased to be a substantial holder in Alterity Therapeutics Ltd as of March 20, 2025. This change follows various transactions involving the rehypothecation of client securities and changes in relevant interests of JPMorgan's subsidiaries. The previous notice from the company was dated March 11, 2025. No specific risks or optimistic aspects are indicated in the document, leaving the news largely procedural in nature.
Read more →ATHEForm 603 Corporations Act 2001 Section 671B Notice of initial substantial holder To Company Name/Scheme ALTERITY THERAPEUTICS LTD ACN/ARSN/ ABN 37 080 699 065 1. Details of substantial holder (1) Name JPMorgan Chase & Co
JPMorgan Chase & Co. has become a substantial holder in Alterity Therapeutics Ltd as of March 11, 2025, with a voting power of 5.13%. The total number of votes it holds is 341,554,014 ordinary shares, signifying its significant stake in the company. This status could impact company decision-making, particularly concerning shareholder meetings and votes. The acquisition details also reveal various relevant interests held by JPMorgan's affiliates, further indicating their substantial financial involvement.
Read more →ATHEAlterity Therapeutics Limited Appendix 4D Half-year ended 31 December 2024 Name of entity: Alterity Therapeutics Limited ABN: 37 080 699 065 Half-year ended: 31 December 2024 Previous period: 31 December 2023 Results for
Alterity Therapeutics Limited has reported financial results for the half-year ending December 31, 2024. Revenue decreased by 6% to $111,299 while the net loss rose by 10.2% to $7,173,335 compared to the previous year. Despite these financial challenges, Alterity achieved significant progress in clinical trials for its lead product, ATH434, demonstrating positive results in treating Multiple System Atrophy. The company also secured Orphan Drug Designation from regulatory agencies, highlighting its potential in addressing rare neurodegenerative conditions.
Read more →ATHE▲ +6.6%on this news
Appendix 3B - Proposed issue of securities Announcement Summary Entity name ALTERITY THERAPEUTICS LIMITED Announcement Type New announcement Date of this announcement 24/2/2025 The Proposed issue is: A placement or other
Alterity Therapeutics Limited has announced a proposed placement of securities, specifically offering options with an exercise price of $0.028, expiring on February 26, 2027. This initiative aims to enhance the company's capital resources, and security holder approval is expected to be sought by March 31, 2025. The announcement adheres to ASX Listing Rules and outlines the conditions for the proposed issue.
Read more →ATHE▼ -7%on this newsshared move
ASX ANNOUNCEMENT 17 February 2025 Notice Under Section 708A(5)(e) of the Corporations Act This notice is given by Alterity Therapeutics Limited ACN 080 699 065 (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), unde
Alterity Therapeutics Limited has issued a notice under section 708A(5)(e) of the Corporations Act regarding new shares issued. The announcement states that a total of 1,165,841,830 fully paid ordinary shares have been issued on 17 February 2025. This notice complies with legal requirements pertaining to the reporting of securities by the company. No further details regarding the implications or reasons behind the issuance are provided in this notice.
Read more →ATHE▲ +8.7%on this news
Alterity Therapeutics Raises A$40.0 million in Placement - Funds to be used primarily to advance development of ATH434 in Parkinsonian Disorders - - Capital raising was strongly supported by domestic and international in
Alterity Therapeutics announced a successful capital raise of A$40 million aimed at advancing the development of their drug ATH434 for neurodegenerative diseases. This placement, fully subscribed by domestic and international institutions, reflects strong investor support. The funds will be used to enhance regulatory and development activities for ATH434, which has shown promising results in clinical trials. Notably, ATH434 demonstrated a significant slowing of clinical progression in Multiple System Atrophy during recent Phase 2 trials.
Read more →ATHE▲ +8.7%on this news
Appendix 3B - Proposed issue of securities Announcement Summary Entity name ALTERITY THERAPEUTICS LIMITED Announcement Type New announcement Date of this announcement 10/2/2025 The Proposed issue is: A placement or other
Alterity Therapeutics Limited has announced a proposed issue of securities involving a placement of over 4.8 billion shares, comprising options with an exercise price of AUD 0.028 and fully paid ordinary shares at AUD 0.011 each. The proposal requires security holder approval, which is expected on March 27, 2025. This capital raise aims to enhance the company's financial position by securing additional funds, following ASX regulations.
Read more →ATHE▲ +8.7%on this newsshared move
Form 603 Corporations Act 2001 Section 671B Notice of initial substantial holder To Company Name/Scheme Alterity Therapeutics ltd ACN/ARSN/ABN 37 080 699 065 1. Details of substantial holder (1) Name JPMorgan Chase & Co.
JPMorgan Chase & Co. has reported becoming a substantial holder in Alterity Therapeutics Ltd., acquiring a voting power of 5.11% as of February 3, 2025. The holding includes various relevant interests through its subsidiaries, indicating substantial financial engagements with the company. This move may enhance Alterity's market position and represents JPMorgan's confidence in the firm's future potential.
Read more →ATHE▲ +8.7%on this newsshared move
Market Announcement 6 February 2025 Alterity Therapeutics Limited (ASX: ATH) - Trading Halt Description The securities of Alterity Therapeutics Limited ( ATH') will be placed in trading halt at the request of ATH, pendin
Alterity Therapeutics Limited (ASX: ATH) has requested a trading halt for its securities, effective immediately. This halt is pending the release of an important announcement that could impact the company's stock. The halt will last until either the announcement is made or normal trading resumes on February 10, 2025. Investors are advised to stay alert for further updates from the company.
Read more →ATHE▼ -5.8%on this newsshared move
ASX ANNOUNCEMENT 05 February 2025 Disclosure under Takeovers Panel Guidance Note 20: Equity Derivatives Alterity Therapeutics Limited ACN 080 699 065 (ASX: ATH, NASDAQ: ATHE) ("the Company") advises that it has received
Alterity Therapeutics Limited has received a disclosure under the Australian Takeovers Panel Guidance Note 20 from Point72 Associates, LLC. This notice highlights the Fund's long equity derivative positions, which include a total of 187,910,474 ordinary shares and 135,120 American Depository Receipts (ADRs). Following a private placement on February 3, 2025, the percentage of securities represented by these derivatives slightly decreased from 5.05% to 4.90%. Point72 disclosed that they hold no short positions that would offset these long positions.
Read more →ATHE▼ -9.6%on this newsshared move
ASX ANNOUNCEMENT 04 February 2025 Notice Under Section 708A(5)(e) of the Corporations Act This notice is given by Alterity Therapeutics Limited ACN 080 699 065 (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), unde
Alterity Therapeutics Limited has issued a notice under Section 708A(5)(e) of the Corporations Act regarding the issuance of fully paid ordinary shares. On February 3, 2025, the company issued 164,242,200 shares as part of a previously announced transaction. The notice is a formal declaration to comply with Australian securities regulations, indicating that these securities will be quoted on the ASX. The company has provided details about the issued capital and future potential securities.
Read more →ATHE▲ +57%on this newsshared move
Alterity Therapeutics Announces Positive ATH434 Phase 2 Trial Results in Multiple System Atrophy Led By Robust Clinical Efficacy
Alterity Therapeutics announced positive results from its ATH434 Phase 2 trial for early-stage multiple system atrophy (MSA). The trial demonstrated a statistically significant 48% slowing of clinical progression in patients treated with the 50 mg dose of ATH434 compared to placebo. Key MRI biomarkers indicated a reduction of iron accumulation in brain regions affected by MSA, further suggesting the treatment's effectiveness. With no reported serious adverse events, the company is in discussions to engage with the FDA for potential accelerated development pathways.
Read more →ATHE▲ +57%on this newsshared move
ATH434 - 201 Phase 2 Topline Results
ATH434, a drug candidate for treating Multiple System Atrophy (MSA), has shown promising Phase 2 trial results. The study reported a favorable safety profile with no serious adverse events, alongside strong efficacy results on multiple measures, including a significant reduction in iron content in the brain. Additionally, participants demonstrated improvement in clinical endpoints related to daily living activities and reductions in disease progression compared to placebo. The drug is being developed as a potential disease-modifying therapy for this rare and debilitating neurodegenerative disorder.
Read more →ATHE▲ +57%on this newsshared move
Market Announcement 28 January 2025 Alterity Therapeutics Limited (ASX: ATH) - Trading Halt Description The securities of Alterity Therapeutics Limited ( ATH') will be placed in trading halt at the request of ATH, pendin
Alterity Therapeutics Limited has requested a trading halt of its securities on the ASX as of January 28, 2025. This trading halt is set to last until the earlier of normal trading recommencing on January 30, 2025, or the release of a subsequent announcement. The trading halt is requested in compliance with ASX Listing Rule 17.1, and further details are pending.
Read more →ATHE▼ -12%on this news· ran to +44% by day 3shared move
Appendix 4C - Q2 FY25 Quarterly Cash Flow Report Highlig hts Topline data for ATH434-201 randomized, double-blind Phase 2 clinical trial on track for expected release by early February 2025 ATH434-201 trial in early-stag
Alterity Therapeutics announced the completion of the ATH434-201 Phase 2 clinical trial for treating early-stage Multiple System Atrophy (MSA). The company is set to report topline results by early February 2025, following highly positive interim findings from the ATH434-202 trial, which suggest the drug may slow disease progression. Alterity's recent activities also include presenting various studies and publications reinforcing ATH434's potential across neurodegenerative diseases. The company reported a cash position of A$4.54M with cash outflows of A$5.06M for the last quarter of 2024.
Read more →ATHE▼ -6%on this news· ran to -17% by day 3shared move
Appendix 2A - Application for quotation of securities Announcement Summary Entity name ALTERITY THERAPEUTICS LIMITED Announcement Type New announcement Date of this announcement Wednesday
Alterity Therapeutics Limited announced a new application for the quotation of securities on January 22, 2025. The application pertains to 95,238 ordinary fully paid shares resulting from the exercise of options. This move is in line with ASX Listing Rules, indicating the company's adherence to regulatory procedures. The existing class of securities includes additional shares listed under code ATH.
Read more →ATHEAlterity Therapeutics Issues Shareholder Newsletter Highlighting Pipeline Advances and Key Upcoming Milestones MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA - 17 January 2025: Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE)
Alterity Therapeutics has issued a shareholder newsletter outlining positive developments in its clinical pipeline, particularly for its lead asset ATH434 in treating Multiple System Atrophy (MSA). The company reported significant advancements from its Phase 2 clinical trials, including encouraging preliminary results from an open-label study. The newsletter also highlights upcoming topline data expected in January or February 2025, indicating a pivotal year ahead for the company. Despite optimism, the release notes the inherent risks and uncertainties associated with drug development and clinical trial results.
Read more →ATHEAlterity Therapeutics Issues Shareholder Letter Highlighting Pipeline Advances and Key Upcoming Milestones
Alterity Therapeutics has issued a shareholder letter outlining positive advances in their pipeline, particularly regarding the drug ATH434 for neurodegenerative diseases. The company completed a Phase 2 clinical trial for early-stage Multiple System Atrophy (MSA), with topline data expected soon. Preliminary results indicate clinical benefits from ATH434, including stability in iron levels and brain volumes in responders. Additionally, Alterity has developed a new imaging biomarker through collaboration with Vanderbilt University for assessing MSA progression.
Read more →ATHE▲ +11.5%on this news· ran to +36% by day 3
Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities Announcement Summary Entity name ALTERITY THERAPEUTICS LIMITED Date of this announcement Monday
Alterity Therapeutics Limited announced the issuance of unquoted equity securities under an employee incentive scheme. A total of 170,000,000 unlisted options expiring on December 30, 2027, will be issued at an exercise price of $0.01. Key management personnel have been allocated a significant portion of these options. This issuance is part of the company's strategy to incentivize and retain talent without immediate market implications for the securities.
Read more →ATHE▲ +17.5%on this news· ran to +55% by day 3
Alterity Therapeutics Completes Last Patient Visit in ATH434-201 Phase 2 Clinical Trial in Early-Stage Multiple System Atrophy - ATH434 is a Disease Modifying Drug Candidate Targeting Alpha-Synuclein and Iron in Parkinso
Alterity Therapeutics has completed the last patient visit in its ATH434-201 Phase 2 clinical trial aimed at early-stage Multiple System Atrophy (MSA). This milestone allows the company to focus on data analysis, with topline results expected in late January 2025. ATH434 is positioned as a disease-modifying agent targeting alpha-synuclein and iron imbalances, with high hopes for its efficacy in treating neurodegenerative disorders. The trial's completion underscores the company's progress in developing effective treatments for this debilitating condition.
Read more →ATHEResults of 2024 Annual General Meeting MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA - 22 November 2024: In accordance with ASX Listing Rule 3.13.2 and Section 251AA of the Corporations Act 2001 (Cth), the attached informa
Alterity Therapeutics conducted its Annual General Meeting on November 22, 2024, where shareholders voted on several key resolutions. Notably, the meeting resulted in the approval of options for several directors and ratified prior share issues. The company continues to advance its lead asset, ATH434, which is under evaluation in Phase 2 trials for Parkinsonian disorders.
Read more →ATHEDavid Stamler, MD CEO AGM 22 November 2024 Forward Looking Statements This presentation may contain some statements that may be considered "Forward - Looking Statements", within the meaning of the US Securities Laws . Th
David Stamler, CEO of Alterity, presented at the AGM on November 22, 2024, providing updates on ATH434, a drug targeting Multiple System Atrophy (MSA) and other neurodegenerative diseases. The company's Phase 2 trials are showing promising interim data, highlighting the potential efficacy of ATH434 in treating MSA, a rare and debilitating condition. However, the company cautions that the nature of forward-looking statements carries inherent risks, which may impact the outcome of future studies.
Read more →ATHEChairman's Address 2024 Annual General Meeting Good morning, everyone, and thank you for joining us today here in Melbourne. It is my pleasure to share with you my Chairman's address for Alterity Therapeutics Fiscal Year
Alterity Therapeutics has reported significant achievements during its Fiscal Year 2024, notably the impending completion of its ATH434-201 Phase 2 clinical trial for Multiple System Atrophy (MSA). The trial proceeded without safety concerns, and preliminary results from a related open-label biomarker study show promising outcomes. The company continues to engage the scientific community and utilize advanced technology in their research efforts. Looking ahead, Alterity is optimistic about delivering topline data from both ongoing clinical trials in the coming year.
Read more →ATHEAlterity Therapeutics Appoints Abby Macnish Niven as Company Secretary
Alterity Therapeutics has appointed Abby Macnish Niven as the new Company Secretary, succeeding Phillip Hains. Ms. Macnish Niven, who previously served as the Chief Financial Officer, brings a wealth of experience from her previous roles in private wealth management. She holds degrees in Commerce and Science and is a Chartered Finance Analyst. Alterity is focused on developing treatments for neurodegenerative diseases, with ATH434 currently under evaluation in Phase 2 clinical trials.
Read more →ATHEChange of Company Secretary MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA - 19 November 2024: Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), has announced the appointment of Abby Macnish Nive
Alterity Therapeutics has appointed Abby Macnish Niven as the new Company Secretary, effective November 18, 2024. She previously assumed the role of Chief Financial Officer on September 30, 2024, and brings extensive experience from reputable organizations. The transition follows the departure of Phillip Hains, who the company acknowledges for his valuable contributions. This change underscores the company's commitment to strong governance and leadership as it continues to focus on developing treatments for neurodegenerative diseases.
Read more →ATHEAlterity Therapeutics Announces Presentation on Tracking the Progression of Multiple System Atrophy at International Symposium MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA - 12 November 2024: Alterity Therapeutics (ASX: A
Alterity Therapeutics announced the presentation of findings from its Biomarkers of Progression in Multiple System Atrophy (bioMUSE) study at the 35th International Symposium on the Autonomic Nervous System. The research utilized advanced neuroimaging techniques to track MSA progression, showing significant brain volume reductions correlated with clinical worsening of the disease. This could enhance the evaluation of disease-modifying therapies for MSA. The study has contributed essential data towards optimizing the design of Alterity's Phase 2 clinical trials.
Read more →ATHEAlterity Therapeutics Announces New Publication Describing Novel Mechanism of Action for ATH434 - Peer-Reviewed Publication Describes How ATH434 Uniquely Targets Excess Iron - MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA
Alterity Therapeutics announced a peer-reviewed publication detailing the unique mechanism of action for ATH434, an iron-targeting agent aimed at treating neurodegenerative diseases. The study, published in the journal Metallomics, highlights ATH434's ability to target reactive iron, decreasing oxidative stress and protein aggregation in the brain. The results support its role as an iron chaperone, particularly in conditions such as Parkinson's disease and Multiple System Atrophy. ATH434 has successfully completed Phase 1 trials and is currently being studied in two Phase 2 clinical trials.
Read more →ATHEAppendix 4C - Q1 FY25 Quarterly Cash Flow Report Highlights Topline data for ATH434-201 randomized, double-blind Phase 2 clinical trial on track for release in January 2025 Positive interim data reported from ATH434-202
Alterity Therapeutics has reported positive interim data from its Phase 2 clinical trial ATH434-202 for advanced multiple system atrophy (MSA), indicating potential disease modification through modulation of brain iron levels. The company expects topline results from the ATH434-201 trial, focused on early-stage MSA, to be released in January 2025. Additionally, interim findings from the ATH434-202 trial showed positive safety profiles and clinical responsiveness among participants. These developments were discussed during presentations at the recent International Congress of Parkinson's Disease and Movement Disorders.
Read more →ATHEALTERITY THERAPEUTICS LIMITED ACN 080 699 065 Notice of Annual General Meeting and Explanatory Memorandum Time and Date of Meeting: 9.00am (AEDT) on Friday, 22 November 2024 Registration from 8.30am Location: Deloitte Au
Alterity Therapeutics Limited will hold its Annual General Meeting on November 22, 2024, at Deloitte Australia in Melbourne. Shareholders will discuss resolutions including the adoption of the Remuneration Report and the re-election of Director Geoffrey Kempler. The meeting will also address the ratification of a prior issue of shares and approvals for the issuance of options to various directors. Shareholders are advised to read the accompanying Explanatory Memorandum for detailed information.
Read more →ATHEAlterity Therapeutics to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit on 17 October 2024 MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA - 14 October 2024: Alterity Therapeutics (ASX: ATH, NASDA
Alterity Therapeutics, a biotechnology company focused on neurodegenerative diseases, announced that its CEO, David Stamler, will participate in a fireside chat at the 2024 Maxim Healthcare Virtual Summit. The event is scheduled for 17 October 2024, aiming to showcase the company's efforts in treating diseases like Parkinson's. The chat will be accessible via a webcast on the Alterity website, providing an opportunity for investors and stakeholders to gain insights into the company's developments. Alterity's lead asset, ATH434, is undergoing evaluation in Phase 2 trials for Multiple System Atrophy, highlighting its commitment to innovative treatments.
Read more →ATHEAlterity Therapeutics Announces Presentation of New Data Describing Neuroprotection of ATH434 at Neuroscience Meeting MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA - 11 October 2024: Alterity Therapeutics (ASX: ATH, NASDAQ
Alterity Therapeutics has recently presented data on ATH434 at the Society for Neuroscience 2024 that highlights its neuroprotective properties and potential as a treatment for neurodegenerative diseases, such as Parkinson's. The findings indicate that ATH434 can reduce lipid damage and promote mitochondrial energy production, setting it apart from other iron-binding agents. The compound is currently undergoing two Phase 2 clinical trials for Multiple System Atrophy and has already achieved promising results in Phase 1 studies. The company aims to address oxidative injury, a significant contributor to neurodegeneration, with ATH434's unique properties.
Read more →ATHEChange of Share Registry MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA - 4 October 2024: Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing
Alterity Therapeutics Limited announced a change in its shareholder registry services provider from Computershare Investor Services Pty Ltd to Automic Pty Ltd, effective October 7, 2024. This transition aims to enhance the efficiency with which shareholders can manage their holdings, offering a secure online investor portal for services such as updating details and viewing transaction history. The announcement was authorized by the CEO, David Stamler. No additional changes to the company's operations or drug development programs were mentioned.
Read more →ATHEAlterity Therapeutics Raises Profile with Multiple Data Presentations at the International Congress of Parkinson's Disease and Movement Disorders - ATH434 shows promise as a disease-modifying therapy for MSA - - ATH434-2
Alterity Therapeutics presented multiple findings at the International Congress of Parkinson's Disease and Movement Disorders, highlighting its lead candidate, ATH434. The interim data from the Phase 2 trial for ATH434-202 showed that 30% of clinical responders exhibited stabilization in both symptoms and biomarkers associated with Multiple System Atrophy (MSA). ATH434 is being evaluated in two Phase 2 clinical trials, with further data expected in early 2025. The study aims to demonstrate the potential of ATH434 as a disease-modifying treatment for MSA, a rare neurodegenerative condition.
Read more →ATHEAlterity Therapeutics Appoints Abby Macnish Niven as Chief Financial Officer MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA - 30 September 2024: Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"),
Alterity Therapeutics has appointed Abby Macnish Niven as its new Chief Financial Officer, effective immediately. With extensive experience in private wealth management and consulting for various companies, she is expected to contribute significantly to advancing the company's programs focused on neurodegenerative diseases. Niven replaces Phillip Hains, who previously served as CFO and will continue as Company Secretary. This leadership change is seen as a positive move for the company's growth trajectory.
Read more →ATHEAlterity Therapeutics Limited ACN 080 699 065 Annual report
Alterity Therapeutics Limited's annual report highlights progress in their MSA program, including the development of machine learning-based imaging biomarkers and promising Phase 2 clinical trial data. The ATH434 drug shows potential for treating Multiple System Atrophy, with positive interim findings indicating improvements in patients' daily functioning. The company's approach has garnered excitement in the medical community, and topline data is anticipated in early 2025.
Read more →ATHERules 4.7.3 and 4.10.3 Appendix 4G Key to Disclosures Corporate Governance Council Principles and Recommendations Name of entity Alterity Therapeutics Ltd ABN/ARBN Financial year ended: 37 080 699 065 30 June 2024 Our co
Alterity Therapeutics Ltd has released its corporate governance statement as of September 26, 2024, which conforms to the ASX Corporate Governance Council recommendations. The statement has been approved by the board and highlights disclosure practices. Furthermore, the company provides a web link where stakeholders can access related documents. The governance documentation serves to ensure compliance with financial regulations for the financial year ending June 30, 2024.
Read more →ATHEAlterity Therapeutics Limited Corporate Governance Statement 30 June 2024 This Corporate Governance Statement of Alterity Therapeutics Limited (the "Company") is prepared in accordance with ASX Listing Rule 4.10.3. It is
Alterity Therapeutics Limited released its Corporate Governance Statement for the financial year ending June 30, 2024, highlighting its adherence to ASX Listing Rule 4.10.3. The statement outlines the company's governance framework, detailing principles such as maintaining high ethical standards and providing timely disclosures. Key aspects include the board's structure, commitment to diversity, and performance assessments for management. Importantly, while the board values diversity, it has chosen not to set specific gender diversity objectives at this time due to the small size of the organization.
Read more →ATHEAlterity Therapeutics to Deliver Multiple Oral and Poster Presentations at the International Congress of Parkinson's Disease and Movement Disorders - Late Breaking Abstract and Oral Presentation on ATH434-202 Interim Pha
Alterity Therapeutics will present multiple oral and poster presentations at the International Congress of Parkinson's Disease and Movement Disorders, scheduled for September 27 to October 1, 2024. The highlights include late-breaking interim phase 2 data on their drug ATH434 for treating advanced multiple system atrophy (MSA) and baseline characteristics from their earlier phase 2 study. ATH434 is recognized for its potential to inhibit protein aggregation associated with neurodegeneration. The company aims to demonstrate the efficacy and safety of ATH434 in ongoing clinical trials.
Read more →ATHE▲ +7.1%on this newsshared move
Alterity Therapeutics Limited ACN 080 699 065 Preliminary Final Report - 30 June 2024 2 Alterity Therapeutics Limited Appendix 4E - Preliminary Final Report For the year ended 30 June 2024 Name of entity Alterity Therape
Alterity Therapeutics Limited released its preliminary financial report for the year ending June 30, 2024. The company reported a substantial increase in revenue, up 1,533.1% to $268,419, primarily driven by interest income. However, it incurred a significant net loss, rising by 38.5% to $19,123,464. As of June 30, 2024, the company's net tangible assets per share decreased, indicating financial challenges. The financial statements are undergoing an audit, with potential uncertainties about the company’s future viability.
Read more →ATHE▼ -5.6%on this news· ran to -22% by day 3
Appendix 3H - Notification of cessation of securities Announcement Summary Entity name ALTERITY THERAPEUTICS LIMITED Announcement Type New announcement Date of this announcement Thursday
Alterity Therapeutics Limited announced the cessation of 12,000,000 options that were set to expire on July 31, 2024, without having been exercised or converted. This cessation results from the expiration of a convertible security, which may reflect financial challenges faced by the company. Following this event, no consideration is being paid for the cessation. The company's issued capital remains subject to other ongoing securities processing with the ASX.
Read more →ATHEAppendix 4C - Q4 FY24 Quarterly Cash Flow Report Highlights Positive interim data reported from ATH434-202 Phase 2 clinical trial showing improvement on the UMSARS Activities of Daily Living Scale and stable or improved
Alterity Therapeutics reported positive interim findings from its ATH434-202 Phase 2 clinical trial, showing improvements in daily living activities for patients with advanced Multiple System Atrophy (MSA). Additionally, the company highlighted its strong cash position of A$12.6 million and the continuous guidance provided by its bioMUSE Natural History Study. The interim analysis showcased clinical and biomarker outcomes, suggesting ATH434 might modify the disease's progression. The trial is on track for completion by November 2024, with topline results expected by January 2025.
Read more →ATHEAlterity Therapeutics to Present at MST Financial Webinar MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA - 24 July 2024: Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company
Alterity Therapeutics will host a webinar on July 25, 2024, for investors and shareholders, allowing them to engage with the company regarding its developments. The biotechnology firm focuses on developing treatments for neurodegenerative diseases, particularly through its lead asset, ATH434, currently in Phase 2 trials for treating Multiple System Atrophy. This presentation aims to enhance communication with stakeholders and outline the company’s ongoing projects.
Read more →ATHE▼ -5.3%on this news· ran to -16% by day 3shared move
ASX ANNOUNCEMENT 19 July 2024 Notice Under Section 708A(5)(e) of the Corporations Act This notice is given by Alterity Therapeutics Limited ACN 080 699 065 (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), under se
Alterity Therapeutics Limited announced the issuance of 75,220,800 fully paid ordinary shares as part of their compliance with Section 708A(5)(e) of the Corporations Act. The shares were issued on July 18, 2024. This notice serves to inform stakeholders under the legal requirements of the Corporations Act 2001 (Cth). The announcement reflects procedural compliance rather than a significant event affecting the company's strategic direction.
Read more →ATHE▼ -5.3%on this news· ran to -16% by day 3shared move
Appendix 2A - Application for quotation of securities Announcement Summary Entity name ALTERITY THERAPEUTICS LIMITED Announcement Type New announcement Date of this announcement Friday July 19 , 2024 The +securities to b
Alterity Therapeutics Limited has announced the application for the quotation of 75,220,800 fully paid ordinary shares. This issuance is part of a transaction previously detailed in an Appendix 3B submission. The new securities are part of an overall capital strategy, with the issued capital amounting to over 5.3 billion ordinary shares following the quotation. The announcement was made on July 19, 2024, indicating ongoing activities in the company’s financial maneuvers.
Read more →ATHE▼ -11%on this news· ran to -24% by day 3shared move
Appendix 3B - Proposed issue of securities Announcement Summary Entity name ALTERITY THERAPEUTICS LIMITED Announcement Type New announcement Date of this announcement 18/7/2024 The Proposed issue is: A placement or other
Alterity Therapeutics Limited announced a proposed placement of 75,220,800 ordinary fully paid securities, aimed at providing further research and development funding and enhancing working capital. This announcement is part of the company's strategic efforts to secure necessary financial resources. No approval from security holders is required for this issuance under the relevant listing rules, indicating a swift procedure for the company to access capital.
Read more →ATHE▲ +6.3%on this newsshared move
Alterity Therapeutics Reports Positive Interim Data from ATH434-202 Phase 2 Clinical Trial in Multiple System Atrophy - 43% of Participants Showed Improvement on the UMSARS Activities of Daily Living Scale - - 29% of Par
Alterity Therapeutics has released encouraging interim data from its ATH434-202 Phase 2 clinical trial focusing on multiple system atrophy (MSA). In the trial, 43% of participants exhibited improvement in daily living activities, while 29% showed neurological symptom stability or improvement. The study also highlights objective biomarker improvements that correlate with clinical outcomes. No safety issues were reported, and the initial analysis suggests that ATH434 may have the potential to modify the disease course in MSA patients.
Read more →ATHE▲ +6.3%on this newsshared move
Market Announcement 15 July 2024 Alterity Therapeutics Limited (ASX: ATH) - Trading Halt Description The securities of Alterity Therapeutics Limited ( ATH') will be placed in trading halt at the request of ATH, pending i
Alterity Therapeutics Limited (ASX: ATH) has requested a trading halt for its securities pending the release of an announcement regarding new data from its ATH434 clinical trial. The halt will remain in effect until either the announcement is made or trading resumes on July 17, 2024. The company expresses confidence that there are no issues preventing the trading halt request from being granted.
Read more →ATHEAlterity Therapeutics to Present at the MST Access Hidden Gems in Life Sciences' Webinar MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA - 13 June 2024: Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Comp
Alterity Therapeutics has announced that its CEO, David Stamler, will present at the MST Access Hidden Gems in Life Sciences webinar on June 13, 2024, in Australia, and June 12, 2024, in the United States. This presentation will provide an overview of the company's initiatives and drug development pipeline. Alterity is focused on developing treatments for neurodegenerative diseases and is currently evaluating its lead asset, ATH434, in Phase 2 trials for Multiple System Atrophy. Investors attending the webinar will have the opportunity to ask questions following the presentation.
Read more →ATHEAlterity Therapeutics to Host Webcast Today on New Data from the bioMUSE Natural History Study - New bioMUSE Data Informs ATH434-202 Study Endpoints - - Webcast to Include Key Opinion Leader, Daniel Claassen, M.D., M.S.,
Alterity Therapeutics is hosting a webcast on May 30, 2024, to present new findings from the bioMUSE Natural History Study. The results are expected to impact the endpoints for the ongoing ATH434-202 Phase 2 clinical trial, which aims to address neurodegenerative diseases. Key opinion leader Dr. Daniel Claassen will join CEO Dr. David Stamler to discuss the data's relevance and implications for future studies. Investors will have the opportunity to ask questions during the webcast.
Read more →ATHEAlterity Therapeutics to Host Webcast Today on New Data from the bioMUSE Natural History Study
Alterity Therapeutics is set to host a webcast on May 30, 2024, to discuss new findings from the bioMUSE Natural History Study. CEO Dr. David Stamler will present how these results will influence endpoints for the ATH434-202 Phase 2 clinical trial. The event will also feature insights from Dr. Daniel Claassen of Vanderbilt University. Alterity is focused on creating treatments for neurodegenerative diseases, particularly Multiple System Atrophy, through its lead asset ATH434.
Read more →ATHEAppendix 3H - Notification of cessation of securities Announcement Summary Entity name ALTERITY THERAPEUTICS LIMITED Announcement Type New announcement Date of this announcement Tuesday
Alterity Therapeutics Limited has announced the cessation of 5,000,000 options set to expire on November 29, 2026, which lapsed due to conditions not being satisfied. The cessation is linked to an employee resignation, signaling potential challenges in the company's operations. This event marks a decrease in the company's conditional rights to securities and potentially impacts its capital structure. Following this lapse, the company's issued capital includes over 5 billion ordinary shares and several other options with varying expiration dates.
Read more →ATHEAlterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Third Review - ATH434-201 Trial on Track to Complete in November 2024 - - Top-Line Data Expected in January 20
Alterity Therapeutics has announced that the independent Data Monitoring Committee (DMC) has completed its third review of the ATH434-201 Phase 2 clinical trial data and recommended that the trial continue without modifications. The trial is targeted at patients with early-stage multiple system atrophy (MSA), a condition with no approved treatments to slow its progression. The study is on track for completion in November 2024, with top-line data expected in January 2025. CEO David Stamler emphasized the favorable safety profile of ATH434, which aims to inhibit pathological protein aggregation linked to neurodegeneration.
Read more →ATHEAppendix 4C - Q3 FY24 Quarterly Cash Flow Report Highlights ATH434-201 Phase 2 baseline data confirm approach to target biomarkers for slowing disease progression Presented promising nonclinical data on ATH434 in a prima
Alterity Therapeutics has released its Q3 FY24 Cash Flow Report, highlighting advancements in its clinical programs for neurodegenerative diseases. The company is focusing on ATH434 for Multiple System Atrophy and showcased favorable baseline data during the AAN 2024 Annual Meeting. An independent Data Monitoring Committee has recommended the continuation of the ATH434-201 trial without concerns about safety. Alterity expects to report preliminary data from its ongoing studies by June 2024 and topline results by January 2025.
Read more →ATHE▼ -12.5%on this newsshared move
Alterity Therapeutics Presents New Data Demonstrating Potential of ATH434 to Treat Rare Neurodegenerative Disease Friedreich's Ataxia - New Evidence Indicates ATH434 can Function as an Iron Chaperone to Redistribute Iron
Alterity Therapeutics presented new data on ATH434 at the World Orphan Drug Congress, demonstrating its potential as an iron chaperone for treating Friedreich's Ataxia. The drug selectively targets and redistributes toxic labile iron, which is implicated in the disease. ATH434 has shown promise in preclinical studies and has successfully completed Phase 1 trials, with ongoing Phase 2 studies for both Friedreich's Ataxia and Multiple System Atrophy. The findings may pave the way for a new treatment approach for these neurodegenerative diseases.
Read more →ATHEAlterity Therapeutics Parkinson's Disease and Multiple System Atrophy Data Featured at the American Academy of Neurology (AAN) 2024 Annual Meeting - ATH434 Improved Motor Performance and General Function in a Primate Mod
Alterity Therapeutics presented promising findings for its lead candidate, ATH434, at the AAN 2024 Annual Meeting. The data showcased ATH434's capability to improve motor skills and general functioning in a primate model of Parkinson's disease, along with significant biomarker associations in Multiple System Atrophy (MSA). The ongoing Phase 2 trials aim to further establish ATH434's role in slowing disease progression. Collaboration with Vanderbilt University enhances the understanding of MSA and supports clinical study efficacy.
Read more →ATHE▲ +11.8%on this news· ran to -24% by day 3shared move
Results of Extraordinary General Meeting MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA - 12 April 2024 Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company") advises that all resolutions considered at
Alterity Therapeutics held an Extraordinary General Meeting on April 12, 2024, in which all resolutions were voted on and passed by poll. This outcome indicates strong support from shareholders and signals a positive direction for the company's corporate governance. Details regarding the proxies received and votes cast have been provided in accordance with regulatory requirements. The approval reflects the commitment of Alterity to maintain transparency and compliance.
Read more →ATHE▲ +11.8%on this news· ran to -24% by day 3shared move
ALTERITY THERAPEUTICS LIMITED [ACN 080 699 065] ("the Company") OPTIONS PROSPECTUS This Prospectus contains an offer of 285,087,720 options ( Options ) each with an exercise price of A$0.01 (1 Australian cent), expiry da
Alterity Therapeutics Limited has launched a prospectus offering 285,087,720 options at an exercise price of A$0.01, set to expire on August 31, 2026. The offer is restricted to identified investors and will close on April 16, 2024. The prospectus emphasizes that the offered securities are highly speculative and that investors should seek independent advice before participating. Key risks and financial effects associated with the investment are also highlighted within the document.
Read more →ATHE▲ +14.7%on this news· ran to +38% by day 1shared move
Alterity Therapeutics to Present New Data on ATH434 at the World Orphan Drug Congress USA 2024
Alterity Therapeutics has announced the presentation of new data on their drug ATH434 at the upcoming World Orphan Drug Congress USA 2024 in Boston. ATH434 is designed to inhibit the aggregation of pathological proteins and is currently undergoing clinical evaluation for Multiple System Atrophy (MSA) and Parkinson's disease. The drug has shown preclinical success and is supported by two ongoing Phase 2 trials aimed at evaluating its efficacy and safety. The company's participation in these conferences showcases their commitment to addressing neurodegenerative diseases, an area with high unmet medical needs.
Read more →ATHE▲ +5.3%on this news· ran to +18% by day 1
Alterity Therapeutics Receives a $3.9 million Research & Development Tax Incentive Refund MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA - 26 March 2024. Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) ("Alterity" or
Alterity Therapeutics has announced the receipt of a A$3.9 million cash refund from the Australian Taxation Office under the Research and Development Tax Incentive Scheme. This refund pertains to the costs of eligible R&D activities conducted during the financial year that ended on June 30, 2023. The company plans to use these funds to advance its Phase 2 clinical trials for its lead candidate, ATH434, which targets neurodegenerative diseases. ATH434 has shown promise in treating conditions like Multiple System Atrophy and has been granted Orphan drug designation by regulatory authorities.
Read more →ATHE▲ +5.3%on this news· ran to +18% by day 1
Alterity Therapeutics Receives a A$3.9 Million Research & Development Tax Incentive Refund
Alterity Therapeutics Limited has announced a receipt of A$3.9 million cash refund from the Australian Taxation Office as part of the Research and Development Tax Incentive Scheme. The funds will support their Phase 2 clinical trials for Multiple System Atrophy (MSA) and further research into neurodegenerative diseases. Their lead candidate, ATH434, has shown promise in inhibiting the aggregation of proteins related to neurodegeneration and is currently in two clinical trials. Alterity aims to utilize this funding to enhance their research and potentially progress towards a Phase 3 clinical trial.
Read more →ATHEALTERITY THERAPEUTICS LIMITED ACN 080 699 065 Notice of Extraordinary General Meeting and Explanatory Memorandum Time and Date of Meeting: 10:00 am (AEST) on Friday 12 April 2024 Registration from 9:30 am Location: Level
Alterity Therapeutics Limited has scheduled an Extraordinary General Meeting for 10:00 am AEST on April 12, 2024. The meeting will consider resolutions related to the ratification of a prior issue of shares and the approval for issuing new options to investors. This is part of a capital raising initiative to support ongoing clinical trials and operational funding. Shareholders are encouraged to vote by proxy, with detailed instructions provided in the accompanying documentation.
Read more →ATHEASX ANNOUNCEMENT 4 March 2024 Notice Under Section 708A(5)(e) of the Corporations Act This notice is given by Alterity Therapeutics Limited ACN 080 699 065 (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), under se
Alterity Therapeutics Limited has issued a notice under section 708A(5)(e) of the Corporations Act 2001 regarding the issuance of fully paid ordinary shares. The company announced that it has issued a total of 855,263,158 shares on March 4, 2024. This notice fulfills the regulatory requirements under the Corporations Act and indicates the ongoing financial actions of the company.
Read more →ATHEAlterity Therapeutics Limited Appendix 4D Half-year ended 31 December 2023 Name of entity: Alterity Therapeutics Limited ABN: 37 080 699 065 Half-year ended: 31 December 2023 Previous period: 31 December 2022 Results for
Alterity Therapeutics Limited reported significant progress in its operations for the half-year ended December 31, 2023, with a 940.5% revenue increase to A$118,400, primarily from interest. However, the company still recorded a net loss of A$6,507,183. Advancements in its lead compound ATH434, particularly in Phase 2 trials for multiple system atrophy, highlight its ongoing clinical efforts, while a material uncertainty regarding its going concern was noted by auditors. The firm successfully completed a financing round to support its operations going forward.
Read more →ATHE▼ -16.2%on this news
Appendix 3B - Proposed issue of securities Announcement Summary Entity name ALTERITY THERAPEUTICS LIMITED Announcement Type New announcement Date of this announcement 23/2/2024 The Proposed issue is: A placement or other
Alterity Therapeutics Limited has announced the proposed issuance of 855,263,158 ordinary fully paid securities through a placement. The issue price per security is set at AUD 0.00380. This strategic move aims to secure additional capital, which may enhance the company's operational capabilities and support future initiatives. The announcement was made on February 23, 2024, and further details are expected as the process unfolds.
Read more →ATHE▼ -16.2%on this news
Alterity Therapeutics Raises $3.25 M AUD in Placement - Company Now Fully Funded Through Data Readout for Primary Phase 2 Clinical Trial - MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA - 23 February 2024: Alterity Therapeu
Alterity Therapeutics has successfully raised A$3.25 million through a placement of shares, which allows the company to be fully funded for its primary Phase 2 trial in Multiple System Atrophy (MSA). The funding comes at a critical time as the company prepares for the preliminary data readout from its ongoing biomarker study. The placement price was set at A$0.0038 per share, and options will accompany new shares, subject to shareholder approval. The CEO highlighted the strong interest from investors, paving the way for future clinical development.
Read more →ATHE▼ -16.2%on this newsshared move
Market Announcement 22 February 2024 Alterity Therapeutics Limited (ASX: ATH) - Trading Halt Description The securities of Alterity Therapeutics Limited ( ATH') will be placed in trading halt at the request of ATH, pendi
Alterity Therapeutics Limited has announced a trading halt for its securities, effective immediately. This halt is at the company's request and is due to an upcoming announcement related to a capital raise. Trading will resume either after the announcement is made or on Monday, 26 February 2024, whichever comes first. The company has stated that it is not aware of any reasons why the request for the trading halt should not be granted.
Read more →ATHEAlterity Therapeutics to Present New Data at the Upcoming American Academy of Neurology 2024 Annual Meeting - Positive Efficacy Data for ATH434 in a Primate Model of Parkinson's Disease to be Presented at International C
Alterity Therapeutics announced plans to present new data on ATH434 during the American Academy of Neurology 2024 Annual Meeting. This includes promising efficacy data from a primate model of Parkinson's disease and baseline biomarker data from the ongoing Phase 2 clinical trial for multiple system atrophy (MSA). ATH434 is designed to inhibit pathological protein aggregation, showing potential for treating neurodegenerative diseases. The clinical development efforts, including important presentations in collaboration with Vanderbilt University, reinforce Alterity's commitment to advancing treatments for these conditions.
Read more →ATHEAlterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Second Review - ATH434-201 Trial on Track to Complete in November 2024 - - Top-Line Data Expected in January 2
Alterity Therapeutics announced that the independent Data Monitoring Committee recommended the continuation of the ATH434-201 Phase 2 clinical trial without modifications following its second review. The trial, targeting early-stage multiple system atrophy (MSA), has shown no safety concerns so far. With a planned completion date in November 2024 and anticipated top-line data release in January 2025, the study aims to evaluate ATH434's efficacy and safety further. ATH434 is designed to inhibit aggregation of pathological proteins associated with neurodegeneration, presenting a potential treatment for MSA.
Read more →ATHENot for release to US wire services or distribution in the United States Alterity Therapeutics Successfully Completes Securities Purchase Plan (SPP) MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA - 2 February 2024: Alterity
Alterity Therapeutics announced the successful completion of its Securities Purchase Plan (SPP), which closed on January 25, 2024. Shareholder participation exceeded expectations, allowing the company to raise the maximum of A$2 million, despite oversubscriptions. The funds will primarily support ongoing Phase 2 clinical trials for Multiple System Atrophy and further research into neurodegenerative diseases. The company expressed gratitude to shareholders for their continued support.
Read more →ATHENotification of Issue, Conversion or Payment up of Unquoted Equity Securities Announcement Summary Entity name ALTERITY THERAPEUTICS LIMITED Date of this announcement Friday
Alterity Therapeutics Limited announced the issue of unquoted equity securities, specifically options with an expiration date of August 31, 2024, at a strike price of $0.007. This issuance is part of a previously announced transaction and does not involve securities intended for quotation on the ASX. The total number of unquoted options to be issued is 571,428,556. The announcement notes that these options are attached to shares issued under a Securities Purchase Plan.
Read more →ATHEApplication for quotation of +securities Announcement Summary Entity name ALTERITY THERAPEUTICS LIMITED Announcement Type New announcement Date of this announcement Friday
Alterity Therapeutics Limited has announced the quotation of a significant number of new securities on the ASX, including 571,428,556 fully paid ordinary shares and 190,476,123 options expiring in 2026. This follows a previous announcement regarding the securities issuance, indicating continued development and capital raising efforts by the company. The securities are being issued at a low price, which may attract more investors as the company seeks to bolster its funding for future endeavors.
Read more →ATHE▼ -7%on this newsshared move
Appendix 4C - Q2 FY24 Quarterly Cash Flow Report Highlights Completed enrollment in for ATH434-201 Phase 2 study Delivered promising data on ATH434 in Parkinson's disease and on its novel mechanism of action Strengthened
Alterity Therapeutics reported significant progress in its Q2 FY24 Cash Flow Report, highlighting the completion of enrollment in the ATH434-201 Phase 2 clinical trial for early-stage multiple system atrophy (MSA). The company presented promising efficacy data for ATH434 in a primate model of Parkinson's disease, showcasing its potential to improve motor function and act as a mitochondrial protector. Alterity aims to release topline results for the ATH434-201 trial by January 2025 and preliminary data for the ATH434-202 trial within the first half of 2024. Additionally, the company strengthened its financial position through successful fundraising activities.
Read more →ATHE▲ +5.5%on this newsshared move
Alterity Therapeutics to Participate in the ShareCafe Hidden Gems Webinar This Week
Alterity Therapeutics announced that CEO David Stamler will participate in the ShareCafe Hidden Gems webinar scheduled for February 1-2, 2024. This event aims to generate interest and showcase Alterity's efforts in developing treatments for neurodegenerative diseases, particularly through its lead asset ATH434. The webinar is free to access, and an archived replay will be available afterward. The company's focus reflects its commitment to innovation in addressing serious health concerns in the field of neurodegeneration.
Read more →ATHEAlterity Therapeutics Issues Shareholder Letter Highlighting Pipeline Advances and Key Upcoming Milestones - Preliminary Data from ATH434-202 Study Expected in 1H 2024 - - ATH434-201 Study to Complete in November 2024 -
Alterity Therapeutics has issued a letter to shareholders highlighting significant advances in its pipeline and key milestones for 2024. Notably, the company expects preliminary data from its ATH434-202 study in the first half of 2024, while the ATH434-201 study is set to complete in November 2024. ATH434 shows potential in treating Multiple System Atrophy (MSA) and has received Orphan Drug Designation from the U.S. FDA. The company is optimistic about its trials and the overall development of treatments for neurodegenerative diseases.
Read more →ATHEApplication for quotation of +securities Announcement Summary Entity name ALTERITY THERAPEUTICS LIMITED Announcement Type New announcement Date of this announcement Thursday
Alterity Therapeutics Limited has announced the application for quotation of a new class of options set to expire on August 31, 2026, at an exercise price of $0.01. A total of 457,142,830 options will be quoted, reflecting ongoing support from shareholders as options are exercised. This move aligns with the company's strategy to enhance its capital structure and engage its investors more effectively. Details regarding the exercise of these securities have been provided in adherence to ASX Listing Rules.
Read more →ATHEConfidential Appendix 3Y Change of Director's Interest Notice Rule 3.19A.2 Appendix 3Y Change of Director's Interest Notice Information or documents not available now must be given to ASX as soon as available. Informatio
Alterity Therapeutics Limited announced changes in directors' interests, specifically involving Mr. Peter Marks and Mr. Brian Meltzer. Both directors acquired additional shares that were unlisted options through a placement approved at the extraordinary general meeting held on December 29, 2023. Their total direct and indirect interests were updated accordingly, reflecting a significant retention of shares, which may imply confidence in the company's strategy moving forward.
Read more →ATHEAlterity Therapeutics Launches Security Purchase Plan (SPP) with Continued Support from Institutional Shareholders MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA - 11 January 2024: Alterity Therapeutics (ASX: ATH, NASDAQ: A
Alterity Therapeutics has announced the launch of a Security Purchase Plan (SPP), supported by commitments from institutional shareholders to buy any shares not acquired by individual investors. CEO David Stamler highlighted the initiative as a means to offer existing shareholders an opportunity to purchase shares at favorable prices, reflecting a positive outlook for 2024. The company is currently engaged in developing treatments for neurodegenerative diseases, with its lead asset, ATH434, undergoing Phase 2 trials for Multiple System Atrophy.
Read more →ATHENot for release to US wire services or distribution in the United States Alterity Therapeutics Announces that the Securities Purchase Plan (SPP) Documents have been Dispatched to Eligible Shareholders MELBOURNE, AUSTRALI
Alterity Therapeutics has announced the dispatch of Securities Purchase Plan (SPP) documents to eligible shareholders in Australia and New Zealand. This initiative, approved by shareholders on December 29, 2023, allows eligible participants to acquire shares and options worth up to A$30,000. The proceeds from this plan will be utilized for funding ongoing Phase 2 clinical trials for Multiple System Atrophy, as well as further research in neurodegenerative diseases. The SPP offer represents a maximum total subscription of A$2 million.
Read more →ATHE▼ -5.6%on this newsshared move
ASX ANNOUNCEMENT 8 January 2024 Notice Under Section 708A(5)(e) of the Corporations Act This notice is given by Alterity Therapeutics Limited ACN 080 699 065 (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), under
Alterity Therapeutics Limited has issued a notice under Section 708A(5)(e) of the Corporations Act regarding the issuance of fully paid ordinary shares. On 8 January 2024, the company issued a total of 1,008,965,805 shares. This notice is a routine compliance declaration as part of corporate governance requirements. The company is trading under the ASX code ATH and NASDAQ ticker ATHE. Details regarding the issuance were provided, but no specific business developments or impacts were discussed.
Read more →ATHE▼ -5.6%on this newsshared move
Notification of Issue, Conversion or Payment up of Unquoted Equity Securities Announcement Summary Entity name ALTERITY THERAPEUTICS LIMITED Date of this announcement Monday
Alterity Therapeutics Limited has announced the issuance of unquoted equity securities, including options expiring on August 31, 2024, and August 31, 2026. A total of 1.37 billion options will be issued at an exercise price of $0.007, while 457 million options will be available at $0.01. This issuance is aimed at raising additional working capital, which could enhance the company's financial stability. The security codes for the new classes are yet to be confirmed, but this move reflects the company's ongoing efforts to secure funding.
Read more →ATHE▼ -5.6%on this newsshared move
Application for quotation of +securities Announcement Summary Entity name ALTERITY THERAPEUTICS LIMITED Announcement Type New announcement Date of this announcement Monday
ALTERITY THERAPEUTICS LIMITED announced on January 8, 2024, the application for quotation of new securities, specifically 1,008,965,805 ordinary fully paid shares as part of a previously announced transaction. This move is in alignment with the ASX Listing Rules and follows an earlier announcement regarding the proposed issuance of securities dated November 22, 2023. The offering is expected to bolster the entity's overall capital structure as it continues to navigate its financing strategy.
Read more →ATHE▼ -5.6%on this newsshared move
Not for release to US wire services or distribution in the United States Alterity Therapeutics Completes Tranche Two of Placement Raising A$3.5M MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA - 8 January 2024: Alterity Ther
Alterity Therapeutics has successfully completed Tranche Two of a $4.8 million placement, raising approximately A$3.5 million. This funding will be used to support the company's Phase 2 clinical trials in Multiple System Atrophy and research efforts in neurodegenerative diseases. Eligible shareholders in Australia and New Zealand are invited to participate in a Securities Purchase Plan under similar terms. The Company aims to create treatment options for various Parkinsonian disorders and continues its drug discovery efforts.
Read more →ATHE▼ -9.3%on this news· ran to -19% by day 3shared move
Proposed issue of securities Update Summary Entity name ALTERITY THERAPEUTICS LIMITED Announcement Type Update to previous announcement Date of this announcement 5/1/2024 Reason for update to a previous announcement Prop
ALTERITY THERAPEUTICS LIMITED has provided an update on a proposed issue of securities, which has been approved by shareholders at an extraordinary general meeting held on December 29, 2023. The announcement outlines the compliance with ASX Listing Rules and details regarding the terms under which the new securities will be issued. This update is part of their ongoing efforts to facilitate capital raising through existing and new securities.
Read more →ATHEALTERITY THERAPEUTICS LIMITED [ACN 080 699 065] ("the Company") PROSPECTUS An offer for the issue of: up to an aggregate of 571,428,571 fully paid ordinary shares ( SPP Shares ) at an issue price of $0.0035 (0.35 cents)
Alterity Therapeutics Limited has announced a Security Purchase Plan (SPP) to issue up to 571,428,571 ordinary shares at an issue price of $0.0035 each. The offer seeks to raise up to $2 million before costs and is open to eligible shareholders from January 10 to January 25, 2024. Each eligible investor can apply for a maximum of 8,571,429 shares, along with free-attaching options. It is important for interested parties to carefully read the prospectus and understand the associated risks before applying.
Read more →ATHEAlterity Therapeutics Announces Shareholder Approval of Tranche Two Placement and Security Purchase Plan MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA - 29 December 2023: Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Al
Alterity Therapeutics announced that shareholders have approved Tranche Two of its Placement and Security Purchase Plan during an Extraordinary General Meeting. The approved tranche is expected to raise approximately A$3.5 million to fund clinical trials for Multiple System Atrophy and continue research in neurodegenerative diseases. The company has lodged the necessary documentation with regulatory authorities to proceed with this placement, allowing eligible shareholders in Australia and New Zealand to participate under specific conditions.
Read more →ATHEResults of Extraordinary General Meeting MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA - 29 December 2023 Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company") advises that all resolutions considered
Alterity Therapeutics held an Extraordinary General Meeting on December 29, 2023, where all resolutions were approved by poll. The resolutions included ratification of prior share issues and approvals for new securities placements. A significant majority of votes were cast in favor, indicating considerable shareholder support for these decisions. Detailed voting results are also provided, highlighting the level of agreement among stakeholders.
Read more →ATHEAlterity Therapeutics Appoints Phillip Hains as Chief Financial Officer MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA - 21 December 2023: Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biot
Alterity Therapeutics has announced the appointment of Phillip Hains as its new Chief Financial Officer effective January 31, 2024. Hains, who has been with the company since 2014 as Company Secretary, will replace Kathryn Andrews, who is leaving to pursue other interests but will help during the transition. The change comes as Alterity prepares for a pivotal year in its drug development, particularly around its lead asset, ATH434, targeting neurodegenerative diseases.
Read more →ATHENotification of Issue, Conversion or Payment up of Unquoted Equity Securities Announcement Summary Entity name ALTERITY THERAPEUTICS LIMITED Date of this announcement Thursday
Alterity Therapeutics Limited has announced the issuance of 8 million options under an employee incentive scheme, which are unquoted on the ASX. This issuance is part of a strategy to bolster employee motivation without requiring security holder approval under Listing Rule 7.2. The options have an exercise price of AUD 0.0105 and are set to expire on December 19, 2026. The company continues to expand its incentive offerings aimed at enhancing employee engagement and aligning their interests with company growth.
Read more →ATHEProposed issue of securities Update Summary Entity name ALTERITY THERAPEUTICS LIMITED Announcement Type Update to previous announcement Date of this announcement 18/12/2023 Reason for update to a previous announcement Op
Alterity Therapeutics Limited has issued an update regarding a proposed issue of securities. This announcement is a clarification of previous communications, detailing the terms under which new securities will be issued and associated conditions such as the need for security holder approval. The update includes specifics about the pricing and classification of the securities to be offered, ensuring adherence to ASX regulations.
Read more →ATHE▼ -12.2%on this news
ASX Grants Listing Rule Waiver Addendum to the Notice of Extraordinary General Meeting - 29 December 2023 MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA - 11 December 2023: Alterity Therapeutics Limited (ASX: ATH, NASDAQ: A
Alterity Therapeutics Limited announced that the ASX has granted a waiver of Listing Rule 7.3.9, allowing shareholders to vote on a proposed Securities Purchase Plan (SPP) at the Extraordinary General Meeting scheduled for December 29, 2023. This waiver facilitates eligible shareholders' participation in the voting process for the resolution concerning the SPP. The announcement further clarifies conditions around voting exclusions and the current status of the SPP, which is not underwritten.
Read more →ATHE▼ -6.1%on this news· ran to -17% by day 1shared move
Virtual access to Extraordinary General Meeting 29 December 2023 MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA - 7 December 2023: Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biot
Alterity Therapeutics Limited has scheduled an Extraordinary General Meeting for December 29, 2023, providing both in-person and virtual access for shareholders. This allows greater participation in the meeting, where shareholders can listen, ask questions, and vote. The company, based in Melbourne and San Francisco, focuses on developing treatments for neurodegenerative diseases, particularly through its lead asset, ATH434, which is in Phase 2 trials. Shareholders are encouraged to vote via proxy ahead of the meeting date.
Read more →ATHE▲ +153%on this news
Alterity Therapeutics to Host Webcast to Discuss ATH434 Efficacy Data in Primates and Recent Clinical Progress
Alterity Therapeutics is hosting a webcast on December 5-6, 2023, to discuss new efficacy data for its lead asset ATH434 in primate studies, alongside recent clinical developments. The event will feature CEO Dr. David Stamler and aims to engage investors with information regarding the company's progress and future steps in treating Parkinsonian disorders. The company remains focused on addressing neurodegenerative diseases through innovative biotechnology solutions.
Read more →ATHE▲ +153%on this newsshared move
Alterity Therapeutics Reports Positive Efficacy Data for ATH434 in a Primate Model of Parkinson's Disease - ATH434 improved motor performance and general function - - Webcast to be held this week to discuss new data and
Alterity Therapeutics announced promising efficacy data for its lead drug, ATH434, in a primate model of Parkinson's disease. The results demonstrated significant improvements in motor performance and general function, correlating with reduced iron levels in affected brain regions. This data was presented at the Future of Parkinson's Disease Conference 2023 and contributes to heightened confidence in the ongoing Phase 2 clinical trials for Multiple System Atrophy. A webcast will be held to discuss these findings further.
Read more →ATHEALTERITY THERAPEUTICS LIMITED ACN 080 699 065 Notice of Extraordinary General Meeting and Explanatory Memorandum Time and Date of Meeting: 10.00 am (AEDT) Friday 29 December 2023 Registration from 9:30 am Location: Level
Alterity Therapeutics Limited is set to hold an Extraordinary General Meeting on December 29, 2023, starting at 10:00 am AEDT. Shareholders are urged to vote by appointing a proxy if they cannot attend. The agenda includes several resolutions related to the company's capital raising efforts and shareholder approvals, which are detailed in the accompanying Explanatory Memorandum. Participation is encouraged, with ample provisions for proxy voting outlined in the announcement.
Read more →ATHENotification of cessation of +securities Announcement Summary Entity name ALTERITY THERAPEUTICS LIMITED Announcement Type New announcement Date of this announcement Thursday
Alterity Therapeutics Limited has announced the cessation of 674,694,939 ordinary securities (ATHAAC) due to their expiry without exercise or conversion on November 23, 2023. This cessation means the options will no longer be available, potentially impacting the company’s capital structure. Following this expiry, the company will continue to maintain a diverse portfolio of other options and ordinary shares.
Read more →ATHENot for release to US wire services or distribution in the United States Alterity completes Placement Tranche One raising $1.3M - Tranche Two completes on 29 December 2023 pending shareholder approval raising an addition
Alterity Therapeutics has completed Tranche One of its capital raising initiative, securing approximately $1.3M as part of a broader $4.8M placement. The second tranche, which is expected to raise an additional $3.5M, is subject to shareholder approval at a General Meeting on December 29, 2023. The proceeds will primarily fund Phase 2 clinical trials for Multiple System Atrophy as well as ongoing research and operational costs. The company emphasizes its commitment to developing treatments for neurodegenerative diseases.
Read more →ATHEApplication for quotation of +securities Announcement Summary Entity name ALTERITY THERAPEUTICS LIMITED Announcement Type New announcement Date of this announcement Wednesday
Alterity Therapeutics Limited has announced the application for quotation of new securities on the ASX, totaling 362,462,762 ordinary fully paid shares. The securities were issued as part of a transaction previously announced in an Appendix 3B. Following this issuance, the total number of quoted securities on the ASX will amount to 2,802,360,380. The announcement highlights the company’s ongoing efforts to enhance its capital structure and market presence.
Read more →ATHEASX ANNOUNCEMENT 29 November 2023 Notice Under Section 708A(5)(e) of the Corporations Act This notice is given by Alterity Therapeutics Limited ACN 080 699 065 (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), unde
Alterity Therapeutics Limited has issued a notice under section 708A(5)(e) of the Corporations Act regarding the issuance of fully paid ordinary shares. On 29 November 2023, the company issued 362,462,762 shares as noted in their official communication. This announcement serves as compliance with the regulatory disclosure requirements under Australian law. The shares are identified under the ASX code ATH.
Read more →ATHEChairman's Address 2023 Annual General Meeting Good morning all and thank you for joining us today. I'm pleased to share with you my chairman's address for our FY23 Annual General Meeting for Alterity Therapeutics. We ar
Alterity Therapeutics held its FY23 Annual General Meeting, highlighting significant progress in its clinical trials, particularly the successful enrollment of participants in the ATH434-201 Phase 2 trial for Multiple System Atrophy (MSA). The trial's continuation was backed by favorable feedback from an independent Data Monitoring Committee. The company also initiated a new Phase 2 trial, ATH434-202, and has been productive in securing patents for innovative drug candidates targeting neurodegenerative diseases. Motivated by their advancements, Alterity is set for an ambitious year ahead in fiscal 2024.
Read more →ATHEResults of Annual General Meeting MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA - 29 November 2023 Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company") advises that all resolutions considered at the
Alterity Therapeutics held its Annual General Meeting on November 29, 2023, where all resolutions were passed by poll. The results showed strong support from shareholders, with significant percentages voting in favor of the non-binding remuneration report, the re-election of directors, and the ratification of prior share issues. Additionally, the approval of a 10% placement facility was granted to enhance their financing capabilities.
Read more →ATHEAlterity Therapeutics (NASDAQ:ATHE, ASX:ATH) David Stamler, MD CEO November 2023 Forward Looking Statements This presentation may contain some statements that may be considered "Forward - Looking Statements", within the
Alterity Therapeutics presented their forward-looking statements concerning the development of ATH434, a small molecule drug candidate aimed at neurodegenerative diseases, specifically Multiple System Atrophy (MSA), which currently has no approved therapies. The company has achieved Orphan Drug designation for this candidate in both the US and EU and is currently conducting Phase 2 clinical trials. With a leadership team experienced in neurology and FDA approvals, Alterity aims to address significant unmet medical needs in the treatment of MSA and related disorders.
Read more →ATHE▼ -6.5%on this newsshared move
Alterity Therapeutics Announces Presentation of Novel Biomarker Data for Evaluation of Multiple System Atrophy MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA - 27 November 2023: Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE
Alterity Therapeutics announced a poster presentation detailing novel biomarker data from its bioMUSE Natural History Study at the 34th International Symposium on the Autonomic Nervous System. The study identified N-acetylaspartate (NAA) as a potential biomarker for assessing disease severity in early-stage Multiple System Atrophy (MSA). The findings suggest NAA correlates with neurofilament light chain (NfL) levels, indicating its potential utility in evaluating treatment efficacy for MSA. Alterity's lead candidate, ATH434, is also currently undergoing Phase 2 clinical trials for MSA.
Read more →ATHE▼ -30.3%on this newsshared move
Proposed issue of securities Announcement Summary Entity name ALTERITY THERAPEUTICS LIMITED Announcement Type New announcement Date of this announcement 22/11/2023 The Proposed issue is: A placement or other type of issu
Alterity Therapeutics Limited has announced a proposed issue of securities including short-dated options totaling approximately 1.37 billion and long-dated options of around 457 million. Additionally, 1.01 billion common shares are set for issuance. This initiative aims to raise capital, but it is contingent on receiving security holder approval by the end of December 2023, which introduces a degree of uncertainty. If approved, the new securities will be offered at specific exercise prices and terms on the ASX.
Read more →ATHE▼ -30.3%on this newsshared move
Alterity Therapeutics (NASDAQ:ATHE, ASX:ATH) D av i d S ta ml e r , M D CEO No ve mb e r 2023 Forward Looking Statements This presentation may contain some statements that may be considered "Forward - Looking Statements"
Alterity Therapeutics has presented its forward-looking statements regarding its future plans and objectives concerning the development of its drug candidate ATH434, aimed at treating Multiple System Atrophy and related parkinsonian disorders. The drug is currently in a Phase 2 clinical trial and has received Orphan Drug designation, highlighting its potential to address a significant unmet medical need. The company's leadership team brings a wealth of experience from prior FDA-approved neurological therapies, enhancing its credibility in the biopharmaceutical space.
Read more →ATHE▼ -30.3%on this newsshared move
Alterity Therapeutics Raises $4.8M AUD in Placement - Funds to be used primarily to advance ongoing Phase 2 clinical trials in MSA - MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA - 22 November 2023: Alterity Therapeutics (
Alterity Therapeutics has announced a successful capital raising of A$4.8M through a two-tranche placement aimed at advancing its Phase 2 clinical trials for Multiple System Atrophy (MSA). The funding will enable further clinical development of its lead candidate, ATH434, which is positioned to treat neurodegenerative diseases. Enrollment has recently been completed in the ATH434-201 randomized trial, and the company expects to release preliminary data from the ATH434-202 open-label study in the coming months. Additionally, shareholders in Australia and New Zealand will have the opportunity to participate in a Security Purchase Plan under the same terms as the placement.
Read more →ATHE▼ -30.3%on this newsshared move
Market Announcement 20 November 2023 Alterity Therapeutics Limited (ASX: ATH) - Trading Halt Description The securities of Alterity Therapeutics Limited ( ATH') will be placed in trading halt at the request of ATH, pendi
Alterity Therapeutics Limited requested a trading halt for its securities pending an announcement related to a capital raise. The halt will remain in effect until normal trading resumes on November 22, 2023, or until the announcement is made. The company has stated there are no known reasons against the trading halt or additional information required to inform the market.
Read more →ATHEAlterity Therapeutics Announces Presentation of New Data Demonstrating Novel Mechanisms of ATH434 MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA - 16 November 2023: Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity"
Alterity Therapeutics has announced new data on ATH434, presented at the Society for Neuroscience conference. This data demonstrates ATH434's ability to protect mitochondrial function and exert antioxidant activity independent of its iron-binding properties. The compound is currently undergoing two Phase 2 clinical trials for Multiple System Atrophy and has been granted Orphan drug designation by the FDA and European Commission. The CEO highlighted the potential for ATH434 to slow disease progression in neurodegenerative conditions.
Read more →ATHE▲ +12.8%on this news
Alterity Therapeutics Completes Enrolment in ATH434-201 Phase 2 Clinical Trial in Multiple System Atrophy - ATH434-201 is a randomized, double-blind, placebo-controlled study in early-stage MSA - - Lead clinical developm
Alterity Therapeutics has successfully completed enrolment in its Phase 2 clinical trial, ATH434-201, focusing on early-stage multiple system atrophy (MSA). This randomized, double-blind, placebo-controlled study involved 77 participants across several regions, including the U.S., Europe, and Australia. The trial aims to evaluate the efficacy of ATH434, an oral agent designed to inhibit pathological protein aggregation, by assessing neuroimaging and clinical endpoints. Results are expected by the fourth quarter of 2024, which will inform the potential approval pathway for ATH434.
Read more →ATHEALTERITY THERAPEUTICS LIMITED ACN 080 699 065 Notice of Annual General Meeting and Explanatory Memorandum Time and Date of Meeting: 9:00 am (AEDT) on Wednesday 29 th November 2023 Registration from 8:30 am Location: Leve
Alterity Therapeutics Limited is set to hold its Annual General Meeting on November 29, 2023, at 9:00 am AEDT in Carlton, Victoria. Shareholders are encouraged to vote ahead of the meeting by appointing a proxy or registering online. The agenda includes the review of the company's financial statements and several key resolutions, including director re-elections and share placements. A webcast will allow shareholders to follow along but restricts interaction during the meeting.
Read more →ATHE▼ -6%on this newsshared move
Appendix 4C - Q1 FY24 Quarterly Cash Flow Report Highlights: Participant screening closed for ATH434-201 Phase 2 study Independent Data Monitoring Committee recommended the ATH434-201 Phase 2 study continue as planned Re
Alterity Therapeutics Limited reported significant developments in its quarterly cash flow report for Q1 FY24, including the closure of participant screening for the ATH434-201 Phase 2 study. An independent Data Monitoring Committee recommended that the trial progress as planned without safety concerns. Furthermore, the company secured a new patent in Europe for a class of drug candidates aimed at treating neurodegenerative diseases, strengthening its position in the market. Alterity's ongoing efforts include two Phase 2 trials targeting Multiple System Atrophy (MSA) in different patient populations.
Read more →ATHENotification of cessation of +securities Announcement Summary Entity name ALTERITY THERAPEUTICS LIMITED Announcement Type New announcement Date of this announcement Wednesday
Alterity Therapeutics Limited has announced the cessation of 500,000 options (ATHAAG), which expired on September 11, 2023. The reason for this cessation is the lapse of conditional rights to these securities due to the failure to meet specified conditions. This event may affect the company's financial obligations and future equity structure. Following this cessation, the company's issued capital remains predominantly unchanged, with various other option classes still in place.
Read more →ATHEAlterity Therapeutics Limited Appendix 4E Audited Financial Report For the year ended 30 June 2023 Name of entity Alterity Therapeutics Limited ABN or equivalent company reference 37 080 699 065 Current reporting period
Alterity Therapeutics Limited reported its audited financial results for the year ended June 30, 2023, highlighting a significant increase in revenue from $2,504 to $16,436. Despite this growth, the company experienced a net loss after tax of $13,806,515, which reflects a 7.5% increase compared to the previous year. The company is making progress in its Phase 2 clinical trial of ATH434 for multiple system atrophy, with enrollment ongoing at multiple international sites and no safety concerns reported by an independent Data Monitoring Committee. However, the company's net tangible assets per share have declined significantly from the prior year. The future outlook includes top-line data expected in 2024.
Read more →ATHEAlterity Therapeutics Limited Corporate Governance Statement 30 June 2023 This Corporate Governance Statement of Alterity Therapeutics Limited (the "Company") is prepared in accordance with ASX Listing Rule 4.10.3. It is
Alterity Therapeutics Limited has published its Corporate Governance Statement for the financial year ending June 30, 2023, in conformity with ASX Listing Rule 4.10.3. The report details the company's governance framework, principles adopted by the Board, and its commitment to ethical standards and diversity in staffing. It also highlights the ongoing assessment of board performance and the structure of the Board and its committees. This statement is intended to complement information in the company's Annual Report and is available on its website.
Read more →ATHEAlterity Therapeutics Presents New Data on Multiple System Atrophy, a Rare Parkinsonian Disorder - Presentations Convey Novel Approach for Improving Diagnostic Accuracy and Tracking Disease Severity in MSA - - Data Prese
Alterity Therapeutics announced new findings on the diagnosis and management of Multiple System Atrophy (MSA) at the International Congress of Parkinson's Disease and Movement Disorders. The data, stemming from the bioMUSE natural history study, highlights the importance of biomarkers in accurately diagnosing MSA, which can be challenging due to its similarity to Parkinson's disease. With support from Vanderbilt University, Alterity aims to enhance the patient enrollment process for its Phase 2 clinical trial by incorporating these innovative diagnostic techniques. The study shows promise in addressing the urgent need for effective therapies for patients suffering from this debilitating condition.
Read more →ATHEAlterity Therapeutics Granted New Composition of Matter Patent in Europe for Neurodegenerative Diseases including Parkinson's and Alzheimer's New Patent Covers Over 150 Novel Compounds MELBOURNE, AUSTRALIA AND SAN FRANCI
Alterity Therapeutics has been granted a new composition of matter patent by the European Patent Office, which provides broad protection for a new class of iron chaperone drug candidates aimed at treating neurodegenerative diseases, including Parkinson's and Alzheimer's. The patent encompasses over 150 novel compounds and offers 20 years of exclusivity, facilitating drug development and commercialization. Company CEO David Stamler emphasized the significance of this patent in their strategy to lead in developing disease-modifying treatments for these severe conditions.
Read more →ATHEAlterity Therapeutics Rare Disease Natural History Study to be Featured at the International Congress of Parkinson's Disease and Movement Disorders - Presentations Highlight New Data on Diagnostic Accuracy and Novel Biom
Alterity Therapeutics announced that its Rare Disease Natural History Study will be featured at the upcoming International Congress of Parkinson's Disease and Movement Disorders in Copenhagen. Presentations will focus on new data concerning diagnostic accuracy and biomarkers of Multiple System Atrophy (MSA). The bioMUSE study aims to track the progression of MSA, which currently has no approved therapies, and provides critical insights for the design of Alterity's Phase 2 clinical trial. The collaboration with Vanderbilt University Medical Center enhances the potential impact of the findings presented at the congress.
Read more →ATHEAlterity Therapeutics Receives a $4.74 million Research & Development Tax Incentive Refund MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA - 15 August 2023. Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) ("Alterity"
Alterity Therapeutics announced the receipt of a A$4.74 million cash refund under the Australian Government's Research and Development Tax Incentive Scheme. This funding is earmarked for advancing the clinical development of ATH434, the company's lead drug candidate, currently in Phase 2 trials for Multiple System Atrophy. ATH434 has demonstrated the ability to inhibit protein aggregation involved in neurodegeneration and has achieved favorable outcomes in earlier studies.
Read more →ATHEAppendix 4C - Q4 FY23 Quarterly Cash Flow Report Highlights: ATH434-201 Phase 2 study on track to complete enrollment in Q3 2023 with top-line data expected by the end of 2024 in individuals with Multiple System Atrophy
Alterity Therapeutics Limited recently released its Q4 FY23 cash flow report, emphasizing significant progress in its ATH434-201 Phase 2 clinical trial for Multiple System Atrophy (MSA). The trial is set to complete enrollment in Q3 2023, with top-line data anticipated by the end of 2024. Following the recommendation from the Data Monitoring Committee, the trial will continue without modifications. Additionally, a second Phase 2 study, ATH434-202, has been initiated to investigate ATH434's efficacy in more advanced MSA cases.
Read more →ATHE▲ +6.5%on this newsshared move
Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned - ATH434-201 Trial on Track to Complete Enrollment in Q3 2023 - - Top-Line Data Expected by the End of 2024 - MELBOU
Alterity Therapeutics has announced that the independent Data Monitoring Committee recommended continuing the ATH434-201 Phase 2 clinical trial as planned. This trial is focused on early-stage multiple system atrophy (MSA), a rare neurodegenerative disease without approved treatments. Enrollment is expected to be completed in Q3 2023, with top-line data anticipated by the end of 2024. The study evaluates the effects of ATH434 on neuroimaging and biomarkers important to MSA pathology.
Read more →ATHEAlterity Therapeutics ( N AS D A Q: A T H E , AS X : A T H ) D av i d S t a ml er , M D CEO Jun e 2023 Forward Looking Statements This presentation may contain some statements that may be considered "Forward - Looking St
Alterity Therapeutics is advancing its drug candidate ATH434, targeting Multiple System Atrophy (MSA), a neurodegenerative disease lacking approved treatments. The company has achieved Orphan Drug designation for this asset in both the US and EU, and is currently conducting a Phase 2 clinical study. The leadership team's significant experience in oncology and neurology, highlighted by prior FDA approvals, positions Alterity positively in the competitive biopharmaceutical landscape. The focus on modifying disease progression rather than merely treating symptoms addresses a critical need in Parkinsonian disorders.
Read more →ATHEAlterity Therapeutics to Present in MST Access Rare Diseases, Rich Returns Forum on 22 June 2023 MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA - 21 June 2023: Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "
Alterity Therapeutics announced that its CEO, David Stamler, will present a corporate overview at the MST Access Rare Diseases, Rich Returns Forum on June 22, 2023. The presentation will include a Q&A discussion, providing insights into the company's developments, especially regarding its lead asset, ATH434, which targets Parkinsonian disorders. Alterity is currently engaged in clinical trials for the treatment of Multiple System Atrophy. The event highlights Alterity's commitment to addressing neurodegenerative diseases.
Read more →ATHE▲ +6.5%on this news
Alterity Therapeutics Initiates Second Phase 2 Study in Rare Parkinsonian Disorder - ATH434 now being evaluated in early and more advanced Multiple System Atrophy - - New trial expected to generate data before ongoing Ph
Alterity Therapeutics has launched a new Phase 2 clinical trial to evaluate ATH434 in patients with Multiple System Atrophy (MSA), targeting individuals with more advanced stages than those in the ongoing randomized trial. The trial aims to assess the efficacy of ATH434 on important biomarkers relevant to MSA pathology. Initial data from the new study is anticipated before the conclusion of the existing Phase 2 trial, enabling interim analyses of drug activity. This development reflects the company's commitment to advancing treatments for neurodegenerative diseases and potentially optimizing future drug development.
Read more →ATHE▼ -5.9%on this news
Alterity Therapeutics CEO David Stamler to Present at the SHARE Series Monday Management Update on Monday, May 22, 2023
Alterity Therapeutics announced that its CEO, David Stamler, will present at the SHARE Series Monday Management Update on May 22, 2023. The event will be conducted in a fireside chat format, allowing both retail and institutional investors to engage and ask questions. Alterity is focused on developing disease-modifying treatments for neurodegenerative disorders, with its lead asset, ATH434, showing promise in treating Parkinsonian disorders. The presentation will be accessible via live and archived webcast for 90 days post-event.
Read more →ATHEAlterity Therapeutics Enrolls First Patient in Australia in ATH434 Global Phase 2 Clinical Trial in Multiple System Atrophy MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA - 10 May 2023: Alterity Therapeutics (ASX:ATH, NASDA
Alterity Therapeutics has announced the enrollment and treatment of the first patient in Australia for its ATH434 Phase 2 clinical trial focusing on Multiple System Atrophy (MSA). This trial, which is set to take place in five countries, aims to evaluate the effects of ATH434 on neuroimaging and protein biomarkers. Given the rapid progression of MSA and limited treatment options available, ATH434 presents a potential breakthrough as a disease-modifying agent. The trial uses innovative methods to ensure effective patient monitoring and evaluation.
Read more →ATHEAppendix 4C - Q3 FY23 Quarterly Cash Flow Report Highlights: Continued expansion of ATH434 Phase 2 Clinical Trial with sites open for recruitment in five countries Participants in the US and Europe received first dose as
Alterity Therapeutics Limited reported significant updates in their Q3 FY23 cash flow report, emphasizing the progress of the ATH434 Phase 2 clinical trial for Multiple System Atrophy (MSA). The trial has opened recruitment in five countries, including the U.S. and Italy, with initial participants already dosed. The company also highlighted encouraging data from an independent study suggesting ATH434's neuroprotective potential. In addition, Alterity secured a new patent for novel compounds related to neurodegenerative treatments.
Read more →ATHEAlterity Therapeutics Presents Promising Wearable Sensor Data from the bioMUSE Natural History Study at the American Academy of Neurology - Wearable sensor parameters correlate strongly with clinical scales of motor impa
Alterity Therapeutics presented promising data from its bioMUSE natural history study at the American Academy of Neurology, highlighting the effectiveness of wearable sensors in assessing motor impairment in multiple system atrophy (MSA) patients. The study demonstrated a strong correlation between sensor parameters and clinical scales of motor function, suggesting these sensors could enhance disease progression tracking. The findings will be integrated into Alterity's Phase 2 clinical trial for ATH434, which aims to evaluate the therapeutic's effect on gait stability in early-stage MSA patients.
Read more →ATHENotification of cessation of +securities Announcement Summary Entity name ALTERITY THERAPEUTICS LIMITED Announcement Type New announcement Date of this announcement Tuesday
Alterity Therapeutics Limited has announced the cessation of certain securities, specifically 1.5 million options expiring on November 29, 2026, due to the inability to satisfy their conditions. This lapse means that these options will no longer contribute to the company's capital structure. The announcement provides details about the current issued capital and indicates that the company is not offering any consideration for the cessation. The remaining options and equity securities are listed along with their corresponding details.
Read more →ATHEAlterity Therapeutics Enrols First Patient in the United Kingdom in ATH434 Phase 2 Clinical Trial in Multiple System Atrophy MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA - 4 April 2023: Alterity Therapeutics (ASX: ATH, NA
Alterity Therapeutics has announced the enrollment of the first patient in the United Kingdom for its Phase 2 clinical trial of ATH434, aimed at treating Multiple System Atrophy (MSA). This trial is designed to evaluate ATH434's effects on patients with early-stage MSA, focusing on neuroimaging, biomarker changes, and clinical efficacy after a 12-month treatment period. The trial will involve approximately 60 adults across five countries, further expanding the company's research reach in Europe. ATH434 is an oral agent that has shown potential in preclinical models to inhibit protein aggregation associated with neurodegeneration.
Read more →ATHEAlterity Therapeutics Enrolls First Patient in the United Kingdom in ATH434 Phase 2 Clinical Trial in Multiple System Atrophy
Alterity Therapeutics announced the enrollment of its first patient in the Phase 2 clinical trial of ATH434 for Multiple System Atrophy (MSA) in the United Kingdom. The trial aims to evaluate the drug's effects on neuroimaging, biomarkers, and clinical endpoints over 12 months. ATH434 is designed to target the aggregation of proteins implicated in neurodegeneration, with prior studies suggesting favorable safety and efficacy profiles. The trial is seeking around 60 participants across various locations and hopes to advance the development of treatment for this debilitating disorder.
Read more →ATHE▲ +6.7%on this news
ASX ANNOUNCEMENT 16 March 2023 Notice Under Section 708A(5)(e) of the Corporations Act This notice is given by Alterity Therapeutics Limited ACN 080 699 065 (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), under s
Alterity Therapeutics Limited announced the issuance of 23,479,200 fully paid ordinary shares on March 15, 2023. This notice was given under section 708A(5)(e) of the Corporations Act. The shares were issued at a price of AUD 0.0076 each. The announcement outlines the details necessary for compliance with regulatory requirements.
Read more →ATHE▲ +6.7%on this news
Alterity Therapeutics Enrolls First Patient in the U.S. in ATH434 Phase 2 Clinical Trial in Multiple System Atrophy MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA - 16 March 2023: Alterity Therapeutics (ASX: ATH, NASDAQ: AT
Alterity Therapeutics has initiated its Phase 2 clinical trial for ATH434 in Multiple System Atrophy (MSA) with the dosing of the first patient in the U.S. at Vanderbilt University Medical Center. The trial aims to assess the efficacy and safety of ATH434, an oral treatment designed to inhibit the aggregation of pathological proteins involved in neurodegeneration. With participation from five countries and expected enrollment of about 60 adults, the study seeks to evaluate treatment effects on biomarkers and clinical endpoints over a 12-month period. Previous Phase 1 studies indicated that ATH434 is well tolerated, providing an optimistic outlook for its potential to treat MSA and related disorders.
Read more →ATHE▼ -12.7%on this newsshared move
Proposed issue of securities Announcement Summary Entity name ALTERITY THERAPEUTICS LIMITED Announcement Type New announcement Date of this announcement 15/3/2023 The Proposed issue is: A placement or other type of issue
Alterity Therapeutics Limited has announced a proposed issue of 23,479,200 ordinary fully paid securities for cash consideration at AUD 0.00760 per security. The issuance is intended to be quoted on the ASX and does not require any external approvals. This capital raise could support the company's future projects or operations, leveraging the equity market under existing terms.
Read more →ATHE▼ -7.1%on this news· ran to -19% by day 1shared move
Alterity Therapeutics Announces Granting of New Composition of Matter Patent and Exclusive License Agreement for Assets in Alzheimer's Disease - Composition of matter patent from USPTO covers more than 100 novel compound
Alterity Therapeutics has been granted a new composition of matter patent by the USPTO for over 100 novel compounds aimed at treating Alzheimer's disease. The company announced an exclusive license agreement with Professor Colin Masters to evaluate their legacy asset PBT2 alongside these new compounds. This patent offers a 20-year exclusivity period, potentially bolstering Alterity's position in the neurodegenerative disease market. Notably, the agreement taps into ongoing research advancements that could enhance therapeutic options for Alzheimer’s and related conditions.
Read more →ATHEInvestor Webinar Presentation MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA - 9 March 2023: Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing dise
Alterity Therapeutics announced its participation in the ShareCafe Small Cap 'Hidden Gems' Webinar scheduled for March 10, 2023. CEO Dr. David Stamler will present an overview of the company's focus on developing treatments for neurodegenerative diseases. The webinar will offer attendees an opportunity to engage with a variety of ASX-listed micro and mid-cap companies. A recorded version of the webinar will also be made available after the event.
Read more →ATHEAlterity Therapeutics Enrolls First Patient in Italy in ATH434 Phase 2 Clinical Trial in Multiple System Atrophy MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA - 8 March 2023: Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE)
Alterity Therapeutics has announced the dosing of the first patient in Italy as part of its Phase 2 clinical trial of ATH434 for Multiple System Atrophy (MSA). This trial will evaluate the drug's effectiveness in early-stage MSA patients, utilizing biomarkers and wearable sensors to assess treatment impacts. With a focus on safety and efficacy, ATH434 may offer new therapeutic avenues for this debilitating neurodegenerative disease previously lacking effective treatments. The trial is expected to enroll around 60 participants over 12 months.
Read more →ATHEAlterity Therapeutics Limited Appendix 4D Half-year ended 31 December 2022 Name of entity: Alterity Therapeutics Limited ABN: 37 080 699 065 Half-year ended: 31 December 2022 Previous period: 31 December 2021 Results for
Alterity Therapeutics Limited released its Appendix 4D financial report for the half-year ending December 31, 2022. The company witnessed a remarkable revenue increase of 742.9%, though it also reported a net loss after tax of $8,031,937, a 22% hike compared to the previous period. Importantly, Alterity commenced its Phase 2 clinical trial for ATH434, addressing Multiple System Atrophy, and has initiated patient enrollment across multiple international sites. The progress reflects the company's commitment to developing new therapies for neurodegenerative diseases.
Read more →ATHEAlterity Therapeutics Receives Regulatory Authorization in France and Austria to Proceed with ATH434 Phase 2 Clinical Trial MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA - 16 February 2023: Alterity Therapeutics (ASX: ATH,
Alterity Therapeutics has secured regulatory approval to conduct Phase 2 clinical trials for its drug ATH434 in France and Austria. This trial will focus on patients with early-stage Multiple System Atrophy (MSA), a rare neurodegenerative disease. The randomized, double-blind trial aims to assess the drug's efficacy and safety over a 12-month period, enrolling approximately 60 adults. This regulatory action signifies an important milestone in Alterity's efforts to advance treatments for neurodegenerative conditions.
Read more →ATHE▼ -5.8%on this newsshared move
Appendix 4C - Q2 FY23 Quarterly Cash Flow Report Highlights: Expanded participation in ATH434 Phase 2 clinical trial with sites opened for recruitment in Australia, the United States, and Italy Presented compelling bioMU
Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) has released its Q2 FY23 cash flow report, highlighting the global expansion of its Phase 2 clinical trial for ATH434 in Multiple System Atrophy. The company has opened additional recruitment sites in the United States and Italy, aiming to enroll 60 patients for the study. Furthermore, Alterity has secured a new patent that enhances its intellectual property portfolio, focusing on compounds that may treat various neurodegenerative diseases. The latest data from the bioMUSE study also provides valuable insights into the disease, aiding the ongoing trial efforts.
Read more →ATHE▲ +6.1%on this newsshared move
Alterity's ATH434 Prevents Loss of Brain Cells in Parkinson's Disease Animal Model Independent Study Reports ATH434 Prevented Onset of Motor and Non-Motor Symptoms in Animals with Genetically Induced Parkinson's disease
Alterity Therapeutics announced that its lead asset, ATH434, demonstrated neuroprotective effects in an independent study published in Neurotherapeutics. The study showed that ATH434 prevented the loss of smell and motor impairment in animal models with genetically induced Parkinson's disease. The findings add to the evidence supporting ATH434's potential efficacy in addressing Parkinson's disease pathology. Currently, ATH434 is undergoing a Phase 2 clinical trial for early-stage Multiple System Atrophy (MSA).
Read more →ATHEAlterity Therapeutics Launches ATH434 Phase 2 Clinical Trial in Italy for the Treatment of Individuals with Multiple System Atrophy Recruitment ongoing in Europe, Asia-Pacific, and the U.S. for study of rapidly progressi
Alterity Therapeutics has initiated a Phase 2 clinical trial for ATH434, targeting patients with Multiple System Atrophy (MSA) in Italy. This trial aims to evaluate the efficacy and safety of ATH434, an oral therapy designed to modify the disease rather than just alleviate symptoms. With recruitment ongoing across Europe, Asia-Pacific, and the U.S., the study will enroll about 60 participants to assess various biomarkers associated with MSA. ATH434 has previously passed Phase 1 trials with favorable safety profiles and has been granted Orphan designation by regulatory agencies.
Read more →ATHEAlterity Therapeutics Launches ATH434 Phase 2 Clinical Trial in the United States for the Treatment of Individuals with Multiple System Atrophy U.S. now open for enrollment of rare, rapidly progressive Parkinsonian Disor
Alterity Therapeutics has announced the opening of enrollment for its Phase 2 clinical trial of ATH434, targeting patients with Multiple System Atrophy (MSA). The trial, taking place at Vanderbilt University Medical Center, aims to assess the drug's efficacy in modifying the disease, which currently has no approved treatments. ATH434 is designed to inhibit the aggregation of proteins implicated in neurodegeneration and has shown promise in early studies. The company also plans to expand trial sites in the U.S. and Europe.
Read more →ATHEAlterity Therapeutics Announces 1-for-10 Reverse ADS Split (consolidation) MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA - 6 January 2023: Alterity Therapeutics Limited ("Alterity" or the "Company") (ASX:ATH, NASDAQ:ATHE),
Alterity Therapeutics has announced a 1-for-10 reverse split of its American Depository Shares, effective January 9, 2023. This move aims to regain compliance with NASDAQ’s minimum bid price requirement of $1.00 per share. The company's Board of Directors approved the split amidst challenges in maintaining its listing and the ongoing development of its lead asset, ATH434, which targets neurodegenerative diseases. The success of this strategy, however, remains uncertain as the company has until February 23 to demonstrate compliance.
Read more →ATHEAlterity Therapeutics to Participate in the Sachs Associates 6 th Annual Neuroscience Innovation Forum MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA - 3 January 2023: Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alteri
Alterity Therapeutics will participate in the Sachs Associates 6th Annual Neuroscience Innovation Forum, with CEO David Stamler speaking on a panel about new approaches to Parkinson's and Movement Disorders. The event coincides with the J.P. Morgan Healthcare Conference and aims to showcase recent developments in global bio-partnering and investment in neurodegenerative disease treatments. Alterity's lead asset, ATH434, targets various Parkinsonian disorders, emphasizing the company's commitment to innovation in the field.
Read more →ATHE▲ +16.9%on this newsshared move
Alterity Therapeutics Announces Allowance of New Composition of Matter Patent by the United States Patent and Trademark Office - Patent covers more than 100 novel compounds targeting neurodegenerative diseases including
Alterity Therapeutics Announces Allowance of New Composition of Matter Patent by the United States Patent and Trademark Office - Patent covers more than 100 novel compounds targeting neurodegenerative diseases including Parkinson's and Alzheimer's - AUSTRALIA AND SAN FRANCI
Read more →ATHECONSTITUTION OF ALTERITY THERAPEUTICS LIMITED ACN 080 699 065 (amended by special resolutions of shareholders on 18 November 2020 and 11 November 2022) Contents Clause Number Heading Page 1. Preliminary 1 1.1 Definitions
ALTERITY THERAPEUTICS LIMITED (amended by special resolutions of shareholders on 18 November 2020 and 11 November 2022) Clause Number Heading Page 1. Preliminary 1 1.1 Definitions 1 1.2 Corporations Act and Listing Rules definitions 2 1.3 Interpretation 2 1.4 Repla
Read more →ATHECOMPANY ANNOUNCEMENT (ASX: ATH, NASDAQ: ATHE) RESULTS OF ANNUAL GENERAL MEETING Friday, 11 th November 2022 The Company wishes to advise that all resolutions contained in the Notice of Meeting were carried by poll. In ac
COMPANY ANNOUNCEMENT (ASX: ATH, NASDAQ: ATHE) RESULTS OF ANNUAL GENERAL Friday, 11th November 2022 The Company wishes to advise that all resolutions contained in the Notice of Meeting were carried by poll. In accordance with ASX Listing rule 3.13.2 and Section 251AA(1) of
Read more →ATHEChairman's Address 2022 Annual General Meeting Good morning all and thank you for joining us today for our FY22 Annual General Meeting. I'm pleased to share with you my chairman's address for this year's Annual General M
Chairman's Address 2022 Annual Good morning all and thank you for joining us today for our FY22 Annual General Meeting. pleased to share with you my chairman's address for this year's Annual General Meeting for Alterity Therapeutics. We are hosting this meeting both in person
Read more →ATHEAlterity Therapeutics (NASDAQ:ATHE, ASX:ATH) David Stamler, MD CEO November 2022 Forward Looking Statements This presentation may contain some statements that may be considered "Forward - Looking Statements", within the
Alterity Therapeutics (NASDAQ:ATHE, ASX:ATH) David Stamler, MD CEO November 2022 Forward Looking Statements This presentation may contain some statements that may be considered "Forward - Looking Statements", within the meaning of the US Securities Laws . Thus, any forward - loo
Read more →ATHEAlterity Therapeutics Announces Presentation of Data from the bioMUSE Natural History Study at the American Autonomic Society Annual Meeting MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA - 7 November 2022: Alterity Therape
Alterity Therapeutics Announces Presentation of Data from the bioMUSE Natural History Study at the American Autonomic Society Annual Meeting MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA - 7 November 2022: Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Compan
Read more →ATHEAppendix 4C - Q1 FY23 Quarterly Cash Flow Report First patient dosed in Phase 2 clinical trial for ATH434 in New Zealand, trial opens in Europe and Australia Approval of Investigational New Drug application by FDA to bri
FY23 Quarterly Cash Flow Report MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA - 28 October 2022. Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerati
Read more →ATHEAlterity Therapeutics Announces Presentation of MRI Data from the bioMUSE Natural History Study at the American Neurological Association Annual Meeting MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA - 26 October 2022: Alter
Alterity Therapeutics Announces Presentation of MRI Data from the bioMUSE Natural History Study at the American Neurological Association Annual Meeting MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA - 26 October 2022: Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or
Read more →ATHEAlterity Therapeutics Launches ATH434 Phase 2 Clinical Trial in Australia for the Treatment of Individuals with Multiple System Atrophy Australia now open for study of rare, rapidly progressive Parkinsonian Disorder MELB
Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial in Australia for the Treatment of Individuals with Multiple System Atrophy Australia now open for study of rare, rapidly progressive Parkinsonian Disorder MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA - 13 October 20
Read more →ATHEALTERITY THERAPEUTICS LIMITED ACN 080 699 065 Notice of Annual General Meeting and Explanatory Memorandum Time and Date of Meeting: 9:00 am (AEDT) on Friday 11 th November 2022 Registration from 8:30 am Location: Level 3
ALTERITY THERAPEUTICS LIMITED of Annual General Meeting and Explanatory Memorandum Time and Date of Meeting: 9:00 am (AEDT) on Friday 11 th November 2022 Registration from 8:30 am Location: Level 3, 62 Lygon Street, Carlton, Victoria, 3053 and virtually Shareholders are strong
Read more →ATHEAlterity Therapeutics Announces Presentation of Wearable Sensor Data from the bioMUSE Natural History Study at the International Congress of Parkinson's Disease and Movement Disorders - Wearable sensors strongly correlat
Therapeutics Announces Presentation of Wearable Sensor Data from the bioMUSE Natural History Study at the International Congress of Parkinson's Disease and Movement Disorders - Wearable sensors strongly correlated with clinical scales on motor impairment - - bioMUSE Study Va
Read more →ATHE▼ -10%on this newsshared move
ASX ANNOUNCEMENT 23 September 2022 Notice Under Section 708A(5)(e) of the Corporations Act This notice is given by Alterity Therapeutics Limited ACN 080 699 065 (ATH or Company) under section 708A(5)(e) of the Corporatio
Notice Under Section 708A(5)(e) of the Corporations This notice is given by Alterity Therapeutics Limited ACN 080 699 065 (ATH or Company) under section 708A(5)(e) of the Corporations Act 2001 (Cth) (Corporations Act). Details of securities issued Type: Shares Class/Descriptio
Read more →ATHE▼ -12.5%on this newsshared move
Proposed issue of securities Announcement Summary Entity name ALTERITY THERAPEUTICS LIMITED Announcement Type New announcement Date of this announcement 21/9/2022 The Proposed issue is: A placement or other type of issue
Announcement Summary ALTERITY THERAPEUTICS LIMITED Date of this announcement The Proposed issue is: placement or other type of issue Total number of +securities proposed to be issued for a placement or other type of issue ASX +security code +Security description Maximum N
Read more →ATHE▼ -10.7%on this news· ran to -22% by day 1shared move
Alterity Therapeutics Receives U.S. FDA Approval for Investigational New Drug Application for ATH434 for the Treatment of Multiple System Atrophy Regulatory Authorization Granted to Proceed with ATH434 Phase 2 Clinical T
Alterity Therapeutics Receives U.S. FDA Approval for Investigational New Drug Application for ATH434 for the Treatment of Multiple System Atrophy Regulatory Authorization Granted to Proceed with ATH434 Phase 2 Clinical Trial MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA - 20
Read more →ATHEAlterity Therapeutics filed Form 20-F and XBRL data with SEC MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA - 1 September 2022: Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company") has announced that
Alterity Therapeutics filed Form 20-F and MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA - 1 September 2022: Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company") has announced that it has filed its Annual Report on Form 20-F containing audited consolidated
Read more →ATHE▼ -5.3%on this newsshared move
Rules 4.7.3 and 4.10.3 Appendix 4G Key to Disclosures Corporate Governance Council Principles and Recommendations Name of entity Alterity Therapeutics Ltd ABN/ARBN Financial year ended: 37 080 699 065 30 June 2022 Our co
Rules 4.7.3 and 4.10.3 Governance Council Principles and Recommendations Name of entity Alterity Therapeutics Ltd ABN/ARBN Financial year ended: 37 080 699 065 30 June 2022 Our corporate governance statement1 for the period above These pages of our annual report: This U
Read more →ATHE▼ -5.3%on this newsshared move
Alterity Therapeutics Limited Appendix 4E - Preliminary Final Report For the year ended 30 June 2022 Name of entity Alterity Therapeutics Limited ABN or equivalent company reference 37 080 699 065 Current reporting perio
Alterity Therapeutics Limited Appendix 4E - Preliminary For the year ended 30 June 2022 Name of entity Alterity Therapeutics Limited ABN or equivalent company reference 37 080 699 065 Current reporting period 30 June 2022 Corresponding reporting period 30 June 2021 Results fo
Read more →ATHEAlterity Therapeutics Launches ATH434 Phase 2 Clinical Trial for the Treatment of Patients with Multiple System Atrophy in Europe Second region now open for enrolment for rare, rapidly progressive, neurodegenerative dise
Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial for the Treatment of Patients with Multiple System Atrophy in Europe Second region now open for enrolment for rare, rapidly progressive, neurodegenerative disease MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA - 25 A
Read more →ATHEAlterity Therapeutics granted extension by Nasdaq to regain compliance minimum bid price requirement MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA - 24 August 2022: Alterity Therapeutics Limited ("Alterity" or the "Company
Alterity Therapeutics granted extension by Nasdaq to regain compliance minimum bid price requirement MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA - 24 August 2022: Alterity Therapeutics Limited ("Alterity" or the "Company") (ASX:ATH, NASDAQ:ATHE), a biotechnology company dedi
Read more →ATHEAppendix 4C - Q4 FY22 Quarterly Cash Flow Report Phase 2 clinical trial for ATH434 commences in New Zealand and patient enrolment begins Regulatory approval from the U.K. and Italian regulatory agencies to proceed with t
4C - Q4 FY22 Quarterly Cash Flow Report AUSTRALIA AND SAN FRANCISCO, USA - 22 July 2022. Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative dise
Read more →ATHEAlterity Therapeutics Doses First Patient in ATH434 Phase 2 Clinical Trial in Multiple System Atrophy MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA - 6 July 2022: Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity"
Therapeutics Doses First Patient in ATH434 Phase 2 Clinical Trial in Multiple System Atrophy AUSTRALIA AND SAN FRANCISCO, USA - 6 July 2022: Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease mod
Read more →ATHEAlterity receives a $4.1 million R&D Tax Incentive Refund MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA - 30 June 2022. Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology
Alterity receives a $4.1 million R&D Tax MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA - 30 June 2022. Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodege
Read more →ATHENotification of cessation of +securities Announcement Summary Entity name ALTERITY THERAPEUTICS LIMITED Announcement Type New announcement Date of this announcement Monday
Announcement Summary ALTERITY THERAPEUTICS LIMITED Date of this announcement Monday June 27, 2022 Details of +securities that have ceased ASX +security code Security description Number of +securities that have ceased The +securities have ceased due to Date of cessation ATHAS
Read more →ATHE▲ +5.2%on this newsshared move
Alterity Therapeutics Announces Regulatory Authorization to Proceed with ATH434 Phase 2 Clinical Trial in Italy MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA - 23 June 2022: Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (
Alterity Therapeutics Announces Regulatory Authorization to Proceed with ATH434 Phase 2 Clinical Trial in Italy MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA - 23 June 2022: Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company de
Read more →ATHEAlterity Therapeutics to Present at the at VirtualInvestorConferences.com Life Sciences Investor Forum MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA - 20 June 2022: Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity
Alterity Therapeutics to Present at the at VirtualInvestorConferences.com Life Sciences Investor Forum MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA - 20 June 2022: Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated t
Read more →ATHEAlterity Therapeutics to Present at the VirtualInvestorConferences.com Life Sciences Investor Forum
MELBOURNE, Australia and SAN FRANCISCO, June 20, 2022 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced tha
Read more →ATHEAlterity Therapeutics to Present at the GCFF Virtual Conference 2022 - Investing in Healthcare MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA - 14 June 2022: Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "th
Alterity Therapeutics to Present at the GCFF Virtual Conference 2022 - Investing in Healthcare MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA - 14 June 2022: Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to develo
Read more →ATHEAlterity Therapeutics Launches ATH434 Phase 2 Clinical Trial for the Treatment of Patients with Multiple System Atrophy Multiple System Atrophy is a rare, rapidly progressive, neurodegenerative disease that causes profou
Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial for the Treatment of Patients with Multiple System Atrophy Multiple System Atrophy is a rare, rapidly progressive, neurodegenerative disease that causes profound disability MELBOURNE, AUSTRALIA AND SAN FRANCISCO, U
Read more →ATHEAlterity Therapeutics to Participate in the Benchmark Company Healthcare House Call Conference MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA - 26 May 2022: Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the
Alterity Therapeutics to Participate in the Benchmark Company Healthcare House Call Conference MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA - 26 May 2022: Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to develop
Read more →ATHEAppendix 4C - Q3 FY22 Quarterly Cash Flow Report MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA - 29 April 2022. Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company
FY22 Quarterly Cash Flow Report MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA - 29 April 2022. Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative
Read more →ATHEAlterity Therapeutics Announces Regulatory Authorization to Proceed with ATH434 Phase 2 Clinical Trial in the United Kingdom MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA - 27 April 2022: Alterity Therapeutics (ASX: ATH, N
Alterity Therapeutics Announces Regulatory Authorization to Proceed with ATH434 Phase 2 Clinical Trial in the United Kingdom MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA - 27 April 2022: Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnolo
Read more →ATHEAlterity Therapeutics Announces Presentation of bioMUSE Data at the American Academy of Neurology (AAN) Annual Meeting The data provides further validation of the intended Phase 2 study design MELBOURNE, AUSTRALIA AND SA
Alterity Therapeutics Announces Presentation of bioMUSE Data at the American Academy of Neurology (AAN) Annual Meeting The data provides further validation of the intended Phase 2 study design MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA - 7 April 2022: Alterity Therapeutics
Read more →ATHEAlterity Therapeutics to Participate in the Sachs Associates 5 th Annual Neuroscience Innovation Forum MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA - 15 March 2022: Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterit
Alterity Therapeutics to Participate in the Sachs Associates 5th Annual Neuroscience Innovation Forum MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA - 15 March 2022: Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated t
Read more →ATHEAlterity Therapeutics ( NASDA Q: A T HE, ASX : A T H) D avi d S ta m le r , M D CEO Ma r c h 2022 Forward Looking Statements This presentation may contain some statements that may be considered "Forward - Looking Stateme
Alterity Therapeutics ( NASDA Q: A T HE, ASX : A T H) D avi d S ta m le r , M D CEO Ma r c h 2022 Forward Looking Statements This presentation may contain some statements that may be considered "Forward - Looking Statements", within the meaning of the US Securities Laws. Thus, a
Read more →ATHEAlterity Therapeutics to Present at the 34 th Annual Roth Conference MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA - 7 March 2022: Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnolo
Therapeutics to Present at the 34th Annual Roth Conference AUSTRALIA AND SAN FRANCISCO, USA - 7 March 2022: Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegene
Read more →ATHEAlterity Therapeutics Limited Appendix 4D Half-year ended 31 December 2021 Name of entity: Alterity Therapeutics Limited ABN: 37 080 699 065 Half-year ended: 31 December 2021 Previous period: 31 December 2020 Results for
Alterity Therapeutics Limited Half-year ended 31 December 2021 Name of entity: Alterity Therapeutics Limited ABN: 37 080 699 065 Half-year ended: 31 December 2021 Previous period: 31 December 2020 Results for announcement to the market A$ Revenue from ordinary activities
Read more →ATHEAlterity Therapeutics Receives Non-Compliance Notice Regarding Nasdaq Minimum Bid Price Requirement MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA - 28 February 2022: Alterity Therapeutics Limited ("Alterity" or the "Compan
Alterity Therapeutics Receives Non-Compliance Notice Regarding Nasdaq Minimum Bid Price Requirement MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA - 28 February 2022: Alterity Therapeutics Limited ("Alterity" or the "Company") (ASX:ATH, NASDAQ:ATHE), a biotechnology company dedi
Read more →ATHE▲ +8.9%on this news· ran to +22% by day 1
Alterity Therapeutics Announces Publication Demonstrating that ATH434 is Neuroprotective in Animal Model of Parkinsonian Disorder in the Journal of Parkinson's Disease Study demonstrates reduction of -synuclein aggregati
Therapeutics Announces Publication Demonstrating that ATH434 is Neuroprotective in Animal Model of Parkinsonian Disorder in the Journal of Parkinson's Disease Study demonstrates reduction of -synuclein aggregation and preservation of neurons MELBOURNE, AUSTRALIA AND SAN FRANC
Read more →ATHEAppendix 4C - Q2 FY22 Quarterly Cash Flow Report Highlights: NZ's regulator Medsafe authorizes Phase 2 clinical trial for ATH434; more jurisdictions to follow New poster presentation and publications provide further evid
Appendix 4C - Q2 FY22 NZ's regulator Medsafe authorizes Phase 2 clinical trial for ATH434; more jurisdictions to follow New poster presentation and publications provide further evidence of potential of ATH434 to treat neurodegenerative diseases New US composition of matter
Read more →ATHE▲ +33.8%on this news
Alterity Therapeutics Granted New US Patent for Compounds for Neurodegenerative Diseases Including Parkinson's and Alzheimer's Composition of Matter Patent Covers More than 80 Novel Compounds MELBOURNE, AUSTRALIA AND SAN
Alterity Therapeutics Granted New US Patent for Compounds for Neurodegenerative Diseases Including Parkinson's and Alzheimer's Composition of Matter Patent Covers More than 80 Novel Compounds MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA - 6 January 2022: Alterity Therapeutic
Read more →ATHEAlterity Therapeutics to Present at the H.C. Wainwright BIOCONNECT Virtual Conference MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA - 5 January 2022: Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Compa
Therapeutics to Present at the H.C. Wainwright BIOCONNECT Virtual Conference AUSTRALIA AND SAN FRANCISCO, USA - 5 January 2022: Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatm
Read more →ATHEAlterity Therapeutics Announces Resignation of Non-Executive Directors MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA - 4 January 2022: Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotech
Alterity Therapeutics Announces Resignation of Non-Executive Directors MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA - 4 January 2022: Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying
Read more →ATHEAlterity Therapeutics Announces First Regulatory Authorization to Proceed with ATH434 Phase 2 Clinical Trial Initiation of Phase 2 Clinical Trial Expected in CY Q1 2022 MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA - 14 De
Alterity Therapeutics Announces First Regulatory Authorization to Proceed with ATH434 Phase 2 Clinical Trial Initiation of Phase 2 Clinical Trial Expected MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA - 14 December 2021: Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity
Read more →ATHE▼ -5.6%on this news
Alterity Therapeutics to Participate in Two Upcoming Investor Conferences MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA - 22 November 2021: Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a bi
Alterity Therapeutics to Participate in Two Upcoming Investor Conferences MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA - 22 November 2021: Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modi
Read more →ATHECOMPANY ANNOUNCEMENT (ASX: ATH) RESULTS OF ANNUAL GENERAL MEETING Friday, 12 th November 2021 The Company wishes to advise that all resolutions contained in the Notice of Meeting were carried by poll. In accordance with
OF ANNUAL GENERAL MEETING Company wishes to advise that all resolutions contained in the Notice of Meeting were carried by poll. accordance with ASX Listing rule 3.13.2 and Section 251AA(1) of the Corporations Act 2001, the following page provides information in relation to th
Read more →ATHEAlterity Therapeutics (NASDAQ: A THE, AS X: A TH) AGM CEO Address 2021 Davi d Stamle r , MD CEO 1 2 Novembe r 2021 Forward Looking Statements This presentation may contain some statements that may be considered "Forward
Alterity Therapeutics (NASDAQ: A THE, AS X: A TH) AGM CEO Address 2021 Davi d Stamle r , MD CEO 1 2 Novembe r 2021 Forward Looking Statements This presentation may contain some statements that may be considered "Forward - Looking Statements", within the meaning of the US Securit
Read more →ATHEChairman's Address 2021 Annual General Meeting I am pleased to present my Chairman's address at this year's Annual General Meeting. For the second year in a row, we do this under unique circumstances, and we appreciate t
2021 Annual General Meeting I am pleased to present my Chairman's address at this year's Annual General Meeting. For the second year in a row, we do this under unique circumstances, and we appreciate the involvement of our shareholders and our corporate partners in today's vir
Read more →ATHEAlterity Therapeutics Announces Presentation of ATH434 at the American Autonomic Society Virtual Meeting 2021 MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA - 9 November 2021: Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE)
Therapeutics Announces Presentation of ATH434 at the American Autonomic Society Virtual Meeting 2021 AUSTRALIA AND SAN FRANCISCO, USA - 9 November 2021: Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing
Read more →ATHEAlterity Therapeutics Announces New Publications Providing Further Evidence of the Potential of ATH434 to Treat Neurodegenerative Diseases Colorectal impairment reversed in a preclinical model of Parkinson's Disease ATH4
Therapeutics Announces New Publications Providing Further Evidence of the Potential of ATH434 to Treat Neurodegenerative Diseases impairment reversed in a preclinical model of Parkinson's Disease presents a novel mechanism of action for the treatment of neurodegenerative disea
Read more →ATHEAppendix 4C - Q1 FY22 Quarterly Cash Flow Report Highlights: New details on ATH34 Phase 2 clinical trial released. Data from bioMUSE presented at International Parkinson and Movement Disorder Society Congress. Expanded i
FY22 Quarterly Cash Flow Report MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA - 29 October 2021. Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerati
Read more →ATHEAlterity Therapeutics Announces Expanded ATH434 Phase 2 Clinical Development Program - Clinical trial to enroll patients with early-stage Multiple Systems Atrophy (MSA) - - Expanding bioMUSE Natural History Study - MELBO
Alterity Therapeutics Announces Expanded ATH434 Phase 2 Clinical Development Program - Clinical trial to enroll patients with early-stage Multiple Systems Atrophy (MSA) - - Expanding bioMUSE Natural History Study MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA - 19 October 2021
Read more →ATHEABN 37 080 699 065 Notice of Annual General Meeting and Explanatory Memorandum Alterity Therapeutics Limited: ACN 080 699 065 Date of Meeting: Friday 12 th November 2021 Time of Meeting: 9:00am (AEDT) Registration from 8
of Annual General Meeting and Explanatory Memorandum Alterity Therapeutics Limited: ACN 080 699 065 Date of Meeting: Friday 12 th November 2021 Time of Meeting: 9:00am (AEDT) Registration from 8:45am ahead of attending the Meeting Shareholders are strongly encouraged to vote
Read more →ATHEAlterity Announces Presentation of Biomarker Data at the International Parkinson and Movement Disorder Society Congress 2021 Study Results Successfully Inform the Design of ATH434 Phase 2 Clinical Trial MELBOURNE, AUSTRA
Alterity Announces Presentation of Biomarker Data at the International Parkinson and Movement Disorder Society Congress 2021 Study Results Successfully Inform the Design of ATH434 Phase 2 Clinical Trial MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA - 20th September 2021: Alter
Read more →ATHEAlterity Therapeutics Limited Appendix 4E - Preliminary Final Report For the year ended 30 June 2021 Name of entity Alterity Therapeutics Limited ABN or equivalent company reference 37 080 699 065 Current reporting perio
Alterity Therapeutics Limited Appendix 4E - Preliminary For the year ended 30 June 2021 Name of entity Alterity Therapeutics Limited ABN or equivalent company reference 37 080 699 065 Current reporting period 30 June 2021 Corresponding reporting period 30 June 2020 Results fo
Read more →ATHERules 4.7.3 and 4.10.3 Appendix 4G Key to Disclosures Corporate Governance Council Principles and Recommendations Name of entity Alterity Therapeutics Ltd ABN/ARBN Financial year ended: 37 080 699 065 30 June 2021 Our co
Rules 4.7.3 and 4.10.3 Governance Council Principles and Recommendations Name of entity Alterity Therapeutics Ltd ABN/ARBN Financial year ended: 37 080 699 065 30 June 2021 Our corporate governance statement1 for the period above These pages of our annual report: This U
Read more →ATHEAlterity Therapeutics filed Form 20-F and XBRL data with SEC MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA - 3 September 2021: Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company") has announced that
Alterity Therapeutics filed Form 20-F and XBRL data with SEC MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA - 3 September 2021: Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company") has announced that it has filed its Annual Report on Form 20-F containing
Read more →ATHE▲ +14.3%on this news
Alterity Therapeutics Announces New US Patent to Expand its Portfolio of Compounds for Neurodegenerative Diseases including Alzheimer's and Parkinson's Composition of Matter Patent Covers More than 80 Novel Compounds MEL
Therapeutics Announces New US Patent to Expand its Portfolio of Compounds Neurodegenerative Diseases including Alzheimer's and Parkinson's of Matter Patent Covers More than 80 Novel Compounds AUSTRALIA AND SAN FRANCISCO, USA - 4 August 2021: Alterity Therapeutics (ASX: ATH, NA
Read more →ATHEAppendix 4C - Q4 FY21 Quarterly Cash Flow Report Highlights: Positive Guidance from European Medicines Agency for ATH434 Phase 2 Clinical Trial Publication in Movement Disorders demonstrates that ATH434 reduces -synuclei
4C - Q4 FY21 Quarterly Cash Flow Report AUSTRALIA AND SAN FRANCISCO, USA - 30 July 2021. Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative cond
Read more →ATHE▲ +7.9%on this news
Alterity Therapeutics Announces Publication of Data Demonstrating ATH434 is Neuroprotective and Improves Motor Function MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA - 15 July 2021: Alterity Therapeutics (ASX: ATH, NASDAQ:
Alterity Therapeutics Announces Publication of Data Demonstrating ATH434 is and Improves Motor Function MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA - 15 July 2021: Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated
Read more →ATHEASX ANNOUNCEMENT Notice Under Section 708A(5) of the Corporations Act ASX Code: ATH This notice is given under paragraph (5)(e) of section 708A of the Corporations Act . Type: Shares Class/Description: Fully paid ordinar
Notice Under Section 708A(5) of the Corporations Act This notice is given under paragraph (5)(e) of section 708A of the Corporations Act. Type: Shares Class/Description: Fully paid ordinary shares ASX Code: ATH Date of Issue: 5 July 2021 Number Issued: 322,857,900 Issue Price
Read more →ATHEProposed issue of securities Announcement Summary Entity name ALTERITY THERAPEUTICS LIMITED Announcement Type New announcement Date of this announcement 2/7/2021 The Proposed issue is: A placement or other type of issue
ALTERITY THERAPEUTICS LIMITED Date of this announcement The Proposed issue is: Total number of +securities proposed to be issued for a placement or other type of issue ASX +security code +Security description Maximum Number of +securities to be issued ATH ORDINARY FULLY P
Read more →ATHEAlterity Therapeutics granted a new US patent targeting major neurodegenerative diseases including Alzheimer's and Parkinson's MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA - 1 st July 2021: Alterity Therapeutics (ASX: ATH
Alterity Therapeutics granted a new US patent targeting major neurodegenerative diseases including Alzheimer's and Parkinson's MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA - 1st July 2021: Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company") has today a
Read more →ATHEEuropean Union Regulatory Guidance for ATH434 Phase 2 Clinical Trial Highlights: Alterity receives positive guidance from the European Medicines Agency's Committee for Medicinal Products for Human Use on its Phase 2 clin
European Union Regulatory Guidance for ATH434 Phase 2 Clinical Trial MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA - 23 June 2021. Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company") has received guidance from the European Medicines Agency (EMA)
Read more →ATHEAlterity Therapeutics (NASDAQ: A THE , ASX: A T H) Jun e 2021 Davi d Stamle r , MD CEO Forward Looking Statements This presentation may contain some statements that may be considered "Forward - Looking Statements", withi
Alterity Therapeutics (NASDAQ: A THE , ASX: A T H) Jun e 2021 Davi d Stamle r , MD CEO Forward Looking Statements This presentation may contain some statements that may be considered "Forward - Looking Statements", within the meaning of the US Securities Laws. Thus, any forward
Read more →ATHEAlterity Therapeutics to Present at the MST Access Australian Micro & Small Caps Conference MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA - 16th June 2021. Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) ("Alterity"
Therapeutics to Present at the MST Access Australian Micro & Small Caps Conference AUSTRALIA AND SAN FRANCISCO, USA - 16th June 2021. Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to creating an alternat
Read more →ATHEAppendix 4C - Q3 FY21 Quarterly Cash Flow Report Highlights: Michael J. Fox Foundation grants Alterity $US495K for Parkinson's disease research evaluation Strengthening profile at investment, scientific and clinical conf
Appendix 4C - Q3 FY21 Quarterly Cash Flow Report MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA - 29th April 2021. Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company") releases its Appendix 4C Quarterly Cash Flow Report and update on company activ
Read more →ATHEATH434 protects brain cells and improves motor function in Parkinsonian disorder Oral presentation at the American Academy of Neurology MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA - 21st April 2021: Alterity Therapeutics
protects brain cells and improves motor function Parkinsonian disorder presentation at the American Academy of Neurology AUSTRALIA AND SAN FRANCISCO, USA - 21st April 2021: Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company") today announced an oral pr
Read more →ATHERule 3.10.3A, 3.10.3B, 3.10.3C Appendix 3G Notification of issue, conversion or payment up of equity +securities Information or documents not available now must be given to ASX as soon as available. Information and docum
Notification of issue, conversion or payment up of equity +securities Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public. If you are an entity incorporated o
Read more →ATHEAlterity CEO Dr David Stamler presents to US investors at the HC Wainwright Global Life Science Conference MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA - 10 th March 2021: Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("
Alterity CEO Dr David Stamler presents the HC Wainwright Global Life Science MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA - 10th March 2021: Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company") CEO Dr David Stamler is presenting to US investors this wee
Read more →ATHEAlterity to present at the 7th International Congress of Multiple System Atrophy MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA - 26th February 2021: Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "th
Alterity to present at the 7th International Multiple System Atrophy MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA - 26th February 2021: Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), will present at the upcoming 7th International Congress
Read more →ATHEAlterity Therapeutics Limited Appendix 4D Half year ended 31 December 2020 Name of entity: Alterity Therapeutics Limited ABN: 37 080 699 065 Half-year ended: 31 December 2020 Previous period: 31 December 2019 Results for
Alterity Therapeutics Limited Appendix 4D Half year ended 31 December 2020 Name of entity: Alterity Therapeutics Limited ABN: 37 080 699 065 Half-year ended: 31 December 2020 Previous period: 31 December 2019 Results for announcement to the market A$ Revenue from ordinar
Read more →ATHEAlterity Half Year Results and Investor Webcast Notification MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA - 19th February 2021: Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), today a
Alterity Half Year Results and Investor Webcast Notification MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA - 19th February 2021: Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), today advises it will release its financial results for the six
Read more →ATHERule 2.7 Appendix 2A Application for quotation of +securities Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be
for quotation of +securities Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public. If you are an entity incorporated outside Australia and you are seeking quot
Read more →ATHEProposed issue of securities Announcement Summary Entity name ALTERITY THERAPEUTICS LIMITED Announcement Type New announcement Date of this announcement Wednesday
Announcement Summary ALTERITY THERAPEUTICS LIMITED Date of this announcement Wednesday February 10, 2021 The Proposed issue is: placement or other type of issue Total number of +securities proposed to be issued for a placement or other type of issue Maximum Number of
Read more →ATHEAlterity Therapeutics announces funding from Michael J. Fox Foundation for ATH434 dose optimization for Parkinson's disease clinical trials MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA - 9 th February 2021: Alterity Thera
Alterity Therapeutics announces funding from Michael J. Fox Foundation for ATH434 dose optimization for Parkinson's disease clinical trials MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA - 9th February 2021: Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Comp
Read more →ATHEAppendix 4C - Q2 FY21 Quarterly Cash Flow Report Highlights: Dr David Stamler appointed CEO; Geoffrey Kempler continues as Non-Executive Chairman New commercial opportunity for PBT2 with UniQuest to reverse bacterial res
Q2 FY21 Quarterly Cash Flow Report AUSTRALIA AND SAN FRANCISCO, USA - 28 January 2021. Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company") releases its Appendix 4C Quarterly Cash Flow Report and update on company activities for the quarter endi
Read more →ATHEAlterity participates in world's largest virtual healthcare conference JP Morgan MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA - 11th January 2021: Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company
Alterity participates in world's largest virtual healthcare conference JP Morgan MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA - 11th January 2021: Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company") CEO Dr David Stamler will meet with investors during
Read more →ATHEDr David Stamler Appointed CEO MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA - 7 January 2021: The Board of Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company") is pleased to announce the appointmen
Dr David Stamler Appointed CEO MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA - 7 January 2021: The Board of Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company") is pleased to announce the appointment of Dr David Stamler to the role of Chief Executive Offi
Read more →ATHEAlterity and UniQuest partner to reverse bacterial resistance to antibiotics New commercial opportunity for PBT2 MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA - 21st December 2020: Alterity Therapeutics (ASX: ATH, NASDAQ:
Alterity and UniQuest partner to reverse bacterial resistance to antibiotics New commercial opportunity for PBT2 MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA - 21st December 2020: Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company") has today announced
Read more →ATHEAlterity presents at Finance News Network investor event MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA - 2nd December 2020: Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company") CEO and Chairman Mr G
Alterity presents at Finance News Network MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA - 2nd December 2020: Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company") CEO and Chairman Mr Geoffrey Kempler will present to investors at the Finance News Network ev
Read more →ATHECONSTITUTION OF ALTERITY THERAPEUTICS LIMITED ACN 080 699 065 (as adopted by a special resolution of shareholders on 28 November 2008 and amended by a special resolution of shareholders on 18 November 2020) Contents Clau
ALTERITY THERAPEUTICS (as adopted by a special resolution of shareholders on 28 November 2008 and amended by a special resolution of shareholders on 18 November 2020) Clause Number Heading Page 1. Preliminary 1 1.1 Definitions 1 1.2 Corporations Act and Listing Rules
Read more →ATHECOMPANY ANNOUNCEMENT (ASX: ATH) RESULTS OF ANNUAL GENERAL MEETING Wednesday, 18 th November 2020 The Company wishes to advise that all resolutions contained in the Notice of Meeting were carried by poll. In accordance wi
RESULTS OF ANNUAL GENERAL MEETING Company wishes to advise that all resolutions contained in the Notice of Meeting were carried by poll. accordance with ASX Listing rule 3.13.2 and Section 251AA(1) of the Corporations Act 2001, the following page provides information in relati
Read more →ATHEChairman's Address 2020 Annual General Meeting While the world responds and adjusts to the COVID-19 pandemic, at Alterity we've remained highly focused on preparing our lead compound ATH434 for further clinical developme
Address 2020 Annual General Meeting the world responds and adjusts to the COVID-19 pandemic, at Alterity we've remained highly focused on preparing our lead compound ATH434 for further clinical development. Neurodegenerative diseases like our lead disease indication Multiple Sy
Read more →ATHEAlterity announces approval of US patent for next generation compounds to treat neurodegenerative diseases MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA - 16 th November 2020: Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE)
Alterity announces approval of US patent compounds to treat neurodegenerative diseases MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA - 16th November 2020: Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company") has today announced the allowance of a new com
Read more →ATHEAppendix 4C - Q1 FY21 Quarterly Cash Flow Report Highlights: Continued scientific and clinical validation of lead compound ATH434 End of period cash balance of $7.4M Post reporting period, Alterity raised $35M via an Ins
Appendix 4C - Q1 FY21 Quarterly AUSTRALIA AND SAN FRANCISCO, USA - 30 October 2020. Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company") releases its Appendix 4C Quarterly Cash Flow Report and update on company activities for the quarter ending
Read more →ATHEAlterity commences enrolling Multiple System Atrophy patients in bioMUSE Study MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA - 27th October 2020: Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company")
commences enrolling Multiple System Atrophy patients in bioMUSE Study AUSTRALIA AND SAN FRANCISCO, USA - 27th October 2020: Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company") today announced it has commenced enrolling patients with Multiple System Atr
Read more →ATHENot for release to US wire services or distribution in the United States Alterity completes Placement Tranche 1 raising $10M $25M Second Tranche to complete following shareholder approval Alterity completes Tranche 1 of
for release to US wire services or distribution in the United States completes Placement Tranche 1 raising $10M Second Tranche to complete following shareholder approval AUSTRALIA AND SAN FRANCISCO, USA - 23 October 2020: Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alteri
Read more →ATHEABN 37 080 699 065 Notice of Annual General Meeting and Explanatory Memorandum Alterity Therapeutics Limited: ACN 080 699 065 Date of Meeting: Wednesday 18 th November 2020 Time of Meeting: 09:30am (AEDT) Registration fr
Notice of Annual General Explanatory Memorandum Alterity Therapeutics Limited: ACN 080 699 065 Date of Meeting: Wednesday 18 th November 2020 Time of Meeting: 09:30am (AEDT) Registration from 09:15am Place of Meeting: Attendance at the Meeting - Covid-19 To avoid needing to
Read more →ATHEProposed issue of securities Announcement Summary Entity name ALTERITY THERAPEUTICS LIMITED Announcement Type New announcement Date of this announcement Friday
THERAPEUTICS LIMITED of this announcement or other type of issue number of +securities proposed to be issued for a placement or other type of issue ASX +security code +Security description Maximum Number of +securities to be issued n/a Attaching options 674,694,939 ATH ORDINA
Read more →ATHEMarket Announcement 12 October 2020 Alterity Therapeutics Limited (ASX: ATH) - Trading Halt (2+2) Description The securities of Alterity Therapeutics Limited ( ATH') will be placed in trading halt at the request of ATH,
Alterity Therapeutics Limited (ASX: ATH) - Trading Halt The securities of Alterity Therapeutics Limited ( ATH') will be placed in trading halt at the request of ATH, pending it releasing an announcement regarding a capital raising. Unless ASX decides otherwise, the securities
Read more →ATHEAlterity Therapeutics filed Form 20-F and XBRL data with SEC MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA - 16th September 2020: Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company") has announced t
Alterity Therapeutics filed Form 20-F and XBRL data with SEC MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA - 16th September 2020: Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company") has announced that it has filed its Annual Report on Form 20-F containi
Read more →ATHERules 4.7.3 and 4.10.31 Appendix 4G Key to Disclosures Corporate Governance Council Principles and Recommendations Name of entity: Alterity Therapeutics Limited ABN / ARBN: Financial year ended: 37 080 699 065 30 June 20
Rules 4.7.3 and 4.10.31 Corporate Governance Council Principles and Recommendations ABN / ARBN: Financial year ended: 37 080 699 065 30 June 2020 Our corporate governance statement2 for the above period above These pages of our annual report: This URL on our website: ht
Read more →ATHEAlterity Therapeutics Limited 2020 Annual Report CONTENTS Alterity Therapeutics Limited ACN 080 699 065 Annual report - 30 June 2020 Page Corporate directory 3 Chairman's letter 4 Review of operations and activities 5 In
Therapeutics Limited report - 30 June 2020 Page Corporate directory 3 Chairman's letter 4 Review of operations and activities 5 Intellectual property report 28 Directors' report 30 Auditor's Independence Declaration 48 Consolidated financial statements 49 Independent auditor's
Read more →ATHEAnnual Report MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA - 9th September 2020: Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company") will today release its Annual Report for the year ending 30 Jun
MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA - 9th September 2020: Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company") will today release its Annual Report for the year ending 30 June 2020. There has been a change to the financial statements since the
Read more →ATHEThis appendix is not available as an online form Please fill in and submit as a PDF announcement +Rule 3.10.3A, 3.10.3B, 3.10.3C Appendix 3G Notification of issue, conversion or payment up of equity +securities Informati
of issue, conversion or payment up of equity +securities Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public. If you are an entity incorporated outside Austra
Read more →ATHECOMPANY ANNOUNCEMENT (ASX: ATH) RESULTS OF GENERAL MEETING Thursday, 3rd September 2020 The Company wishes to advise that all resolutions contained in the Notice of Meeting were carried by proxy tally. In accordance with
COMPANY ANNOUNCEMENT RESULTS OF GENERAL MEETING Thursday, 3rd September 2020 The Company wishes to advise that all resolutions contained in the Notice of Meeting were carried by proxy tally. In accordance with ASX Listing rule 3.13.2 and Section 251AA(1) of the Corporations
Read more →ATHEAlterity Therapeutics Limited ACN 080 699 065 Appendix 4E Preliminary Final Report 30 June 2020 Lodged with the ASX under Listing Rule 4.3A. This information should be read in conjunction with the Appendix 4E. Alterity T
Alterity Therapeutics Limited Appendix 4E Preliminary Final Report Lodged with the ASX under This information should be read in conjunction with the Appendix 4E. Alterity Therapeutics Limited 4E - Preliminary Final Report For the year ended 30 June 2020 Name of entity Alte
Read more →ATHEABN 37 080 699 065 Notice of General Meeting and Explanatory Memorandum Alterity Therapeutics Limited: ACN 080 699 065 Date of Meeting: Thursday 3 rd September 2020 Time of Meeting: 10:30am (AEST) Registration from 10:15
Notice of General Meeting and Explanatory Memorandum Alterity Therapeutics Limited: ACN 080 699 065 Date of Meeting: Thursday 3 rd September 2020 Time of Meeting: 10:30am (AEST) Registration from 10:15am Place of Meeting: Attendance at the Meeting - Covid-19 To avoid ne
Read more →ATHENew data independently confirms and extends laboratory findings and expands safety profile of ATH434 MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA - 4th August 2020: Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterit
New data independently confirms and extends and expands safety profile of ATH434 MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA - 4th August 2020: Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company") today announced that new clinical and experimental phar
Read more →ATHEAppendix 4C - Q4 FY20 Quarterly Cash Flow Report Highlights: FDA provides guidance for ATH434 development pathway Company compliant with minimum NASDAQ price End of period cash balance of $9.2M bolstered by $1.5M followi
Appendix 4C - Q4 FY20 Quarterly MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA - 30 July 2020. Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company") releases its Appendix 4C Quarterly Cash Flow Report and update on company activities for the quarter
Read more →ATHEAlterity Therapeutics meeting with US FDA provides development pathway for ATH434 MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA - 30th June 2020: Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company")
Alterity Therapeutics meeting with US FDA provides development pathway for ATH434 AUSTRALIA AND SAN FRANCISCO, USA - 30th June 2020: Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company") is pleased to announce that it has received guidance from the US Fo
Read more →ATHEAlterity Therapeutics presents data on ATH434 to the American Academy of Neurology MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA - 21st May 2020: Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company")
Therapeutics presents data on ATH434 to the American Academy of Neurology AUSTRALIA AND SAN FRANCISCO, USA - 21st May 2020: Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company") has presented data on ATH434 (formerly PBT434) for the treatment of Multiple
Read more →ATHEAppendix 4C - Q3 FY20 Quarterly Cash Flow Report Highlights: European Commission designated Orphan Drug status for ATH434's treatment of Multiple System Atrophy in the European Union Phase 2 preparatory work continues Ca
4C - Q3 FY20 Quarterly Cash Flow Report AUSTRALIA AND SAN FRANCISCO, USA - 30 April 2020. Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company") releases its Appendix 4C Quarterly Cash Flow Report and update on company activities for the quarter e
Read more →ATHEAlterity qualifies for temporary relief from NASDAQ regarding Minimum Bid Price Requirement MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA - 22 April 2020: Alterity Therapeutics Limited (ASX:ATH, NASDAQ:ATHE) has received n
Alterity qualifies for temporary relief from NASDAQ regarding Minimum Bid Price Requirement MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA - 22 April 2020: Alterity Therapeutics Limited (ASX:ATH, NASDAQ:ATHE) has received notification from NASDAQ advising that as a result of NA
Read more →ATHEAppendix 2A Application for quotation of +securities Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made publ
Application for quotation of +securities Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public. If you are an entity incorporated outside Australia and you are
Read more →ATHEProposed issue of securities Announcement Summary Entity name ALTERITY THERAPEUTICS LIMITED Announcement Type New announcement Date of this announcement Thursday
Announcement Summary ALTERITY THERAPEUTICS LIMITED Date of this announcement Thursday March 26, 2020 The Proposed issue is: A placement or other Total number of +securities proposed to be issued for a placement or other type of issue ASX +Security Code +Security Descripti
Read more →ATHEAlterity Therapeutics Limited Appendix 4D Half year ended 31 December 2019 Name of entity: Alterity Therapeutics Limited ABN: 37 080 699 065 Half-year ended: 31 December 2019 Previous period: 31 December 2018 Results for
Therapeutics Limited year ended 31 December 2019 Name of entity: Alterity Therapeutics Limited ABN: 37 080 699 065 Half-year ended: 31 December 2019 Previous period: 31 December 2018 Results for announcement to the market A$ Revenue from ordinar
Read more →ATHEINTERIM CONSOLIDATED FINANCIAL STATEMENTS OF ALTERITY THERAPEUTICS LIMITED AND SUBSIDIARIES, OR THE GROUP (A DEVELOPMENT STAGE ENTERPRISE) AS OF DECEMBER 31, 2019 IN AUSTRALIAN DOLLARS INDEX Page CONSOLIDATED STATEMENT O
INTERIM CONSOLIDATED FINANCIAL STATEMENTS OF ALTERITY THERAPEUTICS LIMITED AND SUBSIDIARIES, OR THE GROUP (A DEVELOPMENT STAGE ENTERPRISE) AS OF DECEMBER 31, 2019 IN AUSTRALIAN DOLLARS Page CONSOLIDATED STATEMENT OF FINANCIAL POSITION 1 CONSOLIDATED STATEMENT OF PROFIT OR L
Read more →ATHEReceives Non-Compliance Notice Regarding NASDAQ
Receives Non-Compliance Notice Regarding NASDAQ Minimum Bid Price Requirement AUSTRALIA AND SAN FRANCISCO, USA - 7 February 2020: Alterity Therapeutics Limited (ASX:ATH, NASDAQ:ATHE) has received notification from the Listing Qualifications Department of NASDAQ advising the Co
Read more →ATHE4C - Q2 FY20 Quarterly Cash Flow Report
4C - Q2 FY20 Quarterly Cash Flow Report European Commission designated Orphan Drug status for PBT434's treatment of Multiple System Atrophy in the European Union Receipt of $4.8M Tax Refund from the Australian Government's R&D Tax Incentive Scheme Cash balance of $12.2M A
Read more →ATHERule 2.7, 3.10.3, 3.10.4, 3.10.5
Rule 2.7, 3.10.3, 3.10.4, 3.10.5 New Issue Announcement, Application for Quotation of Additional Securities and Agreement Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and
Read more →ATHEreceives a $4.8 million R&D Tax Incentive Refund
receives a $4.8 million R&D Tax Incentive Refund AUSTRALIA AND SAN FRANCISCO, USA - 15 January 2020. Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company") has today announced that it has received a A$4.8 million cash refund under the Australian Go
Read more →ATHEUpcoming Release of warrants from Voluntary
Upcoming Release of warrants from Voluntary MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA - Wednesday 11 December 2019. Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) advises that the voluntary escrow of 586,672,964 short term warrants, each to acquire one ordinary share
Read more →ATHERESULTS OF ANNUAL GENERAL MEETING
COMPANY ANNOUNCEMENT RESULTS OF ANNUAL GENERAL MEETING Tuesday, 26th November 2019 The Company wishes to advise that all resolutions contained in the Notice of Meeting were carried on a show of hands. In accordance with ASX Listing rule 3.13.2 and Section 251AA(1) of the Co
Read more →ATHEAddress 2019 Annual General Meeting
Address 2019 Annual General Meeting Good morning ladies and gentlemen and welcome to the AGM for Alterity Therapeutics, our first under this new name which was approved at our last shareholders' meeting. Alterity means to be in an alternative or different state, and this ties
Read more →ATHERule 2.7, 3.10.3, 3.10.4, 3.10.5 Appendix 3B New Issue Announcement, Application for Quotation of Additional Securities and Agreement Information or documents not available now must be given to ASX as soon as available.
3.10.3, 3.10.4, 3.10.5 for Quotation of Additional or documents not available now must be given to ASX as soon as available. and documents given to ASX become ASX's property and may be made public. 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11
Read more →ATHEAlterity AGM Investor Conference Call
Alterity AGM Investor Conference Call MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA - 20 November 2019. Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company") invites investors unable to attend the Company's Annual General Meeting to participate via
Read more →ATHEAlterity's lead drug candidate
Alterity's lead drug candidate receives positive opinion from European medical agency MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA - Monday 18 November 2019. Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company") has received a positive opinion fr
Read more →ATHEAppendix 4C - Q1 FY20 Quarterly
Appendix 4C - Q1 FY20 Quarterly Results of Phase 1 Clinical Trials for lead compound PBT434 announced Presentation of clinical trial data at the 2019 International Congress of Parkinson's Disease and Movement Disorders (MDS Congress) in France Presentation at the Janney He
Read more →ATHEof Annual General Meeting and Explanatory Memorandum
of Annual General Meeting and Explanatory Memorandum Alterity Therapeutics Limited: ACN 080 699 065 Date of Meeting: Tuesday 26th November 2019 Time of Meeting: 09:30am (AEDT) Registration from 09:15am Place of Meeting: Adina Apartment Hotel 189 Queen Street, Melbourne,
Read more →ATHEAlterity presents clinical data on PBT434
Alterity presents clinical data on PBT434 at the 2019 MDS Congress MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA - Tuesday 24 September 2019. Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), presents a poster today titled: A First in Human S
Read more →ATHEto Present at the Janney Healthcare Conference in New York
Alterity Therapeutics to Present at the Janney Healthcare Conference in New York MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA - Monday 9th of September 2019. Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company") is participating in the Janney Hea
Read more →ATHEAlterity Therapeutics filed Form 20-F
Alterity Therapeutics filed Form 20-F and XBRL data with the SEC MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA - September 2nd, 2019. Alterity Therapeutics Limited, (formerly Prana Biotechnology Limited) (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company") has announced that
Read more →ATHE4E - Preliminary Final Report
Therapeutics Limited 4E - Preliminary Final Report the year ended 30 June 2019 Name of entity Alterity Therapeutics Limited ABN or equivalent company reference 37 080 699 065 Current reporting period 30 June 2019 Corresponding reporting period 30 June 2018 for announcement to
Read more →ATHERules 4.7.3 and 4.10.3 1 Appendix 4G Key to Disclosures Corporate Governance Council Principles and Recommendations Name of entity: Alterity Therapeutics Limited ABN / ARBN: Financial year ended: 37 080 699 065 30 June 2
Rules 4.7.3 and 4.10.31 Corporate Governance Council Principles and Recommendations Name of entity: Alterity Therapeutics Limited ABN / ARBN: Financial year ended: 37 080 699 065 30 June 2019 Our corporate governance statement2 for the above period above can be found at:3
Read more →ATHEUpcoming Release of Shares from Voluntary
Upcoming Release of Shares from Voluntary MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA - Monday, 5 August 2019. Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), in accordance with ASX Lising Rule 3.10A, advises that a total of 18,592,577 ord
Read more →ATHEAPPENDIX 3B Exhibit 1 Rule 2.7, 3.10.3, 3.10.4, 3.10.5 Appendix 3B New Issue Announcement, Application for Quotation of Additional Securities and Agreement Information or documents not available now must be given to ASX
2.7, 3.10.3, 3.10.4, 3.10.5 New Issue Announcement, Application for Quotation of Additional Securities and Agreement or documents not available now must be given to ASX as soon as available. and documents given to ASX become ASX's property and may be made public. 01/07/96 O
Read more →ATHEAPPENDIX 4C - QUARTERLY REPORT Exhibit 1 Appendix 4C - Q4 FY19 Quarterly Cash Flow Report Highlights: Completion of Phase 1 Clinical Trial; PBT434 found to be safe and well-tolerated; clinically tested doses achieve conc
4C - Q4 FY19 Quarterly Cash Flow Report AUSTRALIA AND SAN FRANCISCO, USA - Wednesday 31 July 2019. Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), releases its Appendix 4C Quarterly Cash Flow report and update on company activities for the
Read more →ATHEALTERITY THERAPEUTICS ANNOUNCES SUCCESSFUL COMPLETION OF PHASE 1 CLINICAL TRIAL Exhibit 1 Alterity Therapeutics Announces Successful Completion of Phase 1 Clinical Trial MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA - Mond
Alterity Therapeutics Announces Successful Completion of Phase 1 Clinical Trial MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA - Monday 29 July 2019. Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company") today announced that it has successfully com
Read more →ATHEINTERIM CONSOLIDATED FINANCIAL STATEMENTS OF PRANA BIOTECHNOLOGY LIMITED AND SUBSIDIARIES, OR THE GROUP (A DEVELOPMENT STAGE ENTERPRISE)AS OF DECEMBER 31, 2018 IN AUSTRALIAN DOLLARS INDEX Page CONSOLIDATED STATEMENT OF F
INTERIM CONSOLIDATED FINANCIAL STATEMENTS OF PRANA BIOTECHNOLOGY LIMITED AND SUBSIDIARIES, OR THE GROUP (A DEVELOPMENT STAGE ENTERPRISE)AS OF DECEMBER 31, 2018 IN AUSTRALIAN DOLLARS Page CONSOLIDATED STATEMENT OF FINANCIAL POSITION 1 CONSOLIDATED STATEMENT OF PROFIT OR LOS
Read more →ATHEMarket Announcement 24 December 2018 Prana Biotechnology Limited (ASX: PBT) - Trading Halt Description The securities of Prana Biotechnology Limited ( PBT') will be placed in trading halt at the request of PBT, pending i
Prana Biotechnology Limited (ASX: The securities of Prana Biotechnology Limited ( PBT') will be placed in trading halt at the request of PBT, pending it releasing an announcement. Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of the
Read more →ATHEPBT434 data to be presented at the International Congress of Parkinson's Disease and Movement Disorders Prana's PBT434 prevents neuronal loss in a new model of neurodegeneration MELBOURNE, AUSTRALIA AND SAN FRANCISCO, US
PBT434 data to be presented at the International Congress of Parkinson's Disease and Movement Disorders Prana's PBT434 prevents neuronal loss in a new model of neurodegeneration MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA - July 9th 2018: Prana Biotechnology Ltd (ASX PBT: NA
Read more →ATHEFirst volunteers dosed in Phase I clinical trial of PBT434, Prana's lead therapy for parkinsonian diseases Highlights: Prana enrols and doses its first cohort of healthy volunteers in its Phase I clinical trial Evidence
dosed in Phase I clinical trial of PBT434, Prana's lead therapy for parkinsonian diseases MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA - July 4, 2018: Prana Biotechnology Ltd (ASX PBT: NASDAQ PRAN) is pleased to announce the first cohort of volunteers in its Phase I clinical tr
Read more →ATHEINTERIM CONSOLIDATED FINANCIAL STATEMENTS OF PRANA BIOTECHNOLOGY LIMITED AND SUBSIDIARIES (A DEVELOPMENT STAGE ENTERPRISE), OR THE GROUP AS OF DECEMBER 31, 2017 IN AUSTRALIAN DOLLARS INDEX Page CONSOLIDATED STATEMENT OF
INTERIM CONSOLIDATED FINANCIAL STATEMENTS OF PRANA BIOTECHNOLOGY LIMITED AND SUBSIDIARIES (A DEVELOPMENT STAGE ENTERPRISE), OR THE GROUP AS OF DECEMBER 31, 2017 IN AUSTRALIAN DOLLARS Page CONSOLIDATED STATEMENT OF FINANCIAL POSITION 1 CONSOLIDATED STATEMENT OF PROFIT OR LOS
Read more →ATHEPrana commences research collaboration with Takeda for the treatment of Parkinson's disease gastrointestinal neuropathology PBT434, Prana's lead drug in preclinical development for movement disorders, to be profiled in c
Prana commences research collaboration with Takeda for the treatment of Parkinson's disease gastrointestinal neuropathology lead drug in preclinical development for movement disorders, to be profiled in collaborative venture MELBOURNE, Australia, and SAN FRANCISCO USA. 18th Ju
Read more →ATHEPrana's PBT434 Lowers Alpha-Synuclein and Prevents Neurodegeneration Scientific Journal Acta Neuropathologica publishes pre-clinical data MELBOURNE, Australia, and San Francisco USA 3 July 2017: Prana Biotechnology Ltd (
Prana's PBT434 Lowers Alpha-Synuclein and Prevents Neurodegeneration Scientific Journal Acta Neuropathologica publishes pre-clinical data MELBOURNE, Australia, and San Francisco USA 3 July 2017: Prana Biotechnology Ltd (ASX PBT: NASDAQ PRAN) today announced the article "The
Read more →ATHEChange of Address MELBOURNE, June 26 th 2017 In accordance with Listing Rule 3.14, the Company advises that the Registered Office will change effective immediately. The new address is detailed below: Registered Office Le
MELBOURNE, June 26th 2017 In accordance with Listing Rule 3.14, the Company advises that the Registered Office will change effective immediately. The new address is detailed below: Registered Office Level 3 62 Lygon Street Carlton Vic 3053 Australia Phone: +61 (0) 3 9824 5254
Read more →ATHEDavid Stamler as Chief Medical Officer to Lead Clinical Development
David Stamler as Chief Medical Officer to Lead Clinical Development MELBOURNE, AUSTRALIA. 5 June 2017: David Stamler, M.D., has joined Prana Biotechnology (ASX PBT, NASDAQ PRAN) as Chief Medical Officer and Senior Vice President, Clinical Development, based in San Francisco. P
Read more →ATHEPrana Biotechnology's Anti-Parkinsonian compound PBT434 presented at 13 th International Conference for Alzheimer's & Parkinson's Diseases Presentation entitled: PBT434 prevents neuronal loss, motor function and cognitiv
Prana Biotechnology's Anti-Parkinsonian compound PBT434 presented at 13th International Conference for Alzheimer's & Parkinson's Diseases Presentation entitled: PBT434 prevents neuronal loss, motor function and cognitive impairment in preclinical models of movement disorders b
Read more →ATHEINTERIM CONSOLIDATED FINANCIAL STATEMENTS OF PRANA BIOTECHNOLOGY LIMITED AND SUBSIDIARIES (A DEVELOPMENT STAGE ENTERPRISE), OR THE GROUP AS OF DECEMBER 31, 2016 IN AUSTRALIAN DOLLARS INDEX Page CONSOLIDATED STATEMENT OF
INTERIM CONSOLIDATED FINANCIAL STATEMENTS OF PRANA BIOTECHNOLOGY LIMITED AND SUBSIDIARIES DEVELOPMENT STAGE ENTERPRISE), OR THE GROUP AS OF DECEMBER 31, 2016 IN AUSTRALIAN DOLLARS Page CONSOLIDATED STATEMENT OF FINANCIAL POSITION 1 CONSOLIDATED STATEMENT OF PROFIT OR LOSS A
Read more →ATHEPrana Receives Approval For 12-Month Open Label Extension Study In Alzheimer's Disease Melbourne - Wednesday, 3 July, 2013: Prana Biotechnology (NASDAQ:PRAN; ASX:PBT) today announced that it has received approval from th
Prana Receives Approval For 12-Month Open Label Extension Study In Alzheimer's Disease Wednesday, 3 July, 2013: Prana Biotechnology (NASDAQ:PRAN; ASX:PBT) today announced that it has received approval from the Austin Health Human Research Ethics Committee (HREC) to commence a
Read more →ATHEPrana Completes Phase 2 Huntington Disease Trial with PBT2 Melbourne
Prana Completes Phase 2 Huntington Disease July 23, 2013: Prana Biotechnology (NASDAQ:PRAN; ASX:PBT) today announced the successful completion of Reach2HD, a phase 2 clinical trial in patients with early to mid-stage Huntington disease. The Company expects to announce the resul
Read more →ATHEPrana prepares for next steps in the PBT2 development path to market and commercialization with key appointments strategy Melbourne - 1 August, 2013: Prana Biotechnology (NASDAQ:PRAN; ASX:PBT) has today announced the fir
Prana prepares for next steps in the PBT2 development path to market and commercialization with key appointments strategy 1 August, 2013: Prana Biotechnology (NASDAQ:PRAN; ASX:PBT) has today announced the first of several key appointments in the near term to advance PBT2 into
Read more →ATHEPrana Doses First Patient in PBT2 Alzheimer's Extension Study Melbourne - Monday 29 th July, 2013: Prana Biotechnology (NASDAQ:PRAN; ASX:PBT) today announced that the first patient has been dosed in the 12-month open-lab
Prana Doses First Patient in PBT2 Alzheimer's Monday 29th July, 2013: Prana Biotechnology (NASDAQ:PRAN; ASX:PBT) today announced that the first patient has been dosed in the 12-month open-label extension study with Alzheimer's Disease patients participating in Prana's Phase 2
Read more →ATHESECURITIES AND EXCHANGE COMMISSION
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December, 2012 Prana Biotechnology Limited (Name of Registrant) Level 2, 369 Royal Parade Parkville Victor
Read more →ATHEFurther Information - Prana's PBT2 Clinical Trials Cited as Most Advanced in Addressing Neurodegeneration from the Metal Equilibrium Perspective Melbourne
Further Information - Prana's PBT2 Clinical Trials Cited as Most Advanced in Addressing Neurodegeneration Equilibrium Perspective Melbourne - September 20, 2012; Prana Biotechnology (NASDAQ:PRAN; ASX:PBT) today reported that it had been cited in an interview in The Life Scie
Read more →ATHECOMPANY ANNOUNCEMENT (ASX:PBT) Notice under Section 708A (5) of the Corporations Act Monday 17 th September 2012: This notice is given under paragraph (5)(e) of section 708A of the Corporations Act. The following securit
COMPANY ANNOUNCEMENT Notice under Section 708A (5) of the 17th September 2012: This notice is given under paragraph (5)(e) of section 708A of the Corporations Act. The following securities of the Company are issued without disclosure to investors under Part 6D.2 of the Corp
Read more →ATHEMedical science has made a significant number of breakthroughs over the past century. The average life span in western cultures has substantially increased. Heart disease and cancer have been amongst the most successful
science has made a significant number of breakthroughs over the past century. The average life span in western cultures has substantially increased. Heart disease and cancer have been amongst the most successful areas of drug discovery over the last 20 years. The diseases asso
Read more →ATHEPrana Secures $6 million Additional Financing - Provides greater opportunity to advance Prana's clinical assets, including PBT2 into future Alzheimer's trials - New York
Secures $6 million Additional Financing - Provides greater opportunity to advance Prana's clinical assets, including PBT2 into Alzheimer's trials - New York - September 9, 2009 : Prana Biotechnology (ASX:PBT; NASDAQ:PRAN) today announced that it has reached agreement to rai
Read more →ATHEAppendix 4C Quarterly Report for Entities Admitted on the Basis of Commitments Rule 4.7B Appendix 4C - 3 rd Quarter Quarterly report for entities admitted on the basis of commitments Introduced 31/3/2000. Amended 30/9/20
Appendix 4C Quarterly Report for Entities Admitted on the Basis of Commitments Rule 4.7B the basis of commitments 31/3/2000. Amended 30/9/2001 Name of Entity: PRANA BIOTECHNOLOGY LIMITED ABN: Quarter Ended ('Current Quarter') 37 080 699 065 31 st March, 2009 Statement of
Read more →ATHEAPPENDIX 4D: INTERIM FINANCIAL REPORT ex99-1 -- Converted by SECPublisher 2.1.1.8, created by BCL Technologies Inc., for SEC Filing
APPENDIX 4D: INTERIM FINANCIAL REPORT ex99-1 -- Converted by SECPublisher 2.1.1.8, created by BCL Technologies Inc., for SEC Filing
Read more →ATHEAppendix 4C Quarterly Report for Entities Admitted on the Basis of Commitments Rule 4.7B Appendix 4C - 2 nd Quarter Quarterly report for entities admitted on the basis of commitments Introduced 31/3/2000. Amended 30/9/20
Appendix 4C Quarterly Report for Entities Admitted on the Basis of Commitments Rule 4.7B the basis of commitments 31/3/2000. Amended 30/9/2001 Name of Entity: PRANA BIOTECHNOLOGY LIMITED ABN: Quarter Ended ('Current Quarter') 37 080 699 065 31 st December, 2008 Statement
Read more →ATHEAppendix 3B New issue announcement Rule 2.7, 3.10.3, 3.10.4, 3.10.5 Appendix 3B New issue announcement, application for quotation of additional securities and agreement Information or documents not available now must be
2.7, 3.10.3, 3.10.4, 3.10.5 for quotation of additional securities or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made 1/7/96. Origin: Appendix 5. Amended 1/7/98, 1/9/99, 1/7/20
Read more →ATHECOMPANY ANNOUNCEMENT (ASX:PBT) Notice Under Section 708A(5) of the Corporations Act Thursday 4 th December 2008: This notice is given under paragraph (5)(e) of section 708A of the Corporations Act. The following securiti
Under Section 708A(5) of the Corporations Act notice is given under paragraph (5)(e) of section 708A of the Corporations following securities of the Company were issued without disclosure to investors under Part 6D.2 of the Corporations Act: Type: Ordinary Shares Class/Descr
Read more →ATHERESULTS OF ANNUAL GENERAL MEETING 28 th of November 2008 PRANA BIOTECHNOLOGY LIMITED (ASX: PBT) Results of Annual General Meeting The Company wishes to advise that the resolutions contained in the Notice of Meeting were
BIOTECHNOLOGY LIMITED of Annual General Meeting Company wishes to advise that the resolutions contained in the Notice of Meeting were duly carried on a show of hands. accordance with Section 251AA(1) of the Corporations Act 2001, the following information is provided in rela
Read more →ATHECOMPANY ANNOUNCEMENT (ASX:PBT) Notice Under Section 708A(5) of the Corporations Act Monday 17 th November 2008: This notice is given under paragraph (5)(e) of section 708A of the Corporations Act. The following securitie
Under Section 708A(5) of the Corporations Act notice is given under paragraph (5)(e) of section 708A of the Corporations following securities of the Company were issued without disclosure to investors under Part 6D.2 of the Corporations Act: Type: Ordinary Shares Class/Descri
Read more →ATHEAppendix 4C Quarterly Report for Entities Admitted on the Basis of Commitments Rule 4.7B Appendix 4C - 1 st Quarter Quarterly report for entities admitted on the basis of commitments Introduced 31/3/2000. Amended 30/9/20
on the Basis of Commitments the basis of commitments 31/3/2000. Amended 30/9/2001 Name of Entity: PRANA BIOTECHNOLOGY LIMITED ABN: Quarter Ended ('Current Quarter') 37 080 699 065 30 th September, 2008 Statement of Cash Flows Current Quarter $A'000 Year to Date (3 mont
Read more →ATHENotice of Annual General Meeting Incorporating Explanatory Memorandum and Proxy Form To Be Held On: Friday, 28 th of November 2008 At: 10.30am Peppin Merino Room Ground Floor 369 Royal Parade Parkville, Victoria, 3052 Th
of Annual General Meeting accompanying Explanatory Memorandum and the following information for shareholders form part of this Notice of Meeting. OF 2008 ANNUAL GENERAL MEETING given that the 2008 Annual General Meeting of Shareholders (the "Meeting") of Prana Biotechnology
Read more →ATHECOMPANY ANNOUNCEMENT (ASX:PBT) Notice Under Section 708A(5) of the Corporations Act Friday 17 th October 2008: This notice is given under paragraph (5)(e) of section 708A of the Corporations Act. The following securities
Under Section 708A(5) of the Corporations Act notice is given under paragraph (5)(e) of section 708A of the Corporations following securities of the Company were issued without disclosure to investors under Part 6D.2 of the Corporations Act: Type: Unlisted Options Class/Descr
Read more →ATHECOMPANY ANNOUNCEMENT (ASX:PBT) Notice Under Section 708A(5) of the Corporations Act Wednesday 15 th October 2008: This notice is given under paragraph (5)(e) of section 708A of the Corporations Act. The following securit
Under Section 708A(5) of the Corporations Act notice is given under paragraph (5)(e) of section 708A of the Corporations following securities of the Company were issued without disclosure to investors under Part 6D.2 of the Corporations Act: Type: Ordinary Shares Class/Descri
Read more →ATHEPrana Announces Filing of Annual Report, Dated
Filing of Annual Report, Dated September 25, 2008 Australia - September 29, 2008 - Prana Biotechnology Limited (NASDAQ: PRAN biopharmaceutical company focused on the research and development of treatments for neurodegenerative disorders, today announced that it filed its annu
Read more →ATHECOMPANY ANNOUNCEMENT (ASX:PBT) Notice Under Section 708A(5) of the Corporations Act Wednesday 3 rd September 2008: This notice is given under paragraph (5)(e) of section 708A of the Corporations Act. The following securi
Under Section 708A(5) of the Corporations Act notice is given under paragraph (5)(e) of section 708A of the Corporations following securities of the Company were issued without disclosure to investors under Part 6D.2 of the Corporations Act: Type: Ordinary Shares Class/Descri
Read more →ATHEUnassociated Document Appendix 3B New issue announcement Rule 2.7, 3.10.3, 3.10.4, 3.10.5 Appendix 3B New issue announcement, application for quotation of additional securities and agreement Information or documents not
2.7, 3.10.3, 3.10.4, 3.10.5 for quotation of additional securities or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made 1/7/96. Origin: Appendix 5. Amended 1/7/98, 1/9/99, 1/7/20
Read more →ATHEUnassociated Document COMPANY ANNOUNCEMENT (ASX:PBT) Notice Under Section 708A(5) of the Corporations Act Wednesday 27 th August 2008: This notice is given under paragraph (5)(e) of section 708A of the Corporations Act.
Under Section 708A(5) of the Corporations Act notice is given under paragraph (5)(e) of section 708A of the Corporations following securities of the Company were issued without disclosure to investors under Part 6D.2 of the Corporations Act: Type: Ordinary Shares Class/Descri
Read more →ATHEAppendix 4C Quarterly Report for Entities Admitted on the Basis of Commitments Rule 4.7B Appendix 4C - 4 th Quarter Quarterly report for entities admitted on the basis of commitments Introduced 31/3/2000. Amended 30/9/20
on the Basis of Commitments the basis of commitments 31/3/2000. Amended 30/9/2001 Name of Entity: PRANA BIOTECHNOLOGY LIMITED ABN: Quarter Ended ('Current Quarter') 37 080 699 065 30 th June, 2008 Consolidated Statement of Cash Flows Cash Flows Related to Operating Acti
Read more →ATHEPrana Co-Founding Scientist Professor Rudolph Tanzi, Addressed U.S. Senate Special Committee on Aging Comments on Prana Developments and Future Prospects for Therapeutic Approaches for Alzheimer's Disease
Co-Founding Scientist Professor Rudolph Tanzi, U.S. Senate Special Committee on Aging on Prana Developments and Future Prospects for Approaches for Alzheimer's Disease Australia - July 8, 2008 - Rudolph E. Tanzi, Ph.D., Co-Founding Scientist of Prana Biotechnology Limited (
Read more →ATHECOMPANY ANNOUNCEMENT (ASX:PBT) Notice Under Section 708A(5) of the Corporations Act Wednesday 25 th June 2008: This notice is given under paragraph (5)(e) of section 708A of the Corporations Act. The following securities
Under Section 708A(5) of the Corporations Act notice is given under paragraph (5)(e) of section 708A of the Corporations following securities of the Company were issued without disclosure to investors under Part 6D.2 of the Corporations Act: Type: Ordinary Shares Class/Descri
Read more →ATHECOMPANY ANNOUNCEMENT (ASX:PBT) Notice Under Section 708A(5) of the Corporations Act Monday 2 nd June 2008: This notice is given under paragraph (5)(e) of section 708A of the Corporations Act. The following securities of
Under Section 708A(5) of the Corporations Act notice is given under paragraph (5)(e) of section 708A of the Corporations following securities of the Company were issued without disclosure to investors under Part 6D.2 of the Corporations Act: Type: Ordinary Shares Class/Descri
Read more →ATHEPrana Biotechnology Ltd ACN 080 699 065 Annexure to Notice of change of interests of substantial holder: Baywick Pty Ltd ACN 007 226 708 ANNEXURE A 4. Present relevant interests Holder of relevant interest Registered hol
to Notice of change of interests of substantial holder: Present relevant interests Holder of relevant interest Registered holder of Securities Person entitled to be registered as holder (8) Nature of relevant interest (6) Class and number of securities Person's votes Baywick Ba
Read more →ATHECOMPANY ANNOUNCEMENT (ASX:PBT) Notice Under Section 708A(5) of the Corporations Act Tuesday 27 th May 2008: This notice is given under paragraph (5)(e) of section 708A of the Corporations Act. The following securities of
Under Section 708A(5) of the Corporations Act notice is given under paragraph (5)(e) of section 708A of the Corporations following securities of the Company were issued without disclosure to investors under Part 6D.2 of the Corporations Act: Type: Ordinary Shares Class/Descri
Read more →ATHEPrana Announces $7 million Placement to Fund Research Programs -Additional Investment from Existing Shareholders
Announces $7 million Placement to Fund Research Programs Investment from Existing Shareholders - Australia - May 21, 2008 - Prana Biotechnology Limited (NASDAQ: PRAN / ASX: biopharmaceutical company focused on the research and development of treatments for neurodegenerative d
Read more →ATHECOMPANY ANNOUNCEMENT (ASX:PBT) Notice Under Section 708A(5) of the Corporations Act Thursday 15 th May 2008: This notice is given under paragraph (5)(e) of section 708A of the Corporations Act. The following securities o
Under Section 708A(5) of the Corporations Act notice is given under paragraph (5)(e) of section 708A of the Corporations following securities of the Company were issued without disclosure to investors under Part 6D.2 of the Corporations Act: Type: Unlisted Options Class/Descr
Read more →ATHECOMPANY ANNOUNCEMENT (ASX:PBT) Notice Under Section 708A(5) of the Corporations Act Friday, 14 th March 2008: This notice is given under paragraph (5)(e) of section 708A of the Corporations Act. The following securities
Under Section 708A(5) of the Corporations Act notice is given under paragraph (5)(e) of section 708A of the Corporations following securities of the Company were issued without disclosure to investors under Part 6D.2 of the Corporations Act: Type: Unlisted Options Class/Descr
Read more →ATHECOMPANY ANNOUNCEMENT Prana Responds to Press comments on visits by pharmaceutical executives.
Responds to Press comments on visits by pharmaceutical Australia - March 4, 2008: Prana Biotechnology Limited (NASDAQ: PRAN / ASX: become aware of certain comments which appeared in today's press which have followed on from the release of 26 February 2008 when Prana announced
Read more →ATHEv105115_ex99-1 -- Converted by SECPublisher 2.1.1.8, created by BCL Technologies Inc., for SEC Filing
v105115_ex99-1 -- Converted by SECPublisher 2.1.1.8, created by BCL Technologies Inc., for SEC Filing
Read more →ATHEv105113_ex99-1 -- Converted by SECPublisher 2.1.1.8, created by BCL Technologies Inc., for SEC Filing
v105113_ex99-1 -- Converted by SECPublisher 2.1.1.8, created by BCL Technologies Inc., for SEC Filing
Read more →ATHEPrana Announces Success in Phase IIa Clinical Trial of PBT2 in Early Alzheimer's Disease PBT2 demonstrates positive biomarker and cognitive effects
Announces Success in Phase IIa Clinical Trial of PBT2 in Early Alzheimer's demonstrates positive biomarker and cognitive effects Australia - February 26, 2008: Prana Biotechnology Limited (NASDAQ: PRAN / biopharmaceutical company focused on the research and development of trea
Read more →ATHEPrana Announces Completion of Phase IIa Trial of PBT2 in Alzheimer's Disease Patients - Results expected to be submitted in first quarter 2008
Announces Completion of Phase IIa Trial of PBT2 in Alzheimer's Disease Patients Results expected to be submitted in first quarter 2008 - Australia - January 2, 2008 - Prana Biotechnology Limited (NASDAQ: PRAN / ASX: biopharmaceutical company focused on the research and develop
Read more →ATHEth of December 2007 PRANA BIOTECHNOLOGY LIMITED (ASX: PBT) Results of Annual General Meeting The Company wishes to advise that the resolutions contained in the Notice of Meeting were duly carried on a show of hands. In a
BIOTECHNOLOGY LIMITED of Annual General Meeting Company wishes to advise that the resolutions contained in the Notice of Meeting were duly carried on a show of hands. accordance with Section 251AA(1) of the Corporations Act 2001, the following information is provided in rela
Read more →ATHEUnassociated Document COMPANY ANNOUNCEMENT (ASX:PBT) Notice Under Section 708A(5) of the Corporations Act 23 October 2007 This notice is given under paragraph (5)(e) of section 708A of the Corporations Act. The following
Under Section 708A(5) of the Corporations Act notice is given under paragraph (5)(e) of section 708A of the Corporations following securities of the Company were issued without disclosure to investors under Part 6D.2 of the Corporations Act: Type: Shares Unlisted Options Unli
Read more →ATHEPage 1 of 2 15 July 2001 Form 604 Corporations Act 2001 Section 671B Notice of change of interests of substantial holder To Company Name/Scheme Prana Biotechnology Limited ACN/ARSN 080 699 065 1. Details of substantial h
of change of interests of substantial holder To Company Name/Scheme Prana Biotechnology Limited ACN/ARSN 080 699 065 Details of substantial holder (1) Name Baywick Pty Ltd ACN/ARSN (if applicable) 007 226 708 There was a change in the interests of the substantial holder o
Read more →ATHEAppendix 4C Quarterly Report for Entities Admitted on the Basis of Commitments Rule 4.7B Appendix 4C - 4th Quarter Quarterly report for entities admitted on the basis of commitments Introduced 31/3/2000. Amended 30/9/200
on the Basis of Commitments the basis of commitments 31/3/2000. Amended 30/9/2001 Name of Entity: PRANA BIOTECHNOLOGY LIMITED ABN: Quarter Ended ('Current Quarter') 37 080 699 065 30 th June, 2007 Statement of Cash Flows Cash Flows Related to Operating Activities Current
Read more →ATHEPrana Biotechnology Presents New Key Findings on PBT2 PBT2 Alters Biomarkers and Rapidly Improves Cognition in two distinct models of Alzheimer's Disease
Biotechnology Presents New Key Findings on PBT2 Alters Biomarkers and Rapidly Improves Cognition in two distinct models of Australia - June 6, 2007 - Prana Biotechnology Limited (NASDAQ: PRAN / ASX: biopharmaceutical company focused on the research and development of treatment
Read more →ATHEv074599_ex99-1 -- Converted by SECPublisher 2.1.1.8, created by BCL Technologies Inc., for SEC Filing
v074599_ex99-1 -- Converted by SECPublisher 2.1.1.8, created by BCL Technologies Inc., for SEC Filing
Read more →ATHEcorresponding period: half year ended 31 December 2005)
corresponding period: half year ended 31 December 2005) conjunction with the 30 June 2006 Annual Report. with Listing Rule 4.2A Prana Biotechnology Ltd ABN 37 080 699 065 1 of 16 Your directors present report on the consolidated entity consisiting of Prana Biotechnology L
Read more →ATHEDosing Commenced in Phase IIa PBT2 Trial of Alzheimer's Patients - Screening of Patients Under Way and Proceeding as Expected
Commenced in Phase IIa PBT2 Trial of Alzheimer's Patients of Patients Under Way and Proceeding as Expected - Australia - December 19, 2006 - Prana Biotechnology Limited (NASDAQ: PRAN / announced that dosing has commenced in its Phase IIa clinical trial of PBT2 patients with e
Read more →ATHEPrana Biotechnology Co-Founding Scientist Receives Grand Hamdan International Award for Medical Sciences - Professor Colin Masters Honored for His Work in the Field of Molecular and Cellular Pathology of Neurological Dis
Biotechnology Co-Founding Scientist Receives Grand Hamdan Award for Medical Sciences Colin Masters Honored for His Work in the of Molecular and Cellular Pathology of Neurological Disorders Australia - December 19, 2006 - Professor Colin Masters, M.D., Ph.D., co-founding scie
Read more →Competitive Position
How ATHE ranks across every disease it competes inCompetitive Position is a premium feature
See how ATHE ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial